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ABSTRACT
There is increasing interest in the possibility of expanding haemopoietic stem 
and progenitor cells ex vivo. Successful expansion of pluripotent haemopoietic 
stem cells would extend the use of high dose chemotherapy with autologous 
rescue to include those patients for whom we are currently unable to harvest 
sufficient stem cells for transplantation. It is likely that the efficiency of gene 
transduction would be significantly enhanced under conditions in which stem 
cells were proliferating. For cancer treatments, using high dose but non- 
myeloablative chemotherapy, progenitor cell expansion should reduce 
harvesting requirements and, thereby, tumour cell contamination. Finally, the 
primary aim of these studies was to expand, ex vivo, those progenitors cells 
thought to mediate the early phase of engraftment in order to reduce the 
duration of both neutropenia and thrombocytopenia following bone marrow 
transplantation (BMT).
We have attempted to determine optimum ex vivo culture conditions 
which allow maximum amplification of murine transient engrafting stem cells. 
The short term (6 days) incubation of unfractionated bone marrow in liquid 
culture with Stem Cell Factor (SCF), Interleukin-11 (IL-11), with or without 
Macrophage Inflammatory Protein-1 alpha (MIP-la) produced a 50 fold 
amplification of those cells which were shown to rescue lethally irradiated 
recipients in a BMT model. Following ex vivo expansion, ten to twenty fold 
fewer cells were required to rescue lethally irradiated mice. When transplanted 
in cell doses above threshold for engraftment, bone marrow cells expanded ex 
vivo resulted in significantly more rapid haemopoietic recovery. Thus, we 
were able to demonstrate expansion of progenitor cells ex vivo and to assess 
the engraftment potential of the expanded cells. The results suggested two 
potential benefits for patients with cancer if similar data could be obtained 
with human haemopoietic cells.
Although we had demonstrated expansion of progenitor cells, it was 
equally important to assess the effect that ex vivo culture had on those stem 
cells responsible for long term reconstitution following BMT. In a serial 
transplantation model, unmanipulated bone marrow was only able to 
consistently sustain secondary BMT recipients but bone marrow expanded ex 
vivo sustained quaternary BMT recipients which remained alive and well 
more than 120 days after BMT. These findings have important implications 
for transplantation and gene transfer studies since expansion of clonogenic 
cells accompanied by maintenance of long term reconstituting stem cells will 
result, not only in improved early engraftment, but also in sustained long-term 
reconstitution following transplantation and may result in enhanced 
transduction efficiencies with genes of interest.
Following tertiary and quaternary BMT many of the recipients of 
expanded cells developed B-cell chronic lymphocytic leukaemia (B-CLL). 
The group transplanted with SCF / IL-11 / MIP-la expanded marrow 
developed leukaemia earlier and with a greater frequency that those 
transplanted with SCF /  IL-11 expanded cells. The leukaemia was shown to 
have arisen in host haemopoietic cells rather than in the donor bone marrow 
which had been expanded ex vivo. The mechanism underlying the 
development of these leukaemias is not clear and will be the subject of future 
study within our group.
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INTRODUCTION
Chapter 1
1.1  Haemopoiesis
In mammalian development, HSC sequentially occupy the embryonic yolk 
sac, fetal liver, spleen and finally the adult bone marrow (Zon, 1995). In the 
bone marrow, haemopoiesis appears to be a complex cellular and biological 
process which is carefully controlled and rarely gives rise to disease. The 
regulation of haemopoiesis is dependent upon interactions between the bone 
marrow microenvironment, HSC, progenitor cells and an array of both 
stimulatory and inhibitory factors.
The system can be arbitrarily divided into several types of cell 
population: pluripotent stem cells, multipotent progenitors, committed 
progenitors and maturing cells. The hierarchy of these cell subsets is 
established on the basis of decreasing ability to generate new stem cells (self­
renewal), decreasing proliferative potential and increasing lineage 
commitment.
The production and maturation of blood cells of the eight major 
lineages is a continuous process, largely controlled by specific glycoprotein 
regulators. These cytokines, or growth factors, promote the survival and 
proliferation of stem and progenitor cells and in their absence the cells 
undergo apoptosis and die (Ogawa, 1993; Sachs & Lotem, 1994). Under 
steady state conditions total blood cell production to maintain homeostasis in 
humans is approximately 350-400 x 10^ cells per day (Moore, 1995) and this 
can be amplified up to ten fold under conditions of stress. Although cytokines 
appear to play a crucial role in cell survival, proliferation and differentiation, 
regulation of haemopoiesis is dependent also on the interaction of the
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haemopoietic stem and progenitor cells with the cells making up the bone 
marrow microenvironment.
1.2 The bone marrow microenvironment, long term bone marrow culture 
(LTBMC) and the role of stroma
HSC are found in close contact with stromal cells in the haemopoietic 
microenvironment, both in vitro and in vivo. Most knowledge regarding 
stromal cell function has been derived from in vitro systems, in particular the 
LTBMC (Dexter et al., 1977). The basis of the LTBMC assay is the 
development of a complex marrow stromal cell layer containing fibroblasts, 
adipocytes, endothelial cells and macrophages among which HSC and 
progenitor cells reside.
Stromal cell lines cloned from murine LTBMC have proven invaluable 
in revealing the role of locally produced cytokines and adhesion molecules in 
the regulation of haemopoiesis. In LTBMC the more mature precursors and 
terminally differentiated cells are found in the supernatant fluid and are 
termed "non-adherent". Haemopoietic stem cells and immature precursor cells 
adhere tightly to the stroma and are termed "adherent" (Coulombel et al., 
1983). The adhesion molecule VLA-4 plays a major role in the interaction 
between HSC and stroma by binding to VCAM-1 (Simmons et al., 1992; 
Williams et al., 1991). Monoclonal antibodies which prevent this binding have 
been shown to release HSC from the stroma both in vitro and in vivo 
(Simmons et al., 1992; Williams et al., 1991). VLA-4 is not the sole 
mechanism by which HSC adhere to stroma and other interactions involve 
cytokine receptors on HSC which bind to membrane or extracellular matrix 
associated factors, such as SCF (Williams & Majumdar, 1994).
It is well established that a proportion of murine stem cells can persist 
for several weeks without differentiation in LTBMC (Fraser et al., 1992) and 
a variety of cloned stromal cell lines support HSC to a varying degree. The
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S17 line appeared more efficient, even than primary murine stromal layers, in 
supporting HSC and HSC cultured on S17 competed efficiently with freshly 
isolated marrow in the competitive repopulation assay (CRA) (Wineman et 
al., 1993) (see later for explanation of assay systems). However, this study 
also showed that the majority of stromal cell lines failed to support HSC 
which retained the capacity to compete with fresh marrow in the CRA, 
therefore, stromal cells capable of supporting primitive stem cells may be 
infrequent in bone marrow or may lose this capacity on culturing in vitro.
Whether support is mediated by the stromal cells themselves or by 
secreted molecules, remains unclear. Those stromal layers which support 
murine haemopoiesis, in general, also support human HSC and, therefore, the 
mechanism responsible for HSC support may not be species specific. Since 
many early acting cytokines are structurally conserved between species, but 
later acting cytokines are often species specific, this suggests a possible role 
for some cytokines in the support of HSC in stromal cultures. However, 
Wineman et al have failed to find a relationship between the cytokines 
produced by stromal layers and HSC support and similarly the ability to 
maintain HSC does not appear to correlate with the extent of expansion of 
mature cells induced by cytokines (Muller-Sieburg & Deryugina, 1995).
Finally, a recent study suggested that very primitive HSC were in fact 
refractory to the effects of combinations of cytokines in suspension culture 
(Berardi et al., 1995). This suggested that the mechanisms which support HSC 
and those which promote maturation and expansion of their progeny may be 
separable. Elegant work by Verfaillie and co-workers suggested that, for 
human HSC, direct contact between the HSC and the stroma was not required 
for long-term haemopoiesis and that a high molecular weight molecule, 
derived from medium conditioned by stroma, in combination with the 
stimulatory cytokine IL-3 and the inhibitory chemokine M IP-la may
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substitute for primary stroma (Verfaillie, 1992; Verfaillie, 1993; Verfaillie et 
al., 1994).
It appears, therefore, that stromal cell derived factors rather than 
stromal cells themselves, are necessary for HSC support and that it may be 
possible to develop stroma free in vitro culture systems which not only 
support maturation, expansion and proliferation of progenitor cells, but also 
support HSC maintenance and / or self-renewal.
1.3 Stem Cells and CFU-S
In the 1960s, Till & McCulloch described the colony forming unit spleen 
(CFU-S) assay (Till & McCulloch, 1961), based on the observation that 
macroscopic colonies derived from primitive cells can be observed in spleens 
of lethally irradiated mice 8-14 days after the inoculation of bone marrow. 
These early experiments raised the possibility that RBC, WBC and 
megakaryocytes were all derived from the same precursor but could not prove 
this in the absence of a marker such as a cytogenetic abnormality (Till & 
McCulloch, 1961). Two years later Becker et al reported cytogenetic evidence 
which further supported this conclusion (Becker et al., 1963), however it was 
not until 1967 that Wu et al succeeded in demonstrating that each spleen 
colony was a clone and that cells for these three lineages were derived from a 
single precursor (Wu et al., 1967). Further studies, using chromosomal 
markers, confirmed that a progenitor cell capable of myeloid differentiation 
was also capable of forming T and B lymphocytes (Abramson et al., 1977). In 
their study, bone marrow cells with chromosomal abnormalities induced by 
radiation were used to transplant stem cell deficient mice (W/WV). Several 
months later bone marrow, spleen and thymus were examined for the presence 
of cells having the same chromosomal marker. In at least five mice a unique 
marker was observed in CFU-S, in T cells stimulated by phytohaemagglutinin
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and in B cells stimulated by lipopolysaccharide. This provided firm evidence 
that myeloid and lymphoid cells derived from a pluripotent stem cell.
Self-renewal of CFU-S was demonstrated using secondary transfer of 
spleen colonies, showing that CFU-S was capable of forming other cells like 
itself (Siminovitch et al., 1963). From this work, Till & McCulloch formed 
the following definition for the HSC: "HSC are, at the single cell level, 
capable of differentiation into all blood cell elements as well as extensive 
proliferation and self-renewal".
In murine marrow HSC are thought to be present at a frequency of 1 in 
104 to 1 in 105. Since true stem cells are so rare, their presence is, in general, 
deduced by the appearance of differentiated cells in the assay systems 
available (see below). In vivo long-term repopulation assays are considered to 
be the most stringent test for very primitive stem cells. The majority of HSC 
are considered to be quiescent under steady state haemopoiesis but to be 
capable of extensive proliferation and self-renewal in situations when marrow 
regeneration is required, for example following chemotherapy or irradiation.
1.4 Stem cells are a heterogeneous population
If one considers the definition of HSC as pluripotent and able to give rise to 
all haemopoietic lineages, then the stem cell population is functionally 
heterogeneous. During the late 1960s and 1970s it became apparent that CFU- 
S was not a homogeneous stem cell population but was heterogeneous, made 
up of cells at varying levels of commitment (Worton et al., 1969). For 
example, it was shown that CFU-S day 8 were less primitive than CFU-S day 
12 (Magli et al., 1982). Furthermore, Hodgson & Bradley demonstrated the 
existence of pre-CFU-S as a class of stem cells which, following primary bone 
marrow transplantation (BMT), homed to the bone marrow and gave rise to 
day 12 CFU-S upon secondary transfer (Hodgson & Bradley, 1979). This 
property of stem cells became known as marrow repopulating ability (MRA).
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More recently, Harrison et al, using the CRA, demonstrated that early after 
BMT, a number of pluripotent cells contributed to repopulation, whereas 
many months later only a few were active (Harrison et al., 1993). Similar data 
have been obtained using stem cells marked using retroviruses (Dick et al., 
1985; Lemischka et al., 1986). This work was corroborated by demonstrating 
heterogeneity, even within highly enriched stem cell populations (Sca-1+ Thy- 
ll° Lin"), by limiting dilution analysis in vivo. Most stem cells in this 
population ceased to contribute to repopulation after only a few weeks (Smith 
et al., 1991; Uchida & Weissman, 1992). It appears, therefore, that only a 
minority of "stem cells" are capable of long term persistence.
1.5 CFU-S are separable from HSC
For 30 years following the original description by Till & McCulloch (Till & 
McCulloch, 1961), the CFU-S assay was used as an indicator of stem cell 
frequency in marrow and spleen suspensions. However, the ability to separate 
bone marrow cells, on the basis of a variety of physical and phenotypic 
properties, demonstrated that the vast majority of CFU-S did not have long 
term repopulating ability. In addition, bone marrow cells depleted of CFU-S 
were shown to be responsible for long-term reconstitution (Jones et al., 1990; 
Ploemacher & Brons, 1989). Thus, CFU-S appeared to contribute to early 
engraftment following BMT, whereas "pre-CFU-S" were responsible for long­
term reconstitution.
In vitro Assays
In the 1960s, groups in Israel and Australia developed in vitro clonogenic 
assays for the growth of normal murine bone marrow cells (Pluznik & Sachs, 
1965; Bradley & Metcalf, 1966; Ichikawa et al., 1966). These culture systems 
were then extended to the cloning of human myeloid cells and to erythrocytes, 
B cells and T cells (Sachs, 1992). Such assays facilitated the discovery of a
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family of cytokines which have been found to regulate cell viability, 
proliferation and differentiation. There is now a wide range of in vitro assay 
systems available to investigators. The most appropriate choice of assay will 
depend on the experimental question to be answered, but also tends to depend 
on the preference of the investigator for a particular assay(s). In vitro assays 
have now been developed which measure progenitors at different stages of 
commitment. For example, committed assays measure myeloid precursor cells 
committed to the granulocyte, eosinophil, macrophage, megakaryocyte or 
erythroid lineage, whereas HPP-CFC and CFU-A measure progenitor cells 
which are still multipotential. The most primitive progenitor cells detected in 
vitro are measured indirectly by using long term culture techniques. A number 
of assays which are in frequent use are described in some detail below.
1.6 Committed progenitor assays
Committed progenitor assays including CFU-GM, BFU-E and CFU-Mix 
became well established in routine haemopoietic cell culture as a result of 
work performed in the 1960s (Pluznik & Sachs, 1965; Bradley & Metcalf, 
1966) and developed thereafter. The colonies which grow in these cultures 
arise from progenitor rather than stem cells.
A number of cytokines have direct stimulatory effects on haemopoietic 
cells in these assays (GM-CSF, G-CSF, M-CSF, IL-3 and erythropoietin 
(Epo)), whilst others have no or modest stimulatory effects when used alone, 
but may exert powerful synergistic effects when used in combination with the 
CSFs mentioned above (IL-1, IL-4, IL-5, IL-6, IL-11, IL-12 and SCF)
(Heyworth & Spooncer, 1993).
Since CSFs and interleukins may themselves be produced by cells 
present in bone marrow it is important to look at effects on highly purified cell 
populations, depleted of accessory cells, before concluding that an effect is 
mediated directly. Additionally, unknown components present in serum, in
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combination with growth factors, may exert effects on haemopoietic cells and 
therefore cell culture performed under serum free or serum deprived 
conditions may be of additional value under certain circumstances.
Although culture of purified cells, in strictly defined media, describes 
the ideal, in general, routine experiments are performed using unfractionated 
bone marrow in the presence of serum, and often conditioned media replace 
purified growth factors. To answer specific questions, however, defined 
conditions should be employed.
The essential components for these assays include a semi-solid 
medium, either agar or methylcellulose, a source of pre-tested serum (or 
specifically devised serum free medium), a source of growth factor(s) and a 
cell population for testing. CFU-Mix detect multipotent myeloid cells, BFU-E 
primitive and more mature erythroid progenitors, and CFU-GM, committed 
granulocyte and macrophage progenitor cells. Variations of these assays may 
be developed to detect megakaryocyte or eosinophil progenitors (Heyworth & 
Spooncer, 1993).
Although the majority of cells comprising these colonies are maturing 
and post-mitotic, a low incidence of clonogenic progenitors may be 
demonstrated by replating the colonies into identical conditions and observing 
for the development of further colonies.
1.7 High Proliferative Potential Colony-Forming Cells (HPP-CFC)
Following the description of the in vivo CFU-S assay in 1961 (Till & 
McCulloch, 1961) the in vitro detection of committed progenitor cells was 
described by two groups (Pluznik & Sachs, 1965; Bradley & Metcalf, 1966). 
Attempts to study the factors responsible for the proliferation and 
differentiation of more primitive cells was, however, hampered by the lack of 
a suitable in vitro assay system. In 1979, Bradley & Hodgson described the 
HPP-CFC assay which detected primitive progenitors with properties similar
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to stem cells (Bradley & Hodgson, 1979). Following the initial description in 
1979, the HPP-CFC assay was further developed and shown to detect at least 
three subpopulations of progenitors stimulated by differing combinations of 
cytokines (McNiece et al., 1986). These were termed HPP-CFC-1, 2 and 3 
and appeared to be developmentally distinct. The various types were shown to 
be responsive to a variety of cytokines including SCF, GM-CSF, M-CSF, G- 
CSF, IL-1, IL-3, IL-4 and IL-6. HPP-CFC-1, the most primitive, were 
resistant to 5-FU and were capable of generating the more mature HPP-CFC-2 
& 3 (Bradley & Hodgson, 1979; Bradley et al., 1986; McNiece et al., 1986). 
HPP-CFC-1 correlated closely with pre-CFU-S (Hodgson & Bradley, 1984), 
were able to generate cells which formed CFU-S and cells which possessed 
marrow repopulating ability (McNiece et al., 1987). The incidence of HPP- 
CFC-1 was estimated at only 1 in 2380 normal murine bone marrow cells 
(Bradley & Hodgson, 1979). Combining different methods of stem cell 
enrichment (see below) Bertoncello et al were able to resolve HPP-CFC-1 
and 2 (Bertoncello et al., 1985; Bertoncello et al., 1989). For example, HPP- 
CFC-1 were rhodaminedull but HPP-CFC-2 were rhodaminebright 
(Bertoncello etal., 1991).
1.8 Colony forming unit-Type A (CFU-A) assay 
Although single cytokines are unable to induce proliferation of more 
primitive progenitor cells, it is clear that synergistic cytokines may interact to 
induce cycling, proliferation and differentiation of such cells in vitro. In 1988, 
Pragnell et al first described an in vitro clonogenic assay which detected a 
multipotential progenitor cell with characteristics very similar to CFU-S day 
12 (Pragnell et al., 1988). In this assay normal murine bone marrow cells were 
grown in agar with serum supplemented medium and a source of synergising 
growth factors. In the original description the growth factors were from 
conditioned media shown to contain high concentrations of both M-CSF and
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GM-CSF (L929 (Stanley & Heard, 1977) and AF1-19T-CM(Franz etal., 
1985)) although subsequently the assay was reproduced using recombinant 
factors (Pragnell etal., 1988). Under these conditions macroscopic (2-5mm) 
colonies, containing on average 4.5 x 10^ cells per colony, developed after 11 
days in culture. The incidence of colony formation ranged from 145-200/10^ 
bone marrow cells depending on the mouse strain. These were shown to be 
derived from multipotential progenitor cells and contained precursors for 
granulocytes and erythroid cells in addition to macrophages (Pragnell et al., 
1988). On further examination, colonies <2mm were found to be derived from 
cells in cycle, whereas colonies >2mm were derived from minimally cycling 
cells. For this reason a 2mm cut off was used for CFU-A determination.
CFU-A were compared with CFU-S day 12 in a number of ways 
(Pragnell et al., 1988; Lorimore et al., 1990). Their recovery profile following 
a single dose of 5-FU showed a main peak at days 12-15, an identical pattern 
to CFU-S day 12. CFU-A were found to be replatable and to produce a low 
number of CFU-A colonies >lmm in diameter. Furthermore, CFU-A plucked 
at day 5 of culture were capable of producing CFU-S day 12, suggesting a 
similar capacity for self-renewal as that described for CFU-S. CFU-A and 
CFU-S day 12, derived from normal bone marrow were found to be out of 
cycle (<10% in S phase), whereas those derived from regenerating bone 
marrow were actively cycling (30% in S phase). When these two respective 
populations (i.e. quiescent and proliferating) were exposed to a proliferation 
stimulator (Lord et al., 1977) or inhibitor (Lord et al., 1976) respectively, both 
CFU-A and CFU-S day 12 responded in an identical manner. The quiescent 
progenitors entered cell cycle and the proliferating progenitors became 
quiescent (Pragnell et al., 1988). Further studies compared the buoyant cell 
density and response to ionising radiation of CFU-A and CFU-S and both 
parameters were found to be similar for the two progenitor populations, but 
different to the more committed CFU-GM progenitor (Lorimore et al., 1990).
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Murine CFU-A therefore derive from that part of the stem cell compartment 
measured by the in vivo CFU-S day 12 assay. The incidence for CFU-A is 
nearly 10 fold greater than for CFU-S but this may be explained by the fact 
that only a proportion of the bone marrow innoculum actually seeds to the 
spleen in the CFU-S assay. CFU-A appear to overlap with that part of the stem 
cell compartment detected by the more mature HPP-CFC. Since the original 
description, the murine CFU-A assay has proven indispensable for studies of 
stem cell regulation and led to the identification and purification of a stem cell 
inhibitor now known to be MIP-la (Graham et al., 1990). More recently an 
equivalent in vitro assay for the detection of human CFU-A was reported 
(Holyoake etal., 1993).
In transplantation studies, CFU-S day 12 have been shown to be 
crucial for transient engraftment following BMT (Jones et al., 1989; Jones et 
al., 1990), therefore an in vitro correlate of CFU-S day 12 should be capable 
of measuring that part of the stem cell compartment responsible for the early 
phase of bone marrow engraftment.
1.9 CFC-blast assay
The original description of murine blast cell colonies was of small colonies 
consisting of only blast cells on day 16 of cultures supported by pokeweed 
mitogen stimulated spleen cell conditioned medium (Nakahata & Ogawa, 
1982a; Nakahata & Ogawa, 1982b). These colonies were derived from cell 
cycle dormant progenitors and, unlike the majority of colonies which develop 
in semisolid cultures, could contain up to 100% replatable CFU-C (Suda et al., 
1983). CFU-blast were slow to proliferate in culture and were more primitive 
than CFC that readily form colonies in semi-solid cultures (Suda et al., 1983). 
This assay, therefore, provides an excellent means of studying the 
commitment and differentiation of primitive cells.
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1.10 Cobblestone Area Forming Cell (CAFC) and Long Term Culture 
Initiating Cell (LTCIC) assays
Cobblestone areas are clones of haemopoietic cells situated beneath the 
stromal layer in LTBMC (Dexter et al., 1977). They can be differentiated 
from the stromal cells and from more mature cells sitting on top of the stroma 
by phase-contrast microscopy. The production of mature CFC in LTBMC has 
been shown to be associated with the presence of these cobblestone areas 
(Ploemacher et al., 1989). These observations prompted Ploemacher et al to 
develop the CAFC assay as a means of scoring stem cell subsets (Ploemacher 
et a l , 1989). The CAFC assay is a miniaturised murine LTBMC performed in 
limiting dilution. It allows detection of subsets of the stem cell compartment 
depending upon the time of appearance of the cobblestone areas. Detection 
and quantification of these in vitro cobblestone areas was shown to correlate 
closely with stem cell subsets detected in vivo (Ploemacher et al., 1989; 
Ploemacher et al., 1991). CAFC detected on day 10 and 28 of culture 
correlated with CFU-S day 12 and long term repopulating cells respectively 
(Ploemacher etal., 1989; Ploemacher etal., 1991). The"test" cells are overlaid 
on pre-established stromal layers in 96-well microtitre plates following a 
limiting dilution protocol. At weekly intervals, or more often, the wells are 
scored for the presence/absence of cobblestone areas. Poisson statistics are 
employed to determine the stem cell frequencies. In normal murine bone 
marrow CAFC numbers per 10^ cells range between 100-300 CAFC-10 (i.e. 
very similar to CFU-A), 1-5 CAFC-28 and 0.3-1.0 CAFC-35 (Ploemacher, 
1994).
The LTCIC assay is an indirect means of quantifying primitive HSC 
by assessment of the number of clonogenic progenitors they produce after at 
least 4 weeks in LTBMC (Van der Sluijs et a l , 1990; Sutherland et al., 1990). 
In the presence of a stromal layer, the clonogenic cell output was shown to be 
linearly related to the input cell number over a wide range of cell
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concentrations (Sutherland et al., 1990). The frequency of LTCIC may be 
determined by limiting dilutions techniques similar to those employed for the 
CAFC except that instead of scoring cobblestone areas, the cultures are fed 
weekly and then both the supernatant cells and the adherent layer are 
sacrificed and replated into clonogenic assays to determine the clonogenic 
progenitor output (Sutherland & Eaves, 1994). CAFC have been correlated 
with LTCIC by first scoring cobblestone areas and then plating the contents of 
the well into CFU-GM assay (Ploemacher et al., 1989). The proliferative 
capacity of individual LTCIC was shown to be highly variable with a range of 
1-30 CFU-GM produced per LTCIC (Sutherland et al., 1990). Therefore, both 
CAFC and LTCIC assays detect a range of stem cell subsets. The CAFC 
appearing late in culture and the LTCIC with high proliferative capacity 
representing the more primitive subsets.
1.11 Self-renewal versus differentiation
Two major models are proposed to explain the concept of stem cell self­
renewal versus differentiation. Stochastic models, supported, for example, by 
Ogawa (Ogawa, 1993), suggest that the decision of HSC, either to self-renew 
or to differentiate may be a random process with survival and proliferation of 
progenitor cells controlled by cytokines.
On the other hand, deterministic models, supported, for example, by 
Uchida et al (Uchida et a l , 1993) suggest that the HSC pool is heterogeneous 
and the outcome for an individual HSC is dependent on some unknown 
property of that cell such as the number of divisions already undergone. 
Commitment to differentiation may then be influenced by the surrounding 
microenvironment and the cytokines / inhibitors present. Currently available 
evidence tends to support the latter model.
There is ample evidence that the HSC pool is a heterogeneous 
population comprised of largely quiescent HSC, self-renewing stem cells and
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multipotential cells which do not self-renew, but expand to give rise to 
committed progenitor cells (Ploemacher & Brons, 1989; Spangrude &
Johnson, 1990; Uchida et al., 1994). Heterogeneity has been demonstrated in 
vivo by transplantation of highly purified cells whose progeny can be detected 
as donor derived at varying time points after BMT (Uchida et al., 1993). In 
this model, the proliferative life history of a single HSC limits its potential for 
further self-renewal, i.e. an individual HSC "ages" after a finite number of 
divisions and leaves the HSC compartment to differentiate.
Evidence suggesting that HSC may be developmentally regulated may 
be found in B and T cell differentiation and in erythroid development.
Firstly, it appears that fetal HSCs are able to give rise both to 
conventional B cells and to CD5 positive (Ly-1) B cells, whereas adult bone 
marrow HSCs may give rise only to conventional B cells (Hayakawa et al., 
1985).
Secondly, Ikuta et al have shown that fetal liver derived HSCs have a 
predetermined developmental potential for T cell differentiation which differs 
from that of adult bone marrow derived HSCs (Ikuta & Weissman, 1991).
Thirdly, fetal erythrocytes differ from adult erythrocytes in terms of 
size, the presence of a nucleus and the expression of fetal-type rather than 
adult-type globin (Fantoni et al., 1967). These findings, taken together, 
suggest that fetal HSCs have the developmental potential to give rise to both 
fetal-type and adult-type cell lineages, but that adult HSC may only 
differentiate into adult-type lineages.
Finally, it has been proposed that loss of telomeric DNA from the 
ends of human chromosomes at the time of cell division, sequentially leads to 
ageing / senescence of that cell. Since telomeres are critical for chromosome 
stability, loss of telomeric length may be responsible for cells exiting from cell 
cycle after a "pre-determined" number of divisions. Recently, Vaziri et al 
demonstrated that highly purified human candidate stem cells at varying
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stages of development (i.e. cells from fetal liver, umbilical cord blood and 
adult bone marrow) had differing telomeric lengths, suggesting that those with 
shorter telomeres (adult bone marrow) had reduced proliferative potential as a 
result of ageing (Vaziri et al., 1994).
These four examples strengthen the argument that stem cells are 
regulated, in part, by pre-determined factors which are integral to the 
individual stem cell subset, be it fetal derived or adult derived. Cytokines may 
then act to modify stem cell responses depending on the requirement for 
differentiated progeny at any point in time.
1.12 Haemopoietic growth factors (cytokines)
The first CSFs to be discovered included M-CSF, G-CSF, GM-CSF and IL-3 
(Sachs, 1992). However, over recent years an array of CSFs, interleukins and 
other cytokines have been cloned. These soluble factors are capable of 
affecting haemopoietic cell growth and differentiation and, in general, 
combinations of synergising growth factors are required for optimum 
proliferation. The function of cytokines is not restricted to the haemopoietic 
system and these factors have important roles in defence against infection, 
wound healing, angiogenesis and inflammation.
Haemopoiesis may be a flexible enough system to respond rapidly 
when an increase in cell production is necessary, but equally to "quench” the 
system when the requirement for increased cell production is over. This 
suggests the need for both inducers and inhibitors of proliferation. Each 
cytokine is the product of multiple cell types and many appear to exhibit 
functions which overlap with other cytokines (i.e. redundancy). Furthermore, 
many cytokines are polyfunctional, with multiple effects both within and 
outwith the haemopoietic system. This produces a network effect which 
includes positive stimulation by CSFs and interleukins, and inhibition by 
negative regulators such as TGF-0, MIP-la and TNF. Normal myeloid
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precursor cells depend on exogenous cytokines for viability as well as 
proliferation and differentiation. In the absence of cytokines, these cells die by 
programmed cell death or apoptosis (Williams et al., 1990b).
There are a numbers of observations which, together, suggest 
redundancy amongst the proliferative regulators of haemopoiesis.
Firstly, several cytokines show common proliferative actions. For 
example, G-CSF, GM-CSF, M-CSF, IL-3, SCF and IL-6 may all promote the 
growth of small granulocyte colonies (Metcalf, 1993).
Secondly, cytokines tend to share a range of biological effects and may 
not only effect cells from different lineages in the haemopoietic system but 
have a range of target cells outwith haemopoiesis. For example, LIF, IL-6, IL- 
11 and OSM share biological effects and are able to promote thrombopoiesis, 
stimulate the production by hepatocytes of acute phase reactants, alter 
neuronal signalling and suppress lipid transport (Metcalf, 1993). Furthermore, 
IL-6, IL-11 and LIF produce similar effects on thrombopoiesis in vivo.
Thirdly, many cytokines share receptor subunits. The receptors for M- 
CSF, and SCF are protein tyrosine kinase containing receptors which show 
structural similarity to the platelet derived growth factor (PDGF) receptor (Qiu 
et al., 1988). The receptors for many growth factors are members of a 
cytokine receptor superfamily. This family is characterised by conserved 
elements in the extracellular domains suggesting the possibility that these 
receptors are derived from a common ancestral receptor (Metcalf, 1993; Ihle 
et a l , 1994). These receptors have a specific a-chain but, whereas GM-CSF, 
IL-3 and IL-5 share the same p-chain, IL-6, LIF, OSM and IL-11 all share 
another common p-chain, the gpl30 molecule (Metcalf, 1993; Ihle et al.,
1994). Since the p-chain appears dominant in intracellular signalling, this may 
explain the similarities of action of GM-CSF, IL-3 and IL-5 and of LIF, IL-6, 
OSM and IL-11. Why then should individual cells require multiple receptors 
which share and signal via the same p-chain?
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The question of cytokine redundancy has, in part, been answered by 
the study of animals in which the gene in question has been deleted or 
functionally inactivated (knockouts). To date, cytokine knockouts of G-CSF, 
GM-CSF, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, LIF, TGF-P and others, yet to be 
published formally, have been engineered (Brandon et al., 1995). In addition, 
mice with a genetic defect causing osteopetrosis (op/op) have been shown to 
have inactivation of the M-CSF gene (Yoshida et al., 1990), and both Steel 
(SI) and white spotting (W) anaemic mice have now been shown to be 
genetically deficient in SCF and c-kit (its receptor) respectively (Russell, 
1979).
The availability of gene knockout animals and mutations occurring 
spontaneously in vivo, have allowed investigators to learn more regarding the 
role of individual cytokines. For example, G-CSF knockouts suffer severe 
neutropenia but some normal mature neutrophils are still present suggesting 
that other cytokines are able to partially compensate for the lack of G-CSF 
(Lieschke et al., 1994). GM-CSF knockouts show pulmonary pathology, but, 
surprisingly, have apparently normal haemopoiesis (Stanley et al., 1994). C- 
Mpl is a proto-oncogene and a member of the cytokine receptor superfamily 
(Gurney et al., 1994). The ligand to c-Mpl, named thrombopoietin, was 
recently cloned and found to have potent effects on megakaryocytopoiesis (de 
Sauvage et al., 1994). C-Mpl knockouts have reduced platelet numbers and 
increased serum thrombopoietin but are still able to produce some functional 
platelets in the absence of signalling via c-Mpl (Gurney et al., 1994).
Likewise, op/op M-CSF deficient mice exhibit a major deficiency in 
macrophage-derived osteoclasts and partial deficiency of other macrophage 
populations which are relieved by injection of M-CSF. However, since these 
mice are not completely devoid of macrophages, other cytokines must be 
partly able to compensate for the deficiency (Yoshida et al., 1990). SI and W
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mice show similar phenotypes including severe anaemia and deficiency of 
very primitive HSC.
The conclusions which may be drawn, from the knowledge currently 
available, are that in certain instances cytokines are essential for normal 
development and blood cell production. Although cytokines have a number of 
such unique effects which cannot be compensated for by other cytokines they 
also possess redundant actions for which alternative cytokines may substitute.
1.13 Stem Cell Factor
The cloning of SCF provided a major advance to the understanding the 
cytokine interactions which controlled the proliferation of early haemopoietic 
stem cells. SCF, first identified in 1990 (Anderson et al., 1990; Copeland et 
al., 1990; Huang et al., 1990; Martin et al., 1990; Williams et al. 1990a;
Zsebo et al., 1990a; Zsebo et al., 1990b), is the ligand for the receptor 
encoded by the c-kit proto-oncogene (Qiu et al., 1988). In mice, mutations 
may either effect the locus of c-kit (White Spotting W locus) or its ligand 
(Steel SI locus), resulting in variable defects in pigmentation, fertility and 
haemopoiesis (reviewed by Williams et al., 1992).
SCF exists in both soluble and membrane bound forms. SI mutant 
mice synthesise soluble SCF, which is active in vitro, but fail to make the 
membrane bound form. Since these mice exhibit an obvious phenotype, this 
suggests that membrane bound SCF has a critical role in stem cell-stromal 
interactions in the intact organism that is not duplicated by the soluble 
molecule. The fact that defects in the production or action of SCF lead to 
bone marrow failure in mice, suggests that this cytokine is likely to play a 
major physiological role in stem cell development and in haemopoiesis.
Ogawa et al used an anti-c-kit antibody to demonstrate that nearly all in vitro 
clonogenic cells, including CFU-S, derived from bone marrow or spleen
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expressed c-kit (Ogawa et al., 1991). Furthermore, bone maiTow stromal cells 
actively produce both soluble and membrane bound SCF.
As predicted, SCF has been shown to be a potent stimulator and 
regulator of early events in haemopoiesis (de Vries et al., 1991; Ogawa et al.,
1991). SCF may shorten the dormant phase of stem cells (Tsuji et al., 1991) 
and enhanced survival of highly enriched murine progenitor cells under serum 
free conditions (Heyworth et al., 1992). To date, no convincing evidence has 
yet been published indicating that SCF promotes self-renewal of HSC.
Acting alone, SCF has little proliferative activity, however it can 
synergise with a number of cytokines to stimulate growth of haemopoietic 
progenitor cells in vitro. For example, the addition of SCF, which did not act 
alone, to low levels of combinations of M-CSF, G-CSF, GM-CSF, IL -la  and 
IL-3, which without SCF showed little or no clonogenic capacity, consistently 
increased HPP-CFC colony number and size to the degree produced when all 
5 growth factors were used at plateau concentration (Lowry et al., 1991;
Lowry et al., 1992). In addition to potent effects on granulocyte and 
macrophage precursors, SCF has been shown to exert effects on erythropoiesis 
(Anderson et al., 1991; Dai et al., 1991), mast cell generation (Huang et al., 
1990; Williams et al., 1990a), T and B cell lymphopoiesis (Williams et al.,
1992), and megakaryopoiesis (Briddell et al., 1991). Although all these 
lineages are affected by SCF in vitro, and often in vivo, the impact of 
mutations in SI mice is preferentially seen in erythroid and mast cell 
differentiation, with minimal effects on the remaining pathways. These 
findings suggest that SCF independent pathways exist for megakaryopoiesis 
and for both granulopoiesis and macrophage production (Williams et al., 
1992).
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1.14 Interleukin-11
IL-11 was first cloned from a primate bone marrow derived stromal cell line, 
PU-34, as a factor which stimulated proliferation of an IL-6 dependent murine 
plasmacytoma cell line (Paul et al., 1990). A second group, working 
separately, cloned a novel adipogenesis inhibitory factor from the human bone 
marrow derived cell line KM-102, which they later found to be identical to IL- 
11 (reviewed in Kawashima & Takiguchi, 1992).
Both the murine and human IL-11 receptors have recently been cloned 
and show 82% sequence homology (Hilton et al., 1994; Cherel et al., 1995). 
IL-11 belongs to the family of cytokines that use the gp 130 transducing 
subunit in their high affinity receptors.
IL-11 is a multifunctional cytokine with a range of biological activities 
which resemble those of IL-6. These effects include stimulation of T cell 
dependent development of immunoglobulin producing B cells (Anderson et 
al., 1992), synergism with other cytokines to support murine and human 
megakaryopoiesis (Paul et al., 1990) and erythropoiesis (Quesniaux et al.,
1992), the ability to shorten the dormant period of stem cells (Musashi et al., 
1991), induction of secretion of acute phase proteins in the liver and the 
inhibition of adipose conversion in the bone marrow (Kawashima & 
Takiguchi, 1992).
Like SCF, IL-11 has little activity as a single factor but was shown to 
act synergistically with other cytokines, such as IL-3 and SCF, to increase 
murine blast and CFU-GEMM colony formation (Tsuji et al., 1992). When 
added to LTBMC, IL-11 stimulated expansion of CFU-GM and CFU-S day 
12, but at the expense of LTRC, suggesting that, in this setting, it may have 
increased commitment of HSC into the multipotential progenitor compartment 
(Du etal., 1995).
In vivo, in normal rodents, IL-11 stimulated a marked increase in the 
numbers of bone marrow megakaryocytes and circulating platelets (Du &
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Williams, 1994). Given to mice following BMT, neutrophil and platelet 
recovery was enhanced, and this was accompanied by increased numbers of 
progenitors in the bone marrow and spleen (Du etal., 1993b). Haemopoietic 
recovery, following administration of cytotoxic agents, was also accelerated 
by IL-11 administration (Du & Williams, 1994). More recently IL-11 was 
shown to protect clonogenic stem cells in murine gastrointestinal mucosa from 
the effects of radiation and chemotherapy (Keith etal., 1994; Potten, 1995).
IL-11 is, therefore, a stromal derived cytokine with a distinct 
biological profile from IL-6. It shows pleiotropic effects on haemopoiesis, 
presumably depending on the surrounding cellular and cytokine environment. 
Some of its effects are consistent however, and include stimulation of 
megakaryopoiesis and early HSC.
1.15 SCF / IL-11 interactions in vitro and in vivo 
SCF and IL-11 are both stromal derived cytokines which, though relatively 
inactive as single factors, synergise with a range of cytokines to promote 
proliferation and differentiation of HSC. SCF, used alone, promoted HSC 
survival but did not induce their proliferation (Katayama et al., 1993). In 
combination with other cytokines, both SCF and IL-11 were able to shorten 
the dormant period of HSC and so trigger their entry into cell cycle (Musashi 
et al., 1991; Tsuji et al., 1991). Both cytokines have effects on early and late 
stages of myelopoiesis, including erythropoiesis and megakaryopoiesis.
It would be expected, therefore, that combination of these two 
cytokines should stimulate potent synergistic effects in terms of progenitor 
expansion in vitro. Several groups have demonstrated that this is, indeed, the 
case. Tsuji et al showed that SCF and IL-11, in the presence of serum, 
interacted to support formation of multilineage colonies (Tsuji et al., 1992). 
Quesniaux et al, showed, that in the presence of either IL-3 or SCF, IL-11 had 
profound stimulatory effects on primitive multilineage progenitor cells and on
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various stages of erythroid differentiation. In addition, SCF with IL-11 
stimulated the growth of very large, highly proliferative, erythroid colonies 
which, upon morphological examination, were pure erythroblast colonies 
(Quesniaux et al., 1992). Neben et al examined the effects of SCF, IL-3, IL-11 
and IL-6 as single factors and in different combinations for their ability to 
induce expansion of CFU-S, CAFC and LTRC. Although several 
combinations promoted expansion of more committed progenitors, the 
recovery of LTRC was found to be enhanced four fold when SCF and IL-11 
were combined, compared with the use of SCF alone (Neben et al., 1994).
In vivo studies have also shown that SCF and IL-11 synergise, when 
administered in combination, to promote accelerated haemopoietic recovery, 
following BMT and to promote mobilisation of HSC (Du et al., 1993a; Mauch 
et al., 1995).
1.16 Macrophage Inflammatory Protein-1 a
M IP-la is one member of the chemokine (chemotactic cytokine), or platelet 
factor 4 (PF4) superfamily. The members of this group of cytokines are 
related by structural similarities and by the conservation of a four cysteine 
motif. The family is further subdivided on the basis of this cysteine motif, 
with the "C-X-C" branch characterised by separation of the first two cysteines 
by an intervening amino acid, and the "C-C" branch having the first two 
cysteines directly adjacent. MIP-la belongs to the "C-C" branch of the family 
(Schall, 1991).
In 1988, Wolpe and co-workers identified MIP-1, (now known to be 
composed of MIP-la and MIP-1 P), in mouse macrophages (Wolpe et al., 
1988). At that time, MIP-1 was described as an acidic, heparin-binding 
protein, that resolved as a doublet of 8,000 daltons on SDS-PAGE. This 
protein caused inflammatory reactions in the footpads of mice. In 1990, 
Graham et al, identified and characterised a potent, reversible, inhibitor of that
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part of the stem cell compartment measured by CFU-S day 12/CFU-A, which 
was shown to be identical to the major component of the doublet, MIP-la, 
and to the previously reported CFU-S inhibitory activity obtained from 
primary cultures of normal bone marrow (Lord et al., 1976; Graham et al., 
1990;).
Members of the chemokine family exhibit a wide range of diverse 
functions including monocyte, T-cell and neutrophil activation (Schall, 1991). 
Although M IP-la 's primary property appears to be as an inflammatory 
mediator, it may also regulate haemopoietic stem cell proliferation under 
certain circumstances (Graham et al., 1990; Graham et al., 1992;). In the 
original report (Graham et al., 1990), conditioned medium from normal bone 
marrow had been shown to inhibit the development of macroscopic colonies 
in the murine CFU-A assay. The macrophage cell line J774.2 was used as a 
source of conditioned medium, and the CFU-A assay, as a read-out for stem 
cell inhibition, to follow purification of MIP-la to homogeneity. The active 
fractions inhibited CFU-A colony formation and reduced the proportion of 
CFU-A or CFU-S day 12 that were in cycle. The components of the doublet 
were resolved as MIP-la and MIP-1 p.
Investigations performed by our group (Graham et al., 1993) revealed 
that members of the C-C family including MIP-la, MIP-1 p, LD78 and ACT-2 
were all active as stem cell inhibitors in the murine CFU-A assay. These more 
recent data, using purified MIP-1 p, were likely to be more accurate than 
earlier reports (in which MIP-1 P levels were not accurately measured) which 
suggested that the chemokine was inactive as a stem cell inhibitor (Graham et 
al., 1990). Although definitely active, both MIP-1 p and its human homologue 
ACT-2 were 10-20 times less active than MIP-la or its human homologue 
LD78. The remaining C-C chemokines including RANTES, MCAF and TCA- 
3 and the C-X-C chemokines IL-8 and MIP-2 were all inactive when used in 
the CFU-A assay (Graham et al., 1993).
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The studies described above were performed using murine cytokines 
(or their human homologues) on a restricted target population (i.e. murine 
CFU-A). Broxmeyer et al have reported data which appear to conflict those of 
our own group (Broxmeyer et al., 1990; Broxmeyer et al., 1991). In an early 
report by Broxmeyer et al, murine MIP-1 (3 was found to be inactive on either 
murine or human CFU-GEMM, BFU-E and CFU-GM, whereas under 
identical circumstances M IP-la was shown to be inhibitory. Since Broxmeyer 
et al have also reported stimulation of more mature CFU-GM by M IP-la 
whilst we have seen no such effect, these differences are likely to reflect 
variation in the assay systems used (Broxmeyer et al., 1990). For example, 
since CFU-A may be inhibited nearly 100% by M IP-la but require 20 fold 
more MIP-1 (3 for the same effect it is possible that more mature progenitors 
described by Broxmeyer (which are only inhibited by approximately 50%) 
may not respond to the weaker inhibitor MIP-1 (3 at the concentrations used. 
Broxmeyer also observed no effect with MIP-1 P when used in vivo (Maze et 
al., 1992). The more recent study by Broxmeyer et al was even more difficult 
to compare with our own work since only human cytokines were tested for 
their effects on human haemopoietic cells (Broxmeyer et al., 1993). In that 
study, chemokines from both the C-C and C-X-C families were assessed for 
their ability to inhibit colony formation (CFU-GEMM, BFU-E and CFU-GM). 
The chemokines were each tested at concentrations up to lOOOng/ml. M IP-la 
(C-C), MIP-2a (C-X-C), PF4 (C-X-C), IL-8 (C-X-C) and MCAF (C-C) all 
inhibited colony formation by approximately 50% of control whereas MIP-1 P 
(C-C), MIP-2P (C-X-C), GRO-a (C-X-C), NAP-2 (C-X-C) and RANTES (C- 
C) were inactive. Using the murine CFU-A assay, our group has never 
demonstrated inhibition by members of the C-X-C family but consistently 
observed inhibition by MIP-1 P within the concentration range tested by 
Broxmeyer et al (Broxmeyer et al., 1993). Using the more mature progenitor 
assays (compared with CFU-A), Broxmeyer was unable to demonstrate 100%
24
inhibition even if five active chemokines were combined, each at lOOng/ml 
(Broxmeyer et al., 1993). This suggests that the target population detected by 
these assays contains progenitors which are both responsive and unresponsive 
to the effects of chemokines. In the same report, Broxmeyer showed that those 
chemokines with inhibitory properties were able to synergise when combined 
with each other to produce the same level of inhibition (i.e. 50%) even at 
concentrations reduced by 2, 500 fold (Broxmeyer et al., 1993). The 
inhibitory effects of IL-8 and PF4 on human myeloid cells have been 
confirmed in a further very recent report by the same group (Daly et al.,
1995). In addition a novel member of the C-C family called MIP-related 
protein-2 has also been reported to inhibit the growth of both human and 
murine myeloid colonies (Youn et al., 1995).
It is unfortunate that the assay systems used by Broxmeyer's group and 
by our own group were so different. In addition the majority of the work 
performed by Broxmeyer was on human rather than on mouse cells. 
Nevertheless it seems surprising that the differences observed appeared so 
great. It is, however, possible that chemokines may be suppressive, 
stimulatory or have no effect depending both on the target cell involved and 
the surrounding environment including both stromal elements and other 
cytokines present.
A range of investigations have revealed a further area of conflict 
between our results and those of Broxmeyer. When present in solution at 
relatively high concentration, MIP-la is known to aggregate. The M IP-la 
monomer is only 8kDa, however the more usual polymer is often >100kDa in 
size. Graham et al have produced non-aggregating mutants of M IP-la which 
showed an activity identical to the wild type protein (Graham et al., 1994).
The mutant was no more active than the wild type protein, suggesting that the 
aggregation seen at high concentrations resolved upon addition to a solution or 
to the CFU-A assay when a large dilution factor was operating. Both mutant
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and wild type M IP-la were active in vivo at equivalent doses. On the other 
hand, Broxmeyer's group suggested that polymerised M IP-la was completely 
inactive and that the inhibition observed was produced by tiny (<0.3% of 
total) quantities of MIP-la present in monomeric from (Mantel et al., 1993). 
Broxmeyer used MIP-la diluted in acetonitrile to maintain the monomeric 
form. In one report he demonstrated that monomeric M IP-la was fully active 
at concentrations as low as 0.5ng/ml in vitro and 4-8ng per mouse when used 
in vivo (Cooper et al., 1994). Even using the preparation diluted in 
acetonitrile, our group has been completely unable to reproduce these data.
The issues discussed above are clearly difficult to resolve. There are no 
other investigators who have performed such in depth studies of chemokines 
in general, and of MIP-la in particular, to obtain further information from. 
The inhibitory effects of the different family members may only be resolved 
by performing the same progenitor assay, with the same human or murine 
cells and the same cytokine preparation. To my knowledge, this has never 
been done. If possible, it would be better to work with a formulation of MIP- 
l a  that did not aggregate. We have no way of determining whether the non­
aggregating mutant produced in our laboratory would show the same potency 
as the wild type monomer diluted in acetonitrile and investigated in the 
laboratory of Broxmeyer et al. It remains questionable whether such tiny 
quantities of M IP-la could be truly active. No other groups working in the 
area have confirmed this aspect of Broxmeyers work.
The primary structure of the family of receptors for chemokines 
revealed that they are members of the superfamily of G protein-coupled 
receptors containing seven transmembrane domains. The first receptors to be 
cloned belonged to the C-X-C family (discussed in Graham et al., 1993), 
however, more recently, Neote et al cloned a C-C receptor which bound 
human and murine MIP-la, human MIP-1 (3, human MCP-1 and RANTES 
(Neote et al., 1993). This receptor, C-C CKR-1, was expressed by a variety of
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haemopoietic cell lines and was widely expressed in different haemopoietic 
cells. Since the chemokines, MIP-la in particular, showed a range of 
biological activities, it was possible that not all these activities were mediated 
via the cloned C-C receptor. However, since the stem cell inhibitory activities 
of M IP-la were not species specific and C-C CKR-1 bound both human and 
murine M IP-la with equal affinity, this suggested that the C-C receptor was 
probably responsible for affects on stem cell proliferation (Neote et al., 1993). 
This question requires further investigation.
Although the effects of MIP-la on haemopoietic cells were initially 
thought to be restricted to inhibition of stem cell proliferation (i.e. CFU- 
S/CFU-A), Broxmeyer et al demonstrated that MIP-la could be either 
inhibitory or stimulatory, depending on the combination of cytokines selected 
to promote colony growth. For example, when single cytokines, such as M- 
CSF or GM-CSF, were selected to promote the development of mature 
progenitor cells, the addition of MIP-la resulted in enhanced colony 
formation. However, when GM-CSF was combined with IL-3 to promote the 
proliferation of immature progenitors, the effect of MIP-la was consistently 
inhibitory (Broxmeyer et al., 1990). These apparently opposing effects are 
likely to reflect differences between more mature or more primitive progenitor 
cells. For example, primitive cells may express a higher number of receptors 
for MIP-la, or the same number of receptors may be upregulated on primitive 
cells. Equally it is possible that different receptors exist for inhibition versus 
stimulation. Finally, the response of an individual cell is dependent on a 
number of factors acting in conceit. Its overall response (i.e. inhibition versus 
stimulation) may therefore reflect its ability to interact with the haemopoietic 
microenvironment and with other synergising cytokines.
The Vancouver group demonstrated control of primitive progenitor 
cell proliferation by negative regulators in LTBMC. Both TGF-(3 and M IP-la 
were shown to be produced in the adherent layer of LTBMC, in which the
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HSCs resided (Eaves et al., 1991; Otsuka et al., 1991). In undisturbed 
cultures, the primitive stem cells in the adherent layer were maintained in a 
quiescent state, presumably by regulators such as M IP-la and TGF-p. 
However, upon fresh medium change, or addition of stimulatory cytokines, 
these cells were shown to transiently enter cell cycle (Cashman et al., 1985; 
Cashman et al., 1990). It appeared, therefore, that the cycle status of primitive 
progenitors was dependent on the balance of inhibitors and stimulators, either 
produced endogenously in, or added exogenously to, the culture. This was 
confirmed in a series of experiments where either TGF-P or MIP-la, added 
exogeneously at the time of fresh medium change, was able to prevent entry 
of primitive progenitors into cell cycle. These inhibitors were also able to 
prevent the entry into cell cycle induced by addition of IL-1 (Cashman et al., 
1990; Eaves et al., 1993). These effects were restricted to primitive 
progenitors (CFU-GM and BFU-E of larger size and appearing later in 
culture) with no effect on more committed cells.
The inhibitory effects of TGF-p, in LTBMC, were reversible by the 
addition of anti-TGF-p antibody which could prolong or reactivate primitive 
progenitor proliferation when added to either previously stimulated or 
quiescent cultures. The latter effect, on quiescent cultures, was not 
consistently reproducible, perhaps because MIP-la, or another unknown 
inhibitor, was present in sufficient amounts to maintain stem cell quiescence, 
even in the absence of TGF-P, in some of the cultures (Eaves et al., 1991). 
Similar experiments, using an antibody to MIP-la, were never performed. 
Instead, MIP-1 p was used to reverse the effects of MIP-la, as described by 
Broxmeyer et al (Broxmeyer et al., 1991). MIP-1 p, which binds to the same 
receptor and therefore competes with MIP-la for receptor binding, was able 
to maintain progenitors in the activated state several days after fresh medium 
change, suggesting that endogenously elaborated MIP-la was at least partly 
responsible for the return to quiescence which had been observed (Eaves et
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al., 1993). These findings strongly suggested that both TGF-P and MIP-la, 
produced by bone marrow stroma, were required to maintain primitive 
progenitors in a quiescent state. Exactly how these two inhibitory proteins 
interact is unknown, but it seems possible that both play a crucial role in stem 
cell regulation.
In 1995, Cook et al described experiments performed with mice in 
which the gene encoding MIP-la had been disrupted. In view of the inhibitory 
effects of MIP-la on haemopoietic stem cells, these researchers looked 
carefully for evidence of effects on haemopoiesis in the "knock-out" animals. 
The -/- mice were shown to lack any overt haemopoietic abnormalities, 
however they were resistant to Coxsackie virus induced myocarditis and had 
reduced pneumonitis during influenza infection. These experiments confirmed 
the requirement for MIP-la for an inflammatory response and confirmed that 
no other chemokines fulfilled that function in the absence of M IP-la (Cook et 
al., 1995). The lack of a haemopoietic phenotype in the null animals was not 
surprising. As discussed earlier, cytokines are often pleiotropic with 
overlapping functions and apparent redundancy. It is most likely that M IP-la 
plays a role in stem cell inhibition in vivo, but that this role may be performed 
by an alternative negative regulator in the absence of MIP-la.
It is possible that the interaction of negative regulators and stimulatory 
cytokines could be manipulated in vitro to encourage expansion of stem and 
progenitor cells, without exhausting pluripotent stem cells. Whether TGF-P 
and M IP-la require interaction with stroma to exert their effects and whether 
the effects observed are due solely to the negative regulators, or to interactions 
with these and other molecules / factors secreted by marrow stroma remains 
unclear. These questions have been addressed, in part, by Verfaillie and 
colleagues.
Verfaillie et al have carried out a series of experiments using highly 
purified human stem and progenitor cells. Careful comparisons have been
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made between cytokine supplemented, but stroma free, cultures, standard 
LTBMC with the haemopoietic cells in direct contact with bone marrow 
stroma, "stroma non-contact" cultures, in which the stromal layer was 
separated from the stem and progenitor cells by a 0.4jim porous membrane 
called a Transwell insert and stroma free cultures supplemented with 
conditioned medium derived from bone marrow stroma (SCM). The major 
endpoints of these experiments were to determine stroma and cytokine 
requirements which would allow expansion of colony forming cells ex vivo, 
but with maintenance or expansion of LTCIC. Cultures were maintained for 5- 
8 weeks.
The most important findings from these studies were as follows: 
conditions in which human CD34 positive HLA-DR negative (CD34+ DR-,
0.1-0.4% of bone marrow) stem and progenitor cells were cultured, in direct 
contact with stroma for 5 weeks, allowed only 20% of input LTCIC to be 
maintained, however maintenance was improved to 50% for stroma non- 
contact cultures (Verfaillie, 1992). This finding suggested that a proportion of 
HSC maintained in direct contact with stroma were unable to proliferate 
sufficiently to allow maintenance of LTCIC. No efforts have been made, in 
the studies reported to date, to prove whether this was due to close proximity 
of HSC to locally high concentrations of negative regulators such as TGF-P 
and MIP-la. When CD34+ DR- cells were cultured in the presence of 
cytokines, but in the absence of stroma or SCM, maintenance of LTCIC was 
poor (Verfaillie, 1993). These findings suggested that a soluble factor(s), 
which was able to pass through a Transwell insert, was required to induce 
maturation of primitive progenitor cells (to maintain CFU-GM output) and to 
prevent terminal differentiation of the primitive LTCIC pool (LTCIC 
maintenance) (Verfaillie, 1993). This possibility was strengthened by further 
experiments (Verfaillie, 1993). CD34+ DR- cells were cultured in stroma free, 
cytokine free cultures which were then supplemented daily with SCM. In
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these experiments, LTCIC were maintained at 50% of input, equivalent to a 
stroma non-contact culture, confirming that soluble factors were sufficient, in 
the absence of either stroma or additional cytokines to maintain LTCIC at 
50% of output.
The following experiments were aimed to further increase maintenance 
of LTCIC. A range of stimulatory cytokines were used to supplement stroma 
non-contact cultures, either singly or in combination. IL-3 had no effect on 
LTCIC maintenance at 5 weeks, but caused LTCIC exhaustion by 8 weeks 
compared with cultures without cytokines. Multiple cytokines consistently 
produced exhaustion of the cultures with loss of LTCIC (Verfaillie, 1993). 
These results suggested that the "anti differentiation" capacity of stromal 
derived factors may be overwhelmed by persistent stimulation by high 
concentrations of growth promoting cytokines.
Verfaillie et al then reasoned that, since basal haemopoiesis appears to 
be regulated, not only by stimulatory cytokines, but also by inhibitory factors, 
it might be necessary to combine positive and negative regulators of 
haemopoiesis to optimise both progenitor output and LTCIC maintenance 
during ex vivo culture. When TGF-p was combined with IL-3 and used to 
supplement stroma non-contact cultures, both CFC output and LTCIC 
maintenance were significantly decreased compared with unsupplemented 
cultures (Verfaillie et al., 1994). Although M IP-la added alone had no effect, 
when combined with IL-3,100% of input LTCIC were maintained for at least 
8 weeks in stroma non-contact cultures. This result was not reproducible in the 
absence of bone marrow stroma unless the culture was supplemented with 
SCM (Verfaillie et al., 1994).
From all these experiments, it appeared that MIP-la, in combination 
with another stromal derived factor(s), was able to prevent the terminal 
differentiation of LTCIC which had been induced to proliferate by IL-3. Until 
the unknown factor(s) is identified it will be impossible to determine whether
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the effects observed were directly due to M IP-la and IL-3. Once identified 
and purified it should be possible to investigate the combination of IL-3, the 
unknown factor and MIP-la for effects on LTCIC maintenance in stroma free 
cultures of highly purified cells.
The major emphasis of this groups' current work is aimed at 
examination of the role of extracellular matrix components (e.g. fibronectin, 
thrombospondin and proteoglycans) in these cultures. It is likely that such 
components may prove important for normal haemopoiesis. Murine LTBMC 
have been shown to synthesise several types of glycosaminoglycans including 
heparan sulphate, hyaluronic acid and chondroitin sulphate. In an early study, 
heparin and heparan sulphate enhanced the biological activity of acidic and 
basic fibroblast growth factors and prevented their inactivation 
(Gospodarowicz & Cheng, 1986). One year later, Gordon et al showed that 
bone marrow derived glycosaminoglycans were able to bind haemopoietic 
growth factor activity, in particular GM-CSF (Gordon et al., 1987). A later 
study demonstrated that the binding of haemopoietic cells to stromal cells 
involved heparan sulphate (Siczkowski et al., 1992). Such experiments raise 
the exciting possibility that, by careful manipulation of culture conditions, it 
may be possible to expand HSC ex vivo. They also suggest that negative 
regulators, and in particular MIP-la, may play a crucial role in preventing 
stem cell differentiation and raise the possibility that extracellular matrix 
derived factors may be equally important.
Whether MIP-la is essential for stem cell control may be revealed by 
the study of -/- animals (Cook et al., 1995). A recent report, in abstract form, 
showed that LTBMC initiated with bone marrow from MIP-la "knock-out" 
animals continued to proliferate with production of supernatant cells for 
longer than cultures initiated with wild type bone marrow (Boggs et al., 1995). 
At first, this result could be interpreted to suggest that the presence of M IP-la 
had an adverse effect on stem cell maintenance (the opposite of the effects
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shown by Verfaillie et al) however, the known inflammatory properties of 
M IP-la must be taken into account. It is quite possible that, in the absence of 
MIP-la, there was much less macrophage proliferation in the LTBMC which 
would therefore be expected to behave quite differently from wild type 
cultures.
Several studies have reported the use of MIP-la in vivo in animal 
models. When given to normal animals, MIP-la was shown to decrease the 
proportion of primitive progenitor cells in active cell cycle (Dunlop et al., 
1992; Maze et al., 1992). These effects appeared to be both dose dependent 
and reversible. These studies raised the possibility that M IP-la could be used 
to prevent cycling of normal progenitor cells during administration of cycle 
specific cytotoxic agents and thereby prevent the myelosuppression which is 
the primary adverse effect of these drugs when used clinically. M IP-la has 
been shown to be useful in this setting in two animals models. In the first 
study, in mice given two doses of cytosine-arabinoside, M IP-la was able to
protect haemopoietic stem and progenitors cells and to allow faster neutrophil 
recovery in treated animals (Dunlop et al., 1992). In the second study, M IP-la 
was able to protect the CFU-S compartment from the toxic effects of 
hydroxyurea (Lord et al., 1992).
To summarise, although M IP-la is predominantly an inflammatory 
mediator, it has been shown to have inhibitory effects on the proliferation of 
immature haemopoietic progenitor cells. These effects appear to be directed 
towards a relatively restricted part of the stem cell compartment, represented 
by CFU-S day 12 and CFU-A. The fact that M IP-la knockout animals appear 
healthy and have normal blood counts suggests that the inhibitory properties 
of the protein may overlap with those of other negative regulators suggesting 
another example of apparent redundancy. The protective effects of M IP-la on 
cytotoxic induced myelosuppression and the "antidifferentiation" effects
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demonstrated by Verfaillie and colleagues suggest potentially exciting roles 
for this protein in therapeutic use.
1.17 Stem cell purification strategies
Whilst the development of both in vitro and in vivo assay systems enhanced 
the study of regulation of the stem cell compartment, the endogenous 
production and induction of cytokines by accessory cells present in 
unfractionated bone marrow cell cultures prevented definitive conclusions 
regarding the direct actions of individual cytokines added exogeneously. 
Cytokines produced by accessory cells may have direct actions on stem and 
progenitor cells and may also act in synergy with added cytokines. 
Furthermore, in unfractionated bone marrow, HSC are present at very low 
frequencies and it is therefore necessary to enrich or purify stem cell subsets 
to allow accurate study of the mechanism of action of certain cytokines and 
cytokine combinations and to carry out biochemical studies. Cell separation 
techniques, which are now available, are based on both physiochemical and 
immunological approaches. These methods rely on very diverse cell 
characteristics which include density, affinity for plant lectins, differential 
sensitivity to cytotoxic agents, cell surface antigen expression and uptake of a 
fluorescent indicator of metabolic activity (i.e. rhodamine).
Counterflow centrifugal elutriation (CCE) can separate large numbers 
of cells, primarily by size and density (Sanderson & Bird, 1977). The cells are 
placed in a revolving chamber and as they reach equilibrium, the smaller cells 
migrate to the centre of the chamber while the larger ones sediment towards 
the outer end. With changes in the flow rate of elutriation liquid to overcome 
the centrifugal force, cells in different size categories can be collected.
The basis of fluorescence activated cell sorting (FACS) is to label cells 
with one, or a variety, of fluorescent markers to select cell populations, firstly 
on the basis of density, then to sort the cells of interest using a flow cytometer
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on the basis of forward angle light scatter (a measure of cell size) and right 
angle light scatter (a measure of cellular heterogeneity and fluorescence 
intensity).
In the mouse, lineage markers have been identified for B cells (B220, 
IgM), T cells (CD4, CD5 and CD8), myelomonocytic cells (Mac-1 and Gr-1) 
and many other cell phenotypes. More primitive cells express low levels of 
Thy-1.1 and are positive for Sca-1. Other markers used to define primitive 
cells include AA4.1 and c-kit. Therefore, by FACS, a subset of cells may be 
separated (Sca-1+ / Thy-l.l^0 / Lin-) which is highly enriched in activity in 
stem cell assays. As discussed above, despite being enriched, these subsets 
still show marked heterogeneity with respect to in vivo lifespan (Smith et al.t 
1991; Uchida & Weissman, 1992). Sca-1+ / Thy-Ll*0 / Lin- cells may be 
further divided on the basis of rhodamine staining (Spangrude & Johnson, 
1990). Rhodamine is a supravital, cationic fluorescent dye that has relatively 
high affinity for mitochondrial membranes and is retained much better in 
cycling cells than in quiescent cells (Bertoncello et al., 1985; Bertoncello et 
al., 1991). The mechanism underlying these observations is thought to be due 
to more efficient efflux of the dye from primitive cells by the gp 170 efflux 
pump. Rhodamine staining may, therefore, be used to discriminate primitive 
from more mature cells. For example, Bertoncello et showed that HSC with 
long term reconstituting capacity in vivo were rhodaminedull whilst a large 
proportion of HPP-CFC and CFU-S were r h o d a m i n e b r i g h t  (Bertoncello et al., 
1985). In addition to the cell markers and methods mentioned above, there are 
a number of other techniques which are used by different research workers to 
enable purification of specific cell subsets.
The Ly-5 antigen (leucocyte common antigen / CD45) is expressed on 
all myeloid precursors and mature nucleated cells. Allelic differences at Ly-5 
may be detected by monoclonal antibodies specific for Ly-5.1 and Ly-5.2, 
allowing donor cells (e.g. Ly-5.2) to be detected in Ly-5.1, congenic hosts.
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This system allows transplantation without crossing the major 
histocompatibility barrier and has been used in the CRA (Smith et al., 1991; 
Uchida & Weissman, 1992).
1.18 Phases of haemopoietic engraftment following BMT
Following lethal doses of radiation and infusion of bone marrow cells, 
engraftment is thought to occur in overlapping phases. During the early phase 
of "transient engraftment", a relatively large number of stem cells contribute 
to haemopoiesis, however after the first few weeks only a few stem cells 
continue to contribute (Dick et al., 1985; Lemischka et al., 1986; Smith et al., 
1991; Uchida & Weissman, 1992; Harrison etal., 1993). Jones et al separated 
an enriched CFU-S day 12 population from more primitive stem cells by CCE 
and showed that this cell population, upon transplantation following lethal 
dose irradiation, was sufficient to enable rapid return of normal blood counts. 
However, this cell population was not sufficient for long term haemopoiesis. 
This study demonstrated that CFU-S were responsible for the early phase of 
engraftment following BMT but pre-CFU-S were essential for long term 
haemopoiesis (Jones et al., 1990).
For transplantation with enriched cell populations, even small numbers 
of highly purified cells may give rise to sustained long term haemopoiesis 
(Uchida et al., 1994). The work by Uchida et al argued that small numbers of 
Thy-l.ll° Sca-1+ Lin- cells were sufficient, when transplanted alone, to 
produce both transient and long term reconstitution. However, the enrichment 
techniques used were known to enrich not only for HSC, but also for 
progenitor cells, especially CFU-S day 12, thereby producing a heterogeneous 
population which may well have contained both progenitor cells able to 
rapidly reconstitute early haemopoiesis and a further quiescent subset which 
gave rise to an increasing fraction of donor derived cells in each lineage with 
time (Uchida et al., 1994).
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This work was not incompatible with the earlier results described by 
Jones et al (Jones et al., 1990). The cell population obtained by CCE in their 
study, which was virtually depleted in CFU-GM and CFU-S, was not able, 
alone, to rescue lethally irradiated animals. These results, taken together, 
suggest that there are indeed two phases of engraftment following BMT and 
that different progenitor populations may give rise to early haemopoiesis 
depending on the number and purity of the stem cell population transplanted.
1.19 Bone marrow transplantation and radiation protocols
In order to demonstrate "rescue" from the effects of radiation, a protocol 
which ensures close to 100% mortality in the absence of BMT but 100% 
survival with adequate BMT is required. Radiation damage is concentrated in 
rapidly proliferating tissues including the bone marrow, the lung and the 
gastrointestinal tract. The degree of damage is related to the total dose, dose 
rate and use of dose fractionation. It has previously been reported that dose 
fractionation may permit a high total dose of radiation with fewer fatalities 
due to gastrointestinal and pulmonary complications (Geraci et al. , 1977; 
Ferrara et al. , 1987; Spangrude & Scollay, 1990).
In vivo Assays
In vivo stem cell assays have been developed to allow study of the functional 
properties of stem cell populations. Mouse models are available with genetic 
markers that allow accurate measurement of the long-term function of 
transplanted HSC. A number of assays have been described including those 
for colony formation (CFU-S (Till & McCulloch, 1961)), radioprotective 
ability, MRA (Hodgson & Bradley, 1979), serial BMT (Jones et al., 1989), 
and CRA (Harrison et al., 1993). These assays vary considerably with respect 
to assay time and the chimeric mouse model employed and therefore 
comparison of data generated using different assay systems is not always
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possible. Although most of these assays produce only comparative or 
qualitative data, the CRA is fully quantitative and may be accurately assayed 
over the entire lifespan of the recipient.
1.20 Competitive repopulation assay
The CRA, described in detail by Harrison et al (Harrison et al., 1993), directly 
compares the long-term proliferative abilities of two populations of donor 
cells. The first population, the competitor, is a dose of fresh bone marrow 
which serves as a standard and is of sufficient repopulating ability to allow 
successful reconstitution if used alone. The second population, the donor, is of 
unknown HSC content and is measured relative to the competitor. Competitor 
and donor are derived from mice that differ at genes specifying quantitative 
markers and, therefore, the relative percentages of their progeny can be 
determined over time. This allows a very accurate assessment of the potential 
of different cell populations to rescue mice both early and late following 
radiation.
1.21 Serial BMT
Serial BMT may be used to study proliferation and self-renewal of HSC in 
vivo (Ogden & Micklem, 1976; Harrison etal. , 1978; Brecher eta l. , 1988; 
Jones et al.y 1989; Harrison et al. , 1990). One of several models in use 
employs syngeneic BMT with male donors and female recipients. The 
recipients are lethally irradiated prior to transplantation and at varying time 
intervals following primary BMT, the reconstituted recipient mice are then 
used as donors in a second BMT procedure. With repeated serial transfers, the 
ability of the donor marrow to reconstitute is eventually lost. The underlying 
reason for this limited repopulating ability of serially transplanted bone 
marrow is unknown (see discussion).
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The normal proliferative capacity of bone marrow stem cells is 
severely stressed when required to fully regenerate haemopoiesis following 
BMT. In previous studies, serial BMT performed with short intervals (8-10 
weeks) between transfers produced a progressive impairment of the ability of 
donor cells to repopulate irradiated hosts (Siminovitch et al., 1964;
Cudkowicz et al., 1964). By lengthening the interval between transfers the 
repopulating ability was improved, but even with very long (6-12 months) 
intervals, serial transfers could not be continued for more than five generations 
(Siminovitch et al, 1964; Cudkowicz etal., 1964; Ogden & Micklem, 1976; 
Harrison etal., 1978).
Serial BMT is therefore a useful functional test of the ability of cells to 
reconstitute under circumstances requiring enormous stem cell reserve, but it 
cannot measure the number of reconstituting cells present. Although the 
assumption is generally made that serial transfer eventually fails because stem 
cells have a finite capacity for self-renewal, there are a number of other 
possible explanations for this observation (see discussion). The fact that 
leaving intervals of one year between transfers is insufficient to allowed more 
than five transfers suggests that the changes to the stem cell compartment 
induced by BMT are in part irreversible.
Ex vivo Expansion of Stem / progenitor Cells
1.22 Potential clinical applications
Over the last decade autologous bone marrow transplantation has been largely 
replaced by the use of mobilised PBPC (Kessinger & Armitage, 1991). 
Although HSC are present in peripheral blood under steady state conditions, 
their numbers are greatly increased during the recovery phase of treatment 
with myelosuppressive cytotoxic agents or following the administration of 
growth factors such as G-CSF and GM-CSF. More recently the use of PBPC 
has also been investigated for allogeneic transplantation. The key advantage of
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using PBPC for transplantation compared with bone marrow is that PBPC 
significantly accelerate the rate of haematological recovery and hence the 
morbidity and mortality associated with the procedure (Kessinger &
Armitage, 1991). Furthermore, PBPC provide the only source of HSC for 
patients whose bone marrow is fibrotic or involved with tumour and therefore 
unsuitable for harvesting.
The rapid engraftment experienced following PBPC transplantation is 
thought to reflect both the increased number of stem and progenitor cells 
which may be harvested from peripheral blood compared with bone marrow 
and alterations both in phenotype / cycle status and adhesiveness /  homing of 
these cells (reviewed in (Henon, 1995)). Since PBPC collected during steady 
state haemopoiesis, as opposed to following chemotherapy +/- growth factor 
mobilisation, do not accelerate haemopoietic recovery compared with bone 
marrow, it is likely that the effects of growth factors, either administered 
directly, or produced endogenously during marrow regeneration, are in part 
responsible for the acceleration in engraftment which is observed. This raises 
the question whether stem cells could be manipulated ex vivo, in the presence 
of growth factors, to further increase their numbers and / or alter their 
characteristics to produce even more rapid engraftment upon transplantation. 
In certain clinical situations it would be of value to expand the number of 
progenitor cells available, whilst in others it would be more valuable to 
facilitate very rapid haemopoietic recovery.
To ensure rapid engraftment, a critical number of stem and progenitor 
cells must be collected. This usually requires multiple leucapheresis 
procedures, performed on consecutive days. Recent strategies to reduce the 
number of tumour cells contaminating PBPC collections for autologous 
transplantation have involved positive selection of stem and progenitor cells. 
CD34, first described by Civin et al, is an antigen present on the surface of all 
HSCs and progenitor cells (Civin et al., 1984). The availability of monoclonal
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antibodies directed to this antigen have facilitated the development of a range 
of commercially available CD34 selection devices which are based on 
separation of the CD34 positive cells from the remaining CD34 negative cells 
present in PBPC collections. These techniques are not fully efficient and 
although tumour cells may be depleted by 2-3 logs, approximately half of the 
stem and progenitor cells available are lost during the separation procedure.
Thus, considerable attention is currently directed at methods to expand 
stem and progenitor cells ex vivo. The obvious advantages of this approach 
would be to reduce the number and duration of leucapheresis procedures, 
particularly in situations when multiple transplants are planned, to expand 
cord blood derived HSC in order to provide sufficient cells for transplantation, 
to trigger cycling of primitive stem cells to facilitate gene transduction and 
then, perhaps, to selectively expand the transduced population prior to 
transplantation (reviewed in (Moore, 1995)). Intense investigation has also 
been directed towards developing ex vivo culture conditions which promote 
proliferation of progenitors cells which produce prompt engraftment upon 
transplantation. The mechanisms which underlie any observed acceleration in 
haemopoietic recovery are likely to reflect both quantitative and qualitative 
progenitor changes.
1.23 Homing of HSC: Potential modulation by growth factor exposure ex
vivo
The mechanisms which regulate the circulation and homing of HSC, both 
during fetal and adult life, are largely unknown. HSC are known to be present 
in peripheral blood under steady state (i.e. non-mobilised) conditions. Such 
cells are able to provide complete and sustained haemopoietic reconstitution 
in transplant recipients (Kessinger & Armitage, 1991).
In murine studies, bone marrow cells administered intravenously home 
to the bone marrow and produce sustained engraftment, even in the absence of
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myeloablation (Brecher et al., 1982; Stewart et al., 1993). These findings 
suggest that HSC constantly circulate from the bone marrow into the 
peripheral blood and vice versa. Homing to the bone marrow may be greatly 
increased by myeloablation of the transplant recipient. However, the homing 
which occurs following radiation / chemotherapy may differ from that 
occurring in steady state. Similarly, the HSC found in the circulation in steady 
state may differ from those remaining in the bone marrow and those recruited 
into the circulation by cytokines and / or the effects of chemotherapy may 
again be subtly different.
It is clearly of importance to try and establish which factors mediate 
HSC circulation and homing in order to try and manipulate the situation either 
experimentally or therapeutically. Experiments performed by Tavassoli and 
co-workers suggested that homing of HSC to the bone marrow was mediated 
by an unknown lectin on their surface which had an affinity for carbohydrate 
determinants present on stromal cells (reviewed in Tavassoli et al., 1995).
This group designated the lectin, the "haemopoietic homing receptor". They 
proceeded to develop synthetic glycoproteins which could be radiolabelled 
and which competed as ligands for the "homing receptor".
In vivo murine studies revealed that the survival of lethally irradiated, 
splenectomised mice was reduced if bone marrow cells were transplanted in 
conjunction with the synthetic glycoproteins. The effect on survival was much 
less impressive in the presence of a normal spleen, suggesting that homing of 
intravenously transplanted HSC to bone marrow, but not spleen, was mediated 
by an interaction between the lectin (homing receptor) and a glycoprotein 
ligand. In addition to effects on survival, bone marrow cellularity, CFU-S and 
CFU-GM were all reduced by competition with the synthetic glycoproteins 
(Aizawa & Tavassoli, 1988).
Further in vitro studies showed that the synthetic ligands competed 
reversibly with the "homing receptor" to reduce progenitor output in LTBMC
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(Aizawa & Tavassoli, 1987). The "homing receptor" was shown to be present 
on the surface of stem cells, CFU-S and CFU-GM, but not mature 
granulocytes. Interaction of the "homing receptor" with its specific 
carbohydrate ligand present on stromal cells was necessary for binding of 
stem cells to stroma (Tavassoli et al., 1995). These findings suggested that the 
level of expression of the "homing receptor" declined with stem cell 
maturation and differentiation and may explain why, in LTBMC, stem cells 
are found in the adherent layer, whilst more committed progenitor cells and 
mature cells are found in the supernatant. This also raises the possibility that if 
stem cells are manipulated ex vivo to produce more mature, committed 
progenitor cells, these may not express the "homing receptor" in sufficient 
quantity to permit homing to the bone marrow. If this were the case, these 
cells would be likely to be destroyed eventually, in the peripheral circulation.
In addition to this "homing receptor", further adhesive interactions are 
thought to play a role in retaining stem cells within the marrow. One major 
component of the extracellular matrix to which stem cells may bind is 
fibronectin (Williams et al., 1991). Experiments performed using IL-3 
dependent progenitor cell lines have demonstrated that these cells possess a (31 
integrin in their membrane which is presumed to mediate adherence to 
fibronectin. This binding was shown to be cytokine dependent since adherence 
to fibronectin was dramatically, but reversibly, reduced by IL-3 removal 
(Tavassoli et a l 1995). These findings suggest that cytokine manipulation of 
stem and progenitor cells ex vivo might alter their ability to adhere to 
fibronectin and, hence, to home to the bone marrow stroma upon reinfusion.
Proteoglycans are synthesised by stromal cells and are transiently 
present in the cell membrane before being released into the extracellular 
space. In addition, proteoglycans may be present on the HSC surface. Once 
outside the cell, they are able to adhere to the extracellular matrix. In this way 
proteoglycans may be able to present growth factors to stem and progenitor
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cells (Tavassoli et al., 1995). This question was the subject of the study 
performed by Gordon et al (Gordon et al., 1987) in which bone marrow 
derived glycosaminoglycans were used to coat tissue culture plates. These 
were then used to extract GM-stimulating activity from 5637CM or to bind 
purified GM-CSF. The results strongly suggested a role for 
glycosaminoglycans in the binding of cytokines and subsequent presentation 
to stem cells. It remains unclear whether the in vivo situation within the bone 
marrow microenvironment may be reproduced ex vivo, simply by adding 
cytokines to stem cell populations. It seems likely that, in the absence of either 
stroma or proteoglycans, stem cell expansion and proliferation ex vivo may be 
sub-optimal.
The availability of monoclonal antibodies has allowed investigators to 
detect a range of known cytoadhesive molecules on HSC. Antigens expressed 
on the surface of progenitor cells include integrins, members of the 
immunoglobulin superfamily including intracellular adhesion molecule 
(ICAM-1) and lymphocyte function-related antigen (LFA-3), CD44 and L- 
selectin (reviewed in Tavassoli et al., 1995). The inhibition of growth in 
LTBMC by antibodies to CD44 and a4(3l integrin suggests an important role 
for these molecules in the localisation of stem cells to the stromal 
microenvironment (Tavassoli et al., 1995). Since cytokines are known to be 
produced within the bone marrow microenvironment and are thought to play a 
major role in regulating haemopoiesis, it is likely that cytokines may act 
locally to effect the level of expression of certain adhesion molecules and 
thereby influence the localisation of stem and progenitor cells within the bone 
marrow. An example of this was demonstrated for SCF by Kovach et al 
(Kovach et al., 1995). In their study treatment of M07E cells with SCF 
produced a transient increase in adherence to human umbilical vein 
endothelium or to VCAM-1-transfected CHO cells with a peak at 30 minutes, 
however, more prolonged exposure to SCF induced a marked decrease in
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integrin-mediated adherence with maximal inhibition at 24 hours. These 
findings may in part explain why cytokines such as SCF mobilise primitive 
haemopoietic cells from the bone marrow into the peripheral blood.
To investigate whether cytokines regulate stem cell homing and 
engraftment, a number of studies have been performed in which bone marrow 
cells were pre-treated with growth factors prior to transplantation into either 
lethally irradiated adult or "pre-immune" fetal recipients (Fabian et al., 1987; 
Tavassoli et al., 1991; Zanjani et al., 1992). In these studies, short term 
exposure (a number of hours) of bone marrow or fetal liver progenitor cells to 
IL-3 or GM-CSF enhanced their capacity to reconstitute multilineage 
haemopoiesis in recipient animals. Since no expansion of stem and progenitor 
cell numbers could have occurred over such a short period of growth factor 
exposure, these results suggested that part of the capacity of cytokines to 
improve haematological reconstitution after transplantation with cells 
manipulated ex vivo related to effects on homing.
Very recently, however, Van der Loo & Ploemacher reported a similar 
study with contradictory results (Van der Loo & Ploemacher, 1995). In this 
study, a brief preincubation of bone marrow cells with either IL-3 alone or IL- 
3, IL-12 and SCF had a negative effect on the seeding of all haemopoietic 
subsets to bone marrow and spleen. Van der Loo argued that the medium only 
control used in the previous study by Tavassoli et al (Tavassoli et al., 1991) 
may not have maintained stem cell viability since it was incubated at 37°C in 
the absence of cytokines. If this were indeed the case, then the cells incubated 
in the presence of cytokines would have appeared to produce enhanced 
homing compared with cells with poor viability. The control cells used in the 
latter study were maintained in the absence of cytokines, but on ice rather than 
at 37°C (Van der Loo & Ploemacher, 1995). These contradictory results are 
difficult to reconcile. In the absence of studies which use identical controls 
this issue remains open to debate, however, in view of the number of
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investigators who have reported improvements in engraftment and / or homing 
of stem and progenitor cells following growth factor exposure in vitro, the 
balance of evidence is in favour of enhanced homing by cytokines. In 
additional experiments, Tavassoli and co-workers demonstrated that certain 
cytokines had direct effects on the level of expression of the "homing 
receptor" on FDCP-1 and FDCP-Mix murine haemopoietic progenitor cells 
(Tavassoli et al., 1991; Shiota et al. , 1992). In these experiments, the number 
of homing receptors increased 2-3 fold during incubation with IL-3 or GM- 
CSF. Effects on other adhesive proteins in bone marrow have also been 
demonstrated by other groups. For example, the expression of ICAM-1 and 
VCAM-1 on stromal cells was shown to be increased by exposure to IL-1, IL- 
4 or TNF-a (Simmons et al., 1992; Teixido et al., 1992). These cytokine 
effects do suggest that stem cells could be manipulated ex vivo with the 
specific aim of modulating the interaction between molecules present on the 
stem cell surface and others present on stromal cells. This approach could then 
be exploited clinically to obtain enhanced engraftment following 
haemopoietic transplantation.
1.24 Ex vivo expansion: experimental results
In order to achieve, long term ex vivo expansion of HSC for any purpose, 
culture conditions which mimic the in vivo situation, as closely as possible, 
must be developed. It remains unclear whether combinations of stimulatory 
cytokines used alone may recruit primitive cells which have self-renewal 
capacity (e.g. LTRC) into cycle, or whether bone marrow stroma and / or stem 
cell inhibitors are required in addition.
In vivo, and in LTBMC, HSC are found in close association with the 
stroma and appear to be tightly regulated by both positive and negative 
signals. There are, therefore, concerns, that positive cytokines, used in the 
absence of stroma and negative regulators, may result only in terminal
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differentiation of HSC with little or no maintenance of LTRC. Alternatively, 
HSC may be relatively resistant to the action of cytokines which may only 
provide a survival stimulus, such that HSC numbers are maintained, but not 
expanded. Over recent years, a wide range of both stimulatory and inhibitory 
cytokines have been discovered and a number of synergistic cytokine 
combinations have been identified.
In the absence of growth factors, HSC and progenitor cells have been 
shown to die by the process of apoptosis (reviewed by Koury, 1992). When 
undergoing apoptosis, cells decrease in size, their nuclei condense and 
eventually the cells become fragmented. Among the known growth factors, 
Epo, IL-3, GM-CSF and G-CSF have all been shown to suppress apoptosis in 
cells that are dependent upon them for survival (Koury, 1992; Williams et al., 
1990b). Katayama et al and Bodine et al have identified cytokines including 
IL-3, G-CSF and SCF, which appeared to support the survival of quiescent 
murine primitive progenitor cells when cultured ex vivo (Bodine et al. , 1991; 
Bodine et al., 1992; Katayama et al., 1993). These cytokines, used alone, 
supported survival but not proliferation of HSC. Further cytokines were 
required to recruit cells into active cell cycle. Ogawa's group followed the 
development of primitive "blast" cell colonies in response to both single and 
two factor combinations. These serial mapping studies revealed that certain 
cytokines were able to trigger proliferation of primitive progenitor cells and 
appeared to shorten the dormant (Go) period of HSC. These cytokines 
included SCF, IL-11, IL-6 and G-CSF (Musashi et al.t 1991; Tsuji et al., 
1991).
Based on these, and other observations, a number of combinations of 
synergising cytokines have been investigated which promote extensive 
amplification of both committed and multipotential progenitors. Prior to the 
cloning of SCF, the most potent combination was IL-3 and IL-6 (Bodine et 
al., 1989) however, the inclusion of SCF promoted even greater stem and
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progenitor cell amplification (Bodine et al., 1992) and is currently included in 
most growth factor combinations.
Expansion of murine CFU-S in vitro has been achieved by several 
investigators using SCF containing combinations such as SCF / IL -la  (de 
Vries et al., 1991), SCF / IL-6 (Luskey et a l., 1992), SCF / IL-3 / IL-6 
(Bodine et al., 1992), SCF / IL-ip (Muench et a l., 1992) and SCF /  IL-11 
(Neben etal., 1994). Likewise, expansion of primitive multipotential 
progenitor cells detected by in vitro assays including HPP-CFC and CAFC has 
also been achieved with similar combinations (Muench et al., 1992; 
Ploemacher et al., 1993b).
Although these studies showed extensive progenitor expansion in 
vitro, in vivo experiments were required to assess the engraftment potential of 
such expanded populations. Exposure of progenitor cells to growth factors 
may enhance engraftment by two mechanisms. Firstly, such manipulation may 
provide an increased number of progenitors enriched in transient engrafting 
potential and, secondly, may effect the "homing" of stem and progenitor cells 
to the bone marrow microenvironment leading to more rapid engraftment and 
differentiation (Fabian et al., 1987; Tavassoli & Hardy, 1990; Tavassoli et al., 
1991; Zanjani etal., 1992).
In vivo experiments have been used to assess the effect of cytokine 
stimulation on both short term engraftment and LTRC. Significant 
acceleration of short term haemopoietic recovery following transplantation 
with cells expanded ex vivo has now been demonstrated convincingly, and 
confirmed by our own work (Muench & Moore, 1992; Muench et al., 1993; 
Serrano et al., 1994; Holyoake et a l , 1996). Several studies have reported 
greater recovery of either the ability to rescue lethally irradiated animals, or of 
repopulating ability following ex vivo expansion of unfractionated bone 
marrow compared with purified stem cell populations (Okano et al., 1989; 
Knobel et al., 1994; Neben et al., 1994). In the study by Neben et al, under
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identical culture conditions, a significantly higher percentage of primitive 
stem cells was maintained in cultures of unfractionated 2 day post 5-FU bone 
marrow, than in cultures initiated with Sca+ Lin- 2 day post 5-FU bone 
marrow. Unfractionated bone marrow contains stromal elements which may 
elaborate, not only other cytokines, but also negative regulators of 
haemopoiesis. For example, MIP-la is an inducible product of bone marrow 
macrophages and therefore is likely to be present in greater levels in cultures 
of unfractionated bone marrow. At least for human HSC, M IP-la appears to 
play a role in the maintenance of primitive progenitors when used to 
supplement LTBMC initiated with highly purified progenitor cells in 
conjunction with IL-3 (Verfaillie etal., 1994). The stroma present in 
unfractionated bone marrow cultures may also facilitate adherence of HSC to 
stromal elements and thereby interaction between the HSC and regulators 
produced by the stromal cells. These results emphasise that growth factors 
may have different effects depending on the cellular context of their action.
One of the difficulties encountered when attempting to interpret the 
extensive literature relating to effects of growth factor exposure on short and 
LTRC is the degree of variation in methodology employed in the different 
studies. For example, differences are encountered in the starting cell 
population, which may be normal unfractionated bone marrow, post 5-FU 
marrow or cells enriched to varying degrees; the number of growth factors and 
combinations employed; the culture conditions including the use of serum; the 
duration of incubation; the dose of radiation and method of administration; the 
donor and recipient murine strains used in the studies; the route of injection of 
the transplant and, finally, the control cells against which the expanded cells 
are compared.
Some investigators have compared the repopulating ability of cultured 
cells against fresh control cells (Okano et al., 1989; Muench & Moore, 1992; 
Muench et al., 1993; Knobel et al., 1994; Rebel et a l., 1994; Serrano et al.,
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1994) whilst others compared cells expanded with multiple cytokines against 
cells cultured with IL-3, IL-6 or SCF alone (Bodine et al., 1989; Bodine et al., 
1991; Bodine et al., 1992; Luskey et al., 1992; Neben et al., 1994). A more 
appropriate control may be cells which have been cultured under otherwise 
identical conditions, but in the absence of cytokines. This control has rarely 
been included because progenitor cells including CFU-S survive poorly in the 
absence of cytokines (Luskey et al., 1992). Furthermore, Bodine et al have 
demonstrated that bone marrow cells cultured in the absence of cytokines are 
unable to compete against cells cultured with IL-3 alone in the CRA, 
suggesting that at least a single cytokine is required to maintain stem cell 
viability (Bodine et al., 1992). The cytokines which appear to satisfy this 
requirement include IL-3, G-CSF and SCF (Bodine et al., 1991; Bodine et al., 
1992; Katayama etal., 1993).
Although certain cytokine combinations increased committed and 
multipotential progenitor content at the expense of stem cell function (Bodine 
et al., 1991), combinations which allowed at least maintenance of LTRC have 
been determined (Bodine et al., 1989; Bodine et al., 1991; Bodine et al.,
1992; Muench et al., 1993; Neben et al., 1994; Rebel et al., 1994; Serrano et 
al., 1994). Many such studies compare cells expanded with multiple cytokines 
against control cells cultured with a single factor rather than with fresh 
uncultured marrow. Several of these and other studies have demonstrated the 
ability to transduce murine stem cells with genes of interest in the presence of 
such synergising growth factors with efficient infection of reconstituting 
haemopoieitc stem cells in the long term (Dick et al., 1985; Lemischka et al., 
1986; Bodine etal., 1989; Bodine etal., 1991; Luskey et al., 1992; Bemad et 
al., 1994).
A number of conclusions may be drawn from the literature currently 
available regarding ex vivo expansion of murine haemopoietic stem and 
progenitor cells. Although single cytokines are necessary for cell survival,
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synergising cytokine combinations are required to stimulate proliferation and 
expansion of progenitor cells. Cells which have been expanded ex vivo, using 
certain cytokine combinations, produce significantly more rapid 
haematological reconstitution compared with either fresh bone marrow, or 
bone marrow cultured with a single cytokine. Whether this improvement in 
early engraftment relates only to increases in progenitor cells responsible for 
transient engraftment, or to alterations in progenitor homing, or both, remains 
unclear. LTRC do appear to be maintained under certain ex vivo culture 
conditions, but whether this is due to slow turn-over with self-renewal of 
LTRC or to total quiescence of the original LTRC which are resistant to the 
effects of cytokines is not clear. Cytokine manipulation does appear useful for 
gene transduction and long term studies confirm that genes are still expressed 
at relatively high levels many months following transplantation, suggesting 
infection of LTRC, which, despite proliferating, have remained pluripotent. 
Finally, the reported differences, by some groups, comparing unfractionated 
bone marrow with highly purified populations, suggests that bone marrow 
stroma, and / or negative regulators, may play an important role in the 
maintenance of LTRC during ex vivo culture.
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AIMS
Over recent years a wide range of stimulatory and inhibitory cytokines have 
been cloned and investigated for their biological effects on haemopoietic stem 
and progenitor cells. Many attempts have been made to develop in vitro 
systems which closely mimic in vivo haemopoiesis in order to establish the 
role that these cytokines have in the regulation of stem cell proliferation.
The first aim of the work presented in this thesis was to optimise, in 
the absence of stroma, ex vivo culture conditions which would promote 
proliferation and expansion of murine multipotential CFU-A progenitor cells. 
There was sufficient evidence that CFU-A / CFU-S day 12 were of crucial 
importance for the early, but transient phase of engraftment seen after BMT. It 
was hoped, therefore, that by transplanting a greatly expanded population of 
CFU-A, neutrophil and platelet recovery following BMT might be 
accelerated. In addition, if CFU-A numbers could be increased by ex vivo 
culture, then the number of bone marrow cells required for rescue from 
myeloablation could be reduced. If such endpoints could be achieved in a 
murine model, then there would be value in pursuing a similar approach 
clinically since, firstly, the major morbidity following autologous 
transplantation is related to prolonged myelosuppression and, secondly, in a 
significant proportion of patients, for whom autologous transplantation is 
indicated, insufficient stem cells can be harvested to mediate rescue from 
myeloablative therapy.
The second aim of these studies was to develop an appropriate in vivo 
model in which to test the engrafting potential of the progenitor cells which 
had been expanded ex vivo. Although the initial work was directed towards 
expansion of CFU-A and short term engraftment, it was also of importance to 
assess the effect that cytokine induced amplification had on stem cells which 
were responsible for long term reconstitution after BMT. Both for
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transplantation studies and for gene therapy applications, maintenance, or 
preferably expansion, of pluripotent stem cells would be required to ensure 
sustained long term engraftment and gene expression.
The final aim, dependent on the results of preliminary work, was to 
develop suitable culture conditions to allow ex vivo expansion of human 
progenitor cells on a sufficiently large scale to generate enough cells for 
rescue following myeloablative therapy. Although the results of this clinical 
work are not discussed in this thesis, they are mentioned briefly in the 
discussion.
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MATERIALS AND METHODS
MATERIALS
Tissue Culture
SUPPLIER ADDRESS REAGENTS
Beatson Institute 
Central Services Beatson Institute
Bibby Sterilin Ltd. Stone, Staffs, UK
Penicillin (7.5mg/ml)
(10,000 units/ml) 
Streptomycin (lOmg/ml) 
Sterile PBS-A (oxoid)
Sterile Distilled H2O (DW) 
Sterile Glassware and Pipettes
3cm Dishes 
6cm Dishes 
9cm Dishes
Gibco Life Technologies Paisley, Scotland, UK Human Recombinant TGF-pi
Special Liquid Medium 
Fischer's Medium (10X) 
RPMI Medium (10X)
2.5% Trypsin 
200mM Glutamine 
Alpha Minimal Essential 
Medium (a-MEM)
MEM x 100 Vitamins 
Gentamicin Sulphate 
7.5% Sodium Bicarbonate 
Foetal Calf Serum (FCS) 
Colcemid (lOjig/ml)
L-broth
Welwyn Garden City Human Recombinant G-CSF
UK
Oxon, UK Murine Recombinant IL-3
Murine Recombinant IL-6 
Human Recombinant MCP-1 
Human Recombinant PDGF 
Human Recombinant IL-8 
Murine Recombinant LIF 
Human Recombinant Rantes 
Murine Recombinant IL-7 
Murine Recombinant IL-10
Roche Products 
Amgen Roche
R&D Systems
Genetics Institute Cambridge, MA, USA Murine Kit-Ligand (media
conditioned by CHO cells 
expressing soluble Kit- 
Ligand)
Human Recombinant M-CSF 
(CHO cells)
Murine Recombinant GM-CSF 
(COS-1 cells)
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Boehringer Mannheim 
Pharmaceuticals
Genzyme Diagnostics 
Costar
A/S Nunc
Difco Laboratories 
Sigma Chemical Co. Ltd.
The Binding Site
Harlan Olac Ltd.
Fluka Chemika-Biochemika
Fisons Scientific Equipment
Becton Dickinson 
(Falcon)
Coulter Electronics Ltd.
Nycomed
DYNAL
Pharmingen
Lewes, E. Sussex, UK
Cambridge, MA, USA 
Cambridge, MA, USA
Roskilde, Denmark
Detroit, Michigan, USA  
Poole, Dorset, UK
Birmingham University
Bicester, Oxon, UK
Gillingham, UK 
Loughborough, UK 
Cowley, Oxford, UK
Luton, UK
Sheldon, UK 
Bromborough, UK
San Diego, CA, USA
Human G-CSF (crude 
conditioned medium, CHO cell 
line)
Human Recombinant IL-11 (E. 
Coli)
Purified Human Recombinant 
M IP-la (CHO cells)
Human Recombinant 
Erythropoietin
Human Recombinant IL-1 [3
24 Well Culture Plates 
Cell Scrapers
Tissue Culture Flasks 
Nunc Cryotubes 
35mm Plates
Agar Noble
Donor Horse Serum (DHS) 
Cytosine P-D-arabino- 
furanoside (ARA-C) 
5-fluorouracil 
Rhodamine 123 
Purified Rat anti-mouse PE- 
conjugated CD5
Sheep anti-mouse FITC- 
conjugated IgM
Male and Female B6D2F1 
Mice
Methocel MC
Dimethyl Sulfoxide
Tissue Culture Flasks 
50ml & 15ml Centrifuge Tubes 
2ml, 5ml, 10ml, 20ml Plastipak 
Syringes
5ml, 10ml, 25ml Plastic
Pipettes
Cell Strainers
Coulter Counter 
Zap-oglobin
Nycodenz 1.150g/ml
Dynabeads (M-450 sheep anti- 
rat IgG)
Purified Rat Anti-Mouse
Monoclonal Antibodies
Gr-1
B220
Mac 1
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Gelman Sciences Michigan, USA
CD5
CD8a
FITC conjugated-Sca-1 
FITC conjugated-D7 
FITC conjugated-c-kit
Acrodisc Syringe End Filters, 
0.2 and 0.45pm 
Cell Lysing solution
Bacterial Hosts and Media
Gibco Life Technologies Paisley, Scotland, UK E. Coli Host Strain DH5a
Ampicillin
L-broth
Beatson Institute Central Services Beatson Institute, UK Sterile Glassware
Difco Laboratories 
Beta Laboratories
Detroit, Michigan, USA Agar Bacto
Bactotryptone
East Molesey, UK Yeast Extract
Plasmids & Inserts
Dr N. Hole 
Mr K. Ryan
Kits, Columns
Pharmacia Biotech Ltd.
Qiagen Inc.
Schleicher & Schuell
Edinburgh University, pY353/B plasmid 
UK
Beatson Institute, UK GAPDH insert
St. Albans, Herts, UK Random-Primed DNA  
Labelling Kit
NICK Columns Sephadex G- 
50 DNA grade
Chatsworth, CA, USA Qiagen Plasmid Preparation 
Kits
Dassel, Germany Elutip-D Columns
Membranes, Paper and X-ray Film
Amersham International pic. Amersham, Bucks, UK Hybond N nylon Membrane
Vemon-Carus Ltd. Preston, Lancashire, UK Gauze Swabs
Schleicher & Schuell Dassel, Germany 3MM Filter Paper
Eastman Kodak Co. Rochester, NY, USA X-OMAT AR X-ray Film
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Nucleotides, Polynucleotides, DNA
Amersham International, pic Amersham Bucks, UK
Sigma Chemical Co., Ltd. 
Gibco Life Technologies
Gels
Flowgen Instruments Ltd.
Poole, Dorset, UK 
Paisley, Scotland, UK
[a-32P]-dCTP: 3000Ci/mmol
Salmon Sperm DNA
1Kb DNA Ladder 
DNA Mass Ladder
Sittingboume, Kent, UK Agarose and Low Melting 
Point Agarose (LMP)
Enzymes, Enzyme Buffers, Enzyme Inhibitors
Gibco Life Technologies 
NBL Gene Sciences Ltd.
Paisley, Scotland, UK Restriction Endonucleases, 
with Buffer Concentrates
Cramlington, UK Ribonuclease A 
Proteinase K
Chemicals
Fisons Scientific Equipment
Sigma Chemical Co. Ltd.
James Burrough Ltd. 
Rathbum Chemicals Ltd. 
Fluka Chemika-Biochemika 
Northumbria Biologicals Ltd.
Loughborough, UK
Poole, Dorset, UK
Witham, Essex, UK 
Walkerbum, Scotland 
Gillingham, UK 
Cramlington, UK
Chloroform 
Methanol 
Acetic Acid 
Formaldehyde (40%)
Ethidium Bromide 
Bromophenol Blue
Ethanol
Water-Saturated Phenol 
Formamide
Bovine Serum Albumin
Solutions
Alpha stock
Alpha Medium (x2)
PE
51itre pack of a-MEM  
1500ml DW
lOOmg Gentamicin sulphate 
50ml MEM x 100 Vitamins 
Filter sterilise
DHS 25ml 
Alpha stock 21ml 
Sodium Bicarbonate 3ml 
Glutamine 1ml
PBS
0.001MEDTA
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Fischer's Medium
Special Liquid Medium 
Gel Loading Buffer 
2 0 X S S C
DNA extraction buffer
10XTAE
10X TE  
High salt buffer
Low salt buffer
Depurination buffer 
Denaturation buffer
Neutralisation buffer
Blot washing buffer (1)
Blot washing buffer (2)
for DNA precipitation 
50 X Denhart's
pre-hybridisation buffer
Distilled H2O 87.5ml 
lOx Fischer's Medium 10ml 
L-Glutamine 1ml 
Sodium Bicarbonate 1.5ml
Supplemented Modified Eagles Medium 
10% FCS
2mM L-Glutamine
0.25% Bromophenol Blue 
40% w/v Sucrose 
in Distilled H2O
3M Sodium Chloride 
0.3M Tri-Sodium Citrate
0.1M Sodium Chloride 
0.01M Tris (pH 7.4)
0.001MEDTA  
Ribonuclease A 20jag/ml 
0.5% SDS
0.4M Tris Acetate
0.05M Sodium Acetate (trihydrate)
0.01M EDTA
0.1M Tris/HCL (pH 8.0)
0.01M EDTA
1.0M Sodium Chloride 
0.02M Tris/HCL (pH 7.4)
0.001MEDTA
0.2M Sodium Chloride 
0.02M Tris/HCL (pH 7.4)
0.001MEDTA
0.25MHCL
1.5M Sodium Chloride 
0.5N Sodium Hydroxide
1M Tris (pH 7.4)
1.5M Sodium Chloride
2 x SSC 
0.1% SDS
0.1 x SSC 
0.1% SDS
3M Sodium Acetate
1% (w/v) Ficoll-400
1% (w/v) Polyvinylpyrrolidone
1% (w/v) Bovine Serum Albumin (fraction V)
6 X S S C  
5 X Denhart's 
0.5% SDS 
50% Formamide
10(ig/ml Sonicated Salmon Sperm
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soc
L-Amp broth
Fixation medium for 
pathology
2% w/v Bactotryptone 
0.5% w/v Yeast Extract 
0.01M Sodium Chloride 
0.0025M Potassium Chloride 
0.01M Magnesium Chloride 
0.01M Magnesium Sulphate 
0.02M Glucose
0.5% Yeast Extract 
1% Bactotryptone 
1% Sodium Chloride 
Ampicillin (50jig/ml)
10% neutral buffered formaldehyde 
40% Formaldehyde 100ml 
DW 900ml
Disodium hydrogen phosphate 
dihydrate 8.19g 
Sodium dihydrogen phosphate 
dihydrate 4.52g
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METHODS
Cell Culture 
Mice
For all the work presented, the strain B6D2F1, an FI hybrid of C57B1/6 
(females) and DBA2 (males) strains, was used. All mice were housed within 
the animal facility of the Beatson Institute. Female or male mice were used at 
age 6-12 weeks for all experimental procedures.
Murine Blood Sampling
Animals were sacrificed by carbon dioxide (CO2) asphyxiation. All blood 
analyses were performed on blood obtained by cardiac puncture. This was 
performed by Mr. Stephen Bell (Beatson Institute). Full blood count analyses 
were performed using a Coulter counter. Blood films were stained using 
Leishmann stain.
Preparation of Murine Bone Marrow or Spleen Cells
Mice were sacrificed either by cervical dislocation or by CO2  asphyxiation. 
Bone marrow cells were obtained from the femora of mice (Pragnell et al., 
1994). The femora were first cleaned of muscle tissue using a swab soaked in 
70% ethanol, then crushed in Fischer's medium supplemented with 10% DHS 
(F/10), using a mortar and pestle. After crushing, the cell suspension was 
passed through a cell strainer into a 50ml centrifuge tube. After one wash in 
F/10, the bone marrow cells were re-suspended to a single cell suspension and 
counted in the Coulter counter after lysing the red cells with Zap-oglobin.
Spleens were carefully removed under sterile conditions using scissors 
and forceps. The spleens were disaggregated by crushing with the plunger end 
of a 2ml syringe through a cell strainer into a 50ml centrifuge tube. F/10 was
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used to recover cells from the cell strainer. The cells were counted as for bone
marrow.
Peritoneal Lavage
Animals were first sacrificed by CO2 asphyxiation. Peritoneal lavage fluid 
was obtained by first injecting 4ml of PBS into the peritoneal cavity of mice 
and then carefully aspirating the fluid which was retained for further analysis.
Pathology of Spleens and Tibias
Samples of spleen or bone marrow were first placed in a solution of 1% 
neutral formaldehyde. Samples were then processed for histological section by 
standard methods. This was performed by Mrs Margaret O'Prey (Beatson 
Institute).
Antibody Labelling of Blood, Bone marrow and Spleen Cells
The test cells were first washed in sterile PBS. The required number (10^ per 
test), was then re-suspended in 200|il of PBS for labelling. Antibody was 
added at the concentration recommended by the individual manufacturers. 
After 30 minutes incubation on ice, red cells were lysed if necessary (blood 
only) using 2ml cell lysing solution and, the cells were washed twice in PBS 
then re-suspended in 1% paraformaldehyde. For Rhodamine (Rhl23) staining, 
Rhl23 was dissolved in distilled water, stored frozen as a sterile lmg/ml stock 
solution and serially diluted in PBS containing 5% FCS as required. The test 
cells were incubated in a final Rhl23 concentration of 0.1|ig/ml for 20 
minutes at 37°C. Stained cells were washed twice, re-suspended and 
incubated at 37°C for 15 minutes to remove unbound fluorochrome. The cells 
were then washed and re-suspended in PBS ready for flow cytometry 
(Bertoncello et al., 1991). Flow cytometric analyses were performed either on 
a FACScan (Becton Dickinson) or FACStar (Becton Dickinson) by Mrs Mary
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Freshney and Mrs Elaine McKenzie (Beatson Institute) or Dr Kay Samuel 
(University of Edinburgh).
Maintenance of Cell Lines and Production of Conditioned Media (CM).
All cell lines were obtained from the frozen stocks of the Beatson Institute and 
were maintained in special liquid medium supplemented with 10% foetal calf 
serum (SLM/FCS). Cells were maintained in T75 tissue culture flasks. On 
reaching sub-confluence, cells were replated in fresh medium at one twentieth 
of the number at sub-confluence. Cells were detached from the surface of the 
flask using a 2 minute incubation with trypsin diluted 1:10 in PE. For the 
production of conditioned media (CM), the L929 (Stanley & Heard, 1977), 
and AF1-19T (Franz et al., 1985) cell lines were grown in roller bottles in 
SLM/FCS to half-confluence. Spent medium was then removed, replaced with 
fresh medium, and the cultures allowed to grow for another three days. The 
CM was then removed, passed through 0.45 and 0.22pm filters and stored at 
-20°C. In the CFU-A assay (see below), CM from the murine L929 cell line 
was used as a source of M-CSF and AF1-19T-CM was used as a source of 
GM-CSF.
Clonogenic Assays 
CFU-GM assay
For the CFU-GM assay, 5 x 10^ bone marrow cells were added to 
supplemented a-MEM with 0.9% methylcellulose, 25% donor horse serum 
and recombinant murine GM-CSF (0.2ng/ml). 1ml cultures were plated into 
3cm dishes and incubated at 37°C in 5% C02 in fully humidified conditions. 
After 6 days incubation, granulocyte, macrophage and granulocyte / 
macrophage colonies were scored if they contained > 40 cells.
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CFU-A assay
The protocol for CFU-A has been described in detail previously (Pragnell et 
al., 1994; Pragnell et al., 1988). Briefly, 10^ bone marrow cells were 
suspended in a-MEM, supplemented with 25% DHS and 0.3% agar to a total 
volume of 4ml. This suspension was seeded onto a 4ml feeder layer consisting 
of 0.6% agar in the same medium with 10% L929- CM and 5% AF1-19T-CM 
as a source of synergising growth factors. Dishes were incubated in a 
humidified atmosphere containing 10% CO2 , 5% O2 and 85% N2 for 11 days. 
The "cut-off" for colonies to be included as CFU-A was >2mm in diameter 
and this was not varied. This assay detects multipotential progenitors with 
proliferative properties in common with CFU-S, and as such offers a means of 
measuring read out of transient engrafting populations (Jones et al., 1990; 
Pragnell et al., 1988). The only modification to the CFU-A assay, in some 
instances, was that for read out of lineage negative progenitors, L929-CM and 
AF1-19T-CM were replaced by rhM-CSF (6ng/ml), rmGM-CSF (0.2ng/ml) 
and rmSCF (12ng/ml).
Cycling / Suicide assay
To obtain estimates of the proportion of CFU-GM or CFU-A in S phase, bone 
marrow cells were incubated in vitro as follows. The test bone marrow cells 
were divided into two aliquots of 1-5 x 10^ cells each and each was incubated 
in 1ml F/10 for 1 hour at 37°C; one of the paired tubes also containing 10"^M 
ARA-C. The control aliquots were incubated in F/10 only. After incubation, 
cells were washed three times with F/10, re-suspended to appropriate cell 
concentrations, and used in the respective clonogenic assays mentioned above. 
CFU-GM or CFU-A numbers in these assays were calculated by averaging at 
least 10 plates. The CFU-GM and CFU-A proliferative status in each case was 
derived by comparison of the plus and minus ARA-C data to calculate the
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proportion of progenitors sensitive to ARA-C and, hence, the proportion in S 
phase at the time of ARA-C treatment.
Selection of Lineage Negative Cells and Fluorescence Activated Cell 
Sorting (FACS) for Stem Cell Antigen (Sea) Positive Fractions
For experiments in which lineage negative populations were to be further 
purified to select Sea positive cells, bone marrow cells were harvested from 
tibia and femora of B6D2F1 mice 2 days after a tail vein injection of 5- 
Fluorouracil at 150mg/kg body weight. In other experiments normal bone 
marrow cells were used as the starting population. Bone marrow cells were 
re-suspended in Ca^+, Mg^+ free PBS containing 2% foetal calf serum 
(PBS/2) and enriched by density gradient cell separation by layering 3ml of 
the cell suspension (2.5 x lO^/ml) on top of 3ml Nycodenz mixture (density 
1.077g/ml) and spinning at lOOOg for 30 minutes at room temperature. The 
interface cells were harvested, washed once and re-suspended in PBS/2. These 
cells were further enriched for lineage negative progenitor content by using 
indirect immunomagnetic selection to remove mature cells according to 
previously described methods (Hirayama et al. , 1994; Shih & Ogawa, 1993). 
The antibodies used included Gr-1 to remove mature granulocytes, B220 to 
remove B cells, Mac 1 to remove monocytes and macrophages, CD5 and 
CD8a to remove T cells. Antibody labelling was performed for 45 minutes on 
ice. The labelled cells were washed three times and re -uspended in PBS/2, 
mixed with Dynabeads (M-450 sheep anti-rat IgG) at a 1:30 cell:bead ratio 
and incubated at 4°C for 45 minutes with end-over-end rotation. The tube 
containing the cells was then placed in a Dynal MPC-1 magnetic particle 
concentrator (DYNAL, Great Neck, NY, USA) for 10 minutes. The non- 
rosetted cells were harvested using a Pasteur pipette, washed once, re­
suspended in PBS/2 and kept on ice for further enrichment by cell sorting. 
These cells were designated lineage negative. Prior to FACS, lineage negative
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cells were incubated with Sca-FITC antibody for 45 minutes on ice. The cells 
were then washed three times and re-suspended in PBS/2 for sorting. Flow 
cytometric analyses and cell sorting were performed on a FACStar (Becton 
Dickinson) with an argon-ion laser tuned to 488nm at power 200mW. FITC 
fluorescence was measured through a filter arrangement with peak 
transmittance at 530nm. Cells with medium to high forward scatter intensity, 
low orthogonal scatter intensity and high fluorescent intensity were sorted into 
a 12 x 75 mm round bottom plastic tube containing 2ml of a-MEM. These 
cells were designated Sca+ lin-. Lineage negative populations labelled with 
Sca-FITC, contained approximately 11% (range 8-12.5) Sea positive cells.
Liquid Suspension Cultures for ex vivo Expansion 
Bone marrow cells were suspended in a-MEM, supplemented with 25% DHS 
and the appropriate growth factors, in 24 well plates or in tissue culture flasks 
at a density of 0.5 x 10^ per ml for unfractionated cells, 0.1 x 10^ per ml for 
lineage negative populations and 0.05 x 10^ per ml for Sca-i- lineage negative 
cells. Cultures were incubated at 37°C in a fully humidified atmosphere of 5% 
CO2 in air. For cultures maintained beyond 7 days, medium and growth 
factors were replenished at least every 7 days. Following expansion, the cells 
were harvested by vigorous pipetting, washed once in a-MEM and counted 
using a Coulter counter. The ex vivo amplifcation factor was derived from the 
increase in total cell number over time multiplied by the increase in the 
number of colonies per 10^ cells plated.
Bone Marrow Transplantation (BMT)
B6D2F1 mice received fractionated radiation, titrated to produce 100% 
mortality from bone marrow aplasia by day 30 in control mice (no BMT). A 
total of 11.75-12.5Gy in two fractions three hours apart was given at a dose 
rate of 1.13Gy per minute using a Cobalt-60 source. Fractionated radiation
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exposure is thought to allow some repair of rapidly proliferating tissues such 
as the gastrointestinal tract and lungs and hence to prevent early deaths due to 
radiation toxicity (Spangrude & Scollay, 1990). Using this protocol less than 
5% of test animals (receiving a cell dose above threshold for engraftment) 
died before day 7 from radiation toxicity. The bone marrow infusions were 
given as a single injection (0.1ml) via the tail vein one hour after irradiation. 
All animals which received no bone marrow cells died from bone marrow 
aplasia between days 6-18 post-irradiation.
Transplantation of Spleen Cells
To investigate whether certain test cells were capable of producing a 
transplantable leukaemia, groups of mice were given a 2Gy dose of radiation. 
Spleen cells from a variable number of test animals were pooled and used to 
transplant sublethally irradiated animals (groups of 5 animals) by 
intraperitoneal injection of 10^ cells per mouse. The transplanted animals 
were then observed for survival and upon showing signs of serious malaise 
were sacrificed by CO2 asphyxiation. Analyses were performed for spleen and 
bone marrow pathology, full blood count (FBC), flow cytometric analyses and 
fluorescence in situ hybridisation.
Serial Transplantation and Assessment of Long Term Bone Marrow 
Reconstitution
To assess the ability of expanded populations to sustain haemopoiesis in the 
long term, serial syngeneic BMT, using different test bone marrow samples, 
was performed as follows. Male B6D2F1 mice were used as donors, females 
as recipients. Primary (1°) BMT recipients received a cell dose of 5 x 10  ^
(based on the number of cells at the start of ex vivo expansion culture). For 
secondary (2°) and subsequent BMT the cell dose was 5 x 10^. At various 
time points following BMT, analyses were performed for FBC, femur
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cellularity and CFU-A content, percentage donor haemopoiesis by Southern 
blotting and ability to sustain serial transplantation.
Molecular Techniques
Propagation of Plasmid DNA in Bacterial Cells
DH5a competent cells, were transformed with the plasmid construct of 
interest. DH5a cells were first removed from -70°C and thawed on ice for 20 
minutes. 20|il aliquots were dispensed into pre-chilled sterile 1.5ml eppendorf 
tubes, then three l|il aliquots (neat, 1/10,1/50 dilutions) of plasmid construct 
were added and incubated on ice for 30 minutes. The cells were then "heat 
shocked" at 42°C for 40 seconds exactly, returned to ice for 2 minutes and 
80|il of SOC medium was added. This mixture was shaken at 225 rpm for 1 
hour at 37°C to allow expression of the ampicillin resistance gene. The 
transformed cell mixture was spread evenly, using a glass spreader sterilised 
by flaming in ethanol, onto L-amp plates (5ml of 1% bactotryptone, 0.5% w/v 
yeast extract, 1% sodium chloride, 1.5% bactoagar) supplemented with 
50(ig/ml ampicillin. Plates were then inverted and incubated at 37°C 
overnight.
Growth of Plasmids
A single bacterial colony was plucked from an L-amp plate using a sterile 
loop and added to 10ml of L-amp broth in a universal container. This was 
incubated for 16 hours at 37 °C shaking at 225 rpm. After incubation, 1ml of 
the mixture was added to 100ml of L-amp broth in a one litre conical flask and 
this was incubated under identical conditions for a further 16 hours. The 
suspension was then transferred to 50ml centrifuge tubes and spun at 3000 
rpm for 10 minutes in a Beckmann J-6B centrifuge containing a GS-3 rotor. 
The supernatant was decanted and the pellet was then ready for plasmid 
preparation.
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Plasmid Preparation
Plasmid preparation was performed using the commercially available Qiagen 
plasmid kit. The bacterial pellets were re-suspended in 5ml of re-suspension 
buffer (lOOmg/ml RNase A, 0.05M Tris/HCL, 0.01M EDTA, pH 8.0) in 50ml 
centrifuge tubes (Sorvall Instruments). 4ml of lysis buffer (0.2M NaOH, 1% 
SDS) was then added, the solution was mixed gently by inversion and 
incubated at room temperature for 5 minutes. 4ml of chilled neutralisation 
buffer (3M Potassium Acetate, pH 5.5) was added, mixed and incubated on 
ice for 15 minutes. Tubes were then spun at 4°C for 30 minutes at 10,000 
rpm in a Sorvall RC-5B superspeed centrifuge containing SS-34 rotors. The 
supernatant was then poured through a double layer of gauze swab to remove 
particulate material. To purify the DNA, a Qiagen-tip 100 column was 
equilibrated with 4ml of equilibration buffer (0.75M NaCl, 0.05M MOPS, 
15% ethanol, 0.15% Triton X-100, pH 7.0) and the filtered supernatant was 
applied to the column. The column was then washed twice with 10ml of wash 
buffer (1M NaCl, 0.05M MOPS, 15% ethanol, pH 7.0). The DNA was eluted 
from the column using 5ml of elution buffer (1.25M NaCl, 0.05M Tris/HCL, 
15% ethanol, pH 8.5). DNA was precipitated with 0.7 volumes of isopropanol 
and centrifuged at 10,000 rpm at 4°C for 30 minutes as before. The DNA 
pellet was washed with 5ml of cold 70% ethanol, air dried for 5 minutes, and 
re-suspended in sterile distilled H2O. The DNA concentration was then 
measured by spectrophotometry.
Purification of an Insert from a Plasmid
Plasmid DNA was digested in a solution containing 20|ig DNA, 40pi of 
appropriate 10 x R e a c t ™  buffer, lOpl of appropriate enzyme and H2O to 
400|il. Digestion was carried out for 2 hours at 37°C, after which the DNA 
was precipitated by adding 0.1 volumes of 3M sodium acetate and 2.5
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volumes of ethanol. The tube was then placed on ice for 15 minutes and was 
spun at 13, 000 rpm for 10 minutes in a benchtop micro-Centaur centrifuge. 
The supernatant was carefully removed and the tube was respun for 1 minute 
only. Residual supernatant was removed and the pellet was washed once in 
70% ethanol. Following this wash, the supernatant was again removed 
following a 10 minute and a 1 minute spin. The tube was then placed, open, in 
a 65°C heating block to allow any remaining ethanol to evaporate. The pellet 
was then re-suspended in 20jli1 of 1 x  TE.
DNA restriction fragments were separated by 0.8% low melting point 
(LMP) agarose gel electrophoresis and visualised by ethidium bromide 
staining with ultraviolet illumination. The plasmid insert was excised from the 
gel and placed in a 1.5ml eppendorf tube. The tube was placed at 65°C in a 
heating block to melt the agarose. Low salt buffer (LSB)was equilibrated to 
42°C in a water bath. After completely melting the agarose, this was added to 
10ml of low salt buffer and returned to the 42°C water bath. Two Elutip-D- 
columns were equilibrated, first with 5ml of high salt buffer (HSB, room 
temperature), then with 5ml of LSB at 42°C, in each case by passing the 
buffer through the columns at high pressure using a 5ml syringe. The agarose / 
DNA solution was then applied to the columns (5ml per column) in a similar 
manner, after which the columns were washed with 5ml LSB at 42°C, before 
eluting the DNA from the columns with 0.6ml HSB. The resulting 1.2ml of 
DNA in HSB was precipitated with 3 volumes of ethanol, pelleted by 
microcentrifugation, washed with 70% ethanol, and re-spun to ensure removal 
of all residual ethanol. The sample was then re-suspended in 50|il of 1 x TE. 
The concentration of the re-suspended DNA insert was estimated by 1.5% 
agarose minigel electrophoresis and ethidium bromide staining, in comparison 
with a DNA mass ladder, run in parallel with the sample. A volume equivalent 
to 50ng was then used to make radioactive DNA probes.
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Preparation of Radioactive DNA Probes
DNA inserts were first denatured by boiling for 2 minutes (DNA in solution) 
or 7 minutes (DNA in agarose) and placing on ice for 2 minutes. All DNA 
probes used for hybridisation to Southern blots were labelled for 15 minutes 
(DNA insert in solution) or 1 hour (DNA insert in agarose) at 37 °C with [a- 
32p]-dCTP, using a random priming kit according to the manufacturer's 
instructions. After labelling, the radioactive probe was separated from 
unincorporated 32p_iabeiied nucleotides by passing through a Nick column, 
equilibrated with 1 x TE, according to the manufacturer's instructions. The 
probes were then denatured by boiling for 2 minutes, and placing on ice for 2 
minutes.
Phenol Preparation
Phenol and chloroform were both used to remove protein contamination from 
DNA samples. Before use, phenol was equilibrated to a pH >7.8. For 
equilibration, an equal volume of 10 x TE was added and mixed thoroughly. 
After the two phases had separated, the upper phase was decanted and the 
procedure was repeated once or until pH > 7.8, with 1 x TE.
Phenol / Chloroform Extraction
An equal volume of phenol, phenol / chloroform or chloroform alone was 
added to the lysed cell suspension. The mixture was inverted gently and 
repeatedly for 10 minutes before spinning at 3,000 rpm for 10 minutes. The 
top layer was aspirated and was used for the next step in the same way.
Preparation of Mammalian Genomic DNA
Cells were re-suspended in 1 x TE to a final concentration of 5 x 10^ cells/ml, 
and 10ml of extraction buffer added per ml of cells. After 60 minutes 
incubation at 37°C, mixing gently on a Stuart TR-2 tube rotator, proteinase K
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was added to a final concentration of 0.1 mg/ml. This was gently mixed and 
placed in a 55°C water bath for at least 3 hours, swirling periodically. After 
cooling to room temperature, the protein fragments were removed by two 
phenol only, one phenol/chloroform and one chloroform only extractions. 
DNA was ethanol precipitated (2.5 volumes ethanol and 0.1 volume of 3M 
sodium acetate pH 5.2) and collected by spooling it onto a clean Pasteur 
pipette moulded into a hook shape over a Bunsen. The DNA was allowed to 
air dry for 15 minutes then slowly re-suspended at room temperature for at 
least 24 hours, in a volume of 1 x TE such that 1ml was included for every 2 x 
107 cells in the original sample. The final solution was stored at -20°C: the 
DNA concentration was determined spectrophotometrically just prior to use.
Measurement of DNA Concentration by Spectrophotometry
The absorbence (A) at 260nm and 280nm of DNA in solution was measured 
in a 500pi quartz cuvette. Distilled water was used as a blank. An absorbence 
of 1 unit (i.e. one optical density (OD)) is equivalent to 50pg/ml of plasmid or 
genomic DNA. The OD260/280nm ratio gives an estimate of the purity of the 
DNA. Pure preparations of DNA have an OD260/280nm ratio of 1.8. If the 
OD at 260nm was greater than 1.0, the sample was further diluted in 1 x TE 
and the OD was repeated. If the 260/280nm ratio was significantly < 1.8, 
further phenol, phenol/chloroform, chloroform extractions were performed 
and the OD was repeated.
Digestion of Genomic DNA
Digests of genomic DNA were performed in eppendorf tubes at 37°C. The 
required amount (usually lOpg) of DNA was re-suspended in 1 x TE. 10 x 
buffer was added to 1/10 of the final volume. H2O was added to make up to 
the final volume. The chosen restriction enzyme was added at 1/10 of the total 
digest volume in two aliquots, the first at the start of digestion and the second
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after 2-4 hours. Digestion was usually carried out overnight. Following 
digestion a single phenol/chloroform extraction was performed. The DNA was 
precipitated by adding 2.5 volumes of ethanol and 0.1 volume of sodium 
acetate and placing on ice for 15 minutes. The sample was then centrifuged for 
10 minutes and the supernatant removed. Following salt/precipitation, the 
DNA was washed once in 70% ethanol, then as much ethanol as possible was 
removed before resuspending in 1 x TE overnight.
Agarose Gel Electrophoresis
0.8% agarose gels were made by adding 2g agarose to 250ml 1 x TAE. 12.5|il 
of ethidium bromide was added to the gel (stock 10|ig/ml). Loading buffer 
(6X) was added to the DNA digests to 1/6 of the final voume and the DNA 
samples were loaded into the gel. A 1Kb molecular weight ladder was always 
included in the gel. The gels were run at 100 volts until good separation of the 
higher molecular weight fragments was obtained. The gels were then viewed 
and photographed under ultraviolet illumination. These photographs were 
retained to allow assessment of the quantity of DNA loaded into each well.
Detection of Specific Genomic DNA Sequences by Southern Blotting
After overnight digestion of the test DNA samples, gel loading buffer was 
added, and the DNA was electrophoresed for 4-6 hours at 100 volts on a 0.8% 
agarose gel. The gel was then visualised under ultraviolet light, photographed 
and trimmed to remove excess agarose. The gel was then depurinated by 
soaking in 0.25M HCL for 15 minutes with constant gentle agitation. After 
rinsing with deionised H2O, the gel was denatured by soaking in denaturation 
buffer for 45 minutes, again with constant agitation. This was followed by 
soaking twice for 30 minutes in neutralisation buffer. Following 
neutralisation, the gel was inverted and placed on 3MM paper on a solid 
support over a reservoir of 20 x SSC. The edges of the 3MM paper were under
72
the surface of the 20 x SSC solution. 4 pieces of 3MM paper and in addition a 
piece of Hybond membrane, were cut to the size of the gel, soaked in 2 x SSC 
then placed on top of the gel with the Hybond membrane adjacent to the gel. 
Air bubbles were expressed by rolling the side of a Pasteur pipette across the 
membrane before applying the 3MM paper. Unwanted, used X-ray film was 
placed around the gel in such a way as to ensure that 20 x SSC from the 
reservoir would only diffuse through the gel. Paper towels were then stacked 
on top of the 3MM paper, a glass plate was placed on top and this was 
weighed down with a filled 500ml bottle. This was left overnight to allow 
capillary transfer of the DNA out of the gel and on to the membrane. The 
membrane was then carefully removed, the well positions were marked with a 
biro pen and the membrane was washed once in 2 x SSC to remove traces of 
agarose. The DNA was fixed to the membrane by exposure to ultraviolet light 
(UV Stratalinker). The membrane was incubated overnight in 25ml pre­
hybridisation buffer, then hybridised overnight in 10ml of the same buffer, to 
which the radioactive probe of interest had been added. Following 
hybridisation, the membrane was sequentially washed in: 200ml washing 
solution 1 (2 x SSC, 0.1% SDS) for 15 minutes at room temperature; then in 
the same solution for 30 minutes at 68°C; then with washing solution 2 (0.1 x 
SSC, 0.1% SDS) for 30 minutes at 68°C for one or two washes depending on 
the level of background radioactivity remaining on the membrane. After 
washing, the membrane was sealed in a thin polythene bag and exposed to X- 
ray film at -70°C.
Assessment for Donor Derived Haemopoiesis in Transplantation 
Experiments
The percentage of male donor haemopoiesis was assessed by Southern 
blotting using a Y chromosome specific probe. pY353/B, which consists of a 
1.5-kilobase (kb) fragment, was used to probe EcoRl digested genomic blots
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from the transplanted animals. In addition to the cognate 1.5-kb band, the 
probe detects four homologous bands of 5,7, 9.5 and 15kb (Bishop et al., 
1985). Equal amounts (10pg) of DNA from individual mice were digested 
with EcoRl and then separated on 0.8% agarose gels and transferred to 
Hybond N membrane by Southern blotting. No hybridisation was detected 
with female DNA. A standard titration of male DNA diluted into female DNA 
was included with all test samples to allow quantification of the proportion of 
male DNA (donor) to female DNA (recipient). The comparability of loaded 
DNA was determined as necessary by reprobing membranes with a probe for 
GAPDH. The radiographs were scanned as necessary by densitometry. 
Calculations of percentage male DNA were adjusted based on amounts of 
DNA loaded in each well.
Preparation of Chromosome Spreads for Fluorescence in situ 
Hybridisation (FISH)
Single cell suspensions were first prepared from either spleen or bone marrow 
in RPMI supplemented with 20% FCS, 1% glutamine and colcemid (final 
concentration 0.02fig/ml) to a cell concentration of approximately 5 x 10^/ml. 
These cells were cultured at 37°C, 5% C02 and air for one hour. After 
incubation, the cells were spun at 1200 ipm for 10 minutes, the supemantant 
was decanted, and the pellet was re-suspended by tapping the tube. Freshly 
prepared hypotonic potassium chloride warmed to 37°C (0.5g KC1 in 100ml 
DW) was then added dropwise, whilst flicking constantly to a final volume of 
10ml. The cells were then incubated at 30°C for 20 minutes before spinning at 
1000 rpm for 10 minutes. The hypotonic solution was then decanted and the 
pellet was re-suspended by flicking the tube. Freshly prepared fixative 
(methanol: acetic acid, 3:1) was then added dropwise whilst flicking to a final 
volume of 5ml. Any obvious clumps were removed at this stage. The cells 
were left at room temperature for 10 minutes, then spun at 1200 rpm for 10
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minutes, the supernatant fixative was decanted and the last step was repeated 
once, this time incubating the cells for 30 minutes instead of 10 minutes. The 
cells were then ready for storage at -20°C in 5ml of fixative.
FISH chromosome painting protocol
Chromosome painting was performed by Katherine Harper (MRC, Oxon) 
according to the method described in a recent report by Fennelly et al 
(Fennelly et al., 1996).
Direct bone marrow chromosome preparations
Chromosome preparations were performed by Gwyneth Watson (MRC, Oxon) 
using the methods described by Watson et al (Watson et al.y 1996) and Piper 
& Breckon (Piper & Breckon, 1989).
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RESULTS I
Chapter 3 Cvtokine Interactions In vitro
The primary aim of this work was to determine whether haemopoietic stem 
and progenitor cells may be expanded in vitro, in the presence of growth 
factors, but in the absence of a fully formed bone marrow stromal layer. An 
important endpoint was to develop culture conditions which would encourage 
amplification of "transient engrafting stem cells" and to compare the 
engraftment potential of the cultured cells against unmanipulated bone 
marrow cells in an in vivo BMT model. Finally, if transplantation with 
cultured cells led to more rapid haematological recovery following BMT, 
compared with unmanipulated cells, then the effect of in vitro culture on the 
long term repopulating stem cells should be investigated.
The stimulatory cytokines may be divided into late-acting lineage specific, 
intermediate-acting lineage non-specific, factors which effect the kinetics of 
quiescent primitive progenitors and those which support survival without 
proliferation of primitive progenitors (Ogawa, 1993). Although useful in 
planning growth factor combinations for investigation, this division is 
somewhat arbitrary since, even within the haemopoietic system, cytokines 
have been shown to exhibit multiple functions affecting cells at different 
stages and there appears to be functional redundancy among cytokines, 
particularly those which are considered early-acting. The growth factor 
combination selected for study should include factors which support survival 
and / or proliferation of the most primitive progenitors and promote 
proliferation with limited differentiation of stem cells responsible for transient 
engraftment (CFU-GM, CFU-A, CFU-S). The growth factors considered to 
support survival of dormant primitive progenitors include SCF and IL-3 
(Katayama etal., 1993).
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In the first series of experiments late-acting (EPO, G-CSF, M-CSF), 
intermediate-acting (GM-CSF, IL-3) and early-acting (SCF, IL-11, IL-6, G- 
CSF) cytokines were tested, either alone, or in combination, for their ability to 
amplify transient engrafting stem cells in vitro. Although IL-1 may be 
included with the early acting cytokines, there is evidence that its effects are 
indirect, perhaps mediated by either IL-6 or G-CSF (Leary et al., 1988).
Unfractionated murine bone marrow cells were established in culture in a- 
MEM supplemented with 25% DHS and growth factors in 24 well plates. The 
duration of culture was kept constant at 6 days to allow comparison between 
different growth factor combinations. MRead-out" before and after expansion 
culture was for cell number, CFU-A and CFU-GM progenitors. The 
amplification factor was derived from the increase in both cell number and 
progenitor number. As shown in figure 3.1a, CFU-A progenitors were 
maintained at input numbers, even in the absence of growth factor addition. 
This suggests that DHS may contain sufficient amounts of certain growth 
factors to allow survival of CFU-A progenitors. The only growth factor which 
promoted expansion of CFU-A numbers when used alone was SCF. The SCF 
used in this series of experiments was in medium conditioned by CHO cells 
expressing soluble Kit Ligand, via truncation of the cDNA 51 to the 
transmembrane domain (Anderson et al., 1990). Since this material was not 
purified, this result could be due to synergism between the SCF, known to be 
present in the conditioned medium, and small amounts of other unknown 
factors. In a small number of experiments purified murine recombinant SCF 
was tested, either alone or in combination with IL-11, for its ability to promote 
amplification of CFU-A progenitors. In these experiments, CFU-A 
amplification was of a similar degree to that achieved using the conditioned 
medium (data not shown).
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Figure 3.1 a Cytokine combinations for the amplification of murine 
CFU-A progenitors in culture
Unfractionated murine bone marrow cells were cultured for 6 days in 24 well 
plates as described in materials and methods. Cytokines, either singly or in 
combination, were added at the start of culture only. IL-3 (50ng/ml), IL-6 
(50ng/ml), IL-11 (lOOng/ml), G-CSF (1:10,000), GM-CSF (25ng/ml), M-CSF 
(200ng/ml), Epo (2units /ml), SCF (18ng/ml), IL-1 (3 (lOng/ml). Mean 
amplification factors (AF) (± SEM) for CFU-A progenitors. Each cytokine 
combination presented was tested in at least three separate experiments.
Figure 3.1 b Cytokine combinations for the amplification of murine 
CFU-GM progenitors in culture
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Figure 3.1b
As SCF was active in inducing expansion of CFU-A progenitors, growth 
factor combinations involving SCF plus a second early, or intermediate- 
acting, growth factor were investigated. As shown in Figure 3.1a, SCF 
synergised with IL-11, IL-6, G-CSF and IL-ip to promote CFU-A 
amplification. Although the combination of SCF and IL-11 consistently 
produced the greatest amplification, this was not significantly greater than for 
SCF with IL-6, G-CSF or IL-ip. SCF in combination with IL-3 produced no 
measurable CFU-A amplification and the baseline amplification seen with 
SCF alone was abolished. Similar results were seen when IL-3 was included 
in any combination containing two, three or more growth factors. When cell 
morphology was examined following expansion culture, conditions which 
promoted CFU-A amplification produced a population of myeloid precursors, 
the majority of which were blast cells and promyelocytes with smaller 
numbers of more mature cells. In cultures supplemented with IL-3, few, if 
any, blast cells remained, with neutrophils and macrophages predominating. 
Further investigation of SCF and IL-11 plus additional early, intermediate or 
late acting cytokines failed to detect a combination which produced greater 
CFU-A amplification than for SCF and IL-11 alone. Similar results were 
obtained for more committed CFU-GM progenitors (Figure 3.1b).
Having investigated a range of stimulatory cytokines, both early and late 
acting, experiments were designed to examine whether inhibitory cytokines 
could play a role in stem cell expansion. The negative regulators TGF-P and 
M IP-la have been shown to have bi-directional effects (i.e. either stimulatory 
or inhibitory) depending on the maturational stage of the target population, 
whereas the interferons and TNF-a appear to be lineage non-specific 
inhibitory factors affecting progenitor cells at all developmental stages
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(Ogawa, 1993; Keller et al., 1994). For this reason, only TGF-p and M IP-la 
were studied.
Unfractionated murine bone marrow cells were cultured for 6 days in 24 well 
plates as before. The optimum combination of SCF and IL-11 was used as a 
baseline for its known ability to promote amplification of both CFU-A and 
CFU-GM progenitors. Both negative regulators were added to cultures every 
48 hours to ensure adequate concentrations throughout the culture period. As 
shown in Figure 3.2a-c, neither MIP-la nor TGF-P, when used alone, 
stimulated proliferation of CFU-A or CFU-GM progenitors. When added to 
the combination of SCF and IL-11, MEP-la produced a small but consistent 
increase in the degree of progenitor expansion achieved. This difference over 
SCF and IL-11 alone did not reach statistical significance. The addition of 
M IP-la was never observed to produce an inhibitory effect under the culture 
conditions described. When TGF-P was added to SCF and IL-11 
supplemented cultures, the opposite effect was seen. TGF-P completely 
abolished progenitor expansion, even in the presence of stimulatory cytokines. 
It is well recognised that these negative regulators may exert distinct effects 
depending on the differentiation status of the target cell and the other 
cytokines interacting with the cell.
A time course was then performed, using identical culture conditions and the 
same growth factor combinations, to determine whether the apparent 
stimulatory effect of MIP-la was more obvious at an earlier stage of 
expansion culture. This time course was repeated twice (Figures 3.3 and 3.4) 
with similar results. Very little progenitor expansion was observed prior to 
day 6 of culture and the possible enhancing effect of M IP-la was no more 
apparent earlier in the culture period. The inhibitory effect of TGF-P was seen
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Figure 3.2 a-c Amplification factors for a. cell count, b. CFU-A 
progenitors and c. CFU-GM progenitors during ex vivo culture
Unfractionated murine bone marrow cells were cultured for 6 days in 24 well 
plates as described in materials and methods. SCF and IL-11 were added at 
the start of culture only. M IP-la (lOOng/ml) and TGF-p (lOng/ml) were 
added every 48 hours. Mean amplification factors (± SEM) are shown for 
four replicate experiments.
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Figures 3.3 a-c &3.4 a-c A six day time course for the amplification of a. 
cell count, b. CFU-A progenitors and c. CFU-GM progenitors
Unfractionated murine bone marrow cells were cultured in 24 well plates as 
described in materials and methods. SCF and IL-11 were added at the start of 
culture only. M IP-la and TGF-P were added every 48 hours. Replicate wells 
were harvested on days 2, 4 and 6 to assess the optimum duration of ex vivo 
culture. The results shown are for the mean amplification factors (±SD) for a 
single experiment which was repeated on two occasions.
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from the start of culture and was never overcome by the stimulatory cytokines 
present.
In the next experiment (Figure 3.5) the addition of M IP-la to expansion 
cultures supplemented with SCF and IL-11 was examined in more detail. The 
first culture was supplemented with SCF and IL-11 at the start of incubation 
and was used to standardise the experiment In the second culture, M IP-la 
was added on days 0,2 and 4, as before. In the third culture M IP-la was 
added at the start of culture, and was then washed out on day 2 to determine 
whether its effect occurred very early during expansion culture and whether 
M IP-la was unnecessary thereafter. In the fourth culture M IP-la was added 
only on day 0 but was not washed out, to determine whether alternate day 
addition of MIP-la was necessary to maintain an enhancing effect on 
progenitor expansion. The results of this experiment are difficult to interpret, 
because the degree of enhancement of progenitor expansion seen in the 
presence of MIP-la is small and does not reach statistical significance, 
therefore any changes induced by altering the culture conditions, as done in 
this experiment, are even more difficult to demonstrate. From the results 
shown in Figure 3.5 it appears that M IP-la should be added at least every 48 
hours and that any enhancing effect by this cytokine is abolished if either the 
cytokine is washed out after the first 48 hours of culture, or if it is added only 
at the start of culture.
Having demonstrated that SCF and IL-11 in combination promoted 
amplification of both CFU-A and CFU-GM progenitors during a short (6 day) 
culture period, it was important to try to determine whether this result was due 
only to differentiation of a committed progenitor subset and therefore would 
disappear with prolonged culture or whether a more primitive stem cell subset 
had been triggered into cell cycle. Experiments were therefore designed to
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Figure 3.5 A comparison of repeated addition of MIP-la to ex vivo 
expansion cultures versus addition only at the start of culture
Unfractionated murine bone marrow cells were cultured for 6 days in 24 well 
plates as described in materials and methods. All experimental cultures were 
initially supplemented with SCF and IL-11. Except for the SCF/IL-11 only 
culture (columns 1 & 2), M IP-la (lOOng/ml) was also added on day 0. On 
day 2, culture three (columns 5 & 6) was harvested, washed once and was re­
established in fresh medium, supplemented with SCF (18ng/ml) and IL-11 
(lOOng/ml). No further M IP-la was added to this culture. Culture two 
(columns 3 & 4) was supplemented again with M IP-la (lOOng/ml) on days 2 
and 4. Culture four (columns 7 & 8) was supplemented with MIP-la on day 0 
only. After 6 days culture all four experimental cultures were harvested in the 
usual way and were plated into CFU-A and CFU-GM. The mean 
amplification factors (+ SEM) are shown for both CFU-GM and CFU-A 
progenitors. Results represent the mean of three replicate experiments.
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assess whether CFU-A and CFU-GM expansion could be maintained beyond 
6 days and if so, what effect the addition of M IP-la to SCF and IL-11 would 
have. Figure 3.6 shows the amplification factors for cell count, CFU-GM and 
CFU-A for unfractionated bone marrow cells cultured for five weeks with 
SCF and IL-11. At each time point the expanded populations were washed, 
counted, assayed for CFU-GM and CFU-A and an aliquot re-established in 
culture with fresh medium and growth factors at a cell density of 0.5 x 
lOfyml. The total number of cells in culture increased exponentially over time 
to a maximum 4, 500 (+ 1152) fold by day 39. Although total CFU-GM 
numbers were still increasing (maximum 20, 000 (+ 9839) fold) at day 39 of 
culture, total CFU-A amplification peaked at 1000 (+ 347) fold at day 32 and 
the amplification potential was declining by day 39. The plating efficiency for 
CFU-A increased from 0.15% on day 0, to peak at 5.8% by day 6. Thereafter, 
plating efficiency was maintained above baseline to day 14 and was still close 
to baseline (0.12%) by day 32. Therefore, these cultures do expand over the 
first two weeks and do not appear to exhaust before day 32. These results 
show the profound ability of the SCF and IL-11 cytokine combination to 
expand the transient engrafting stem cell compartment ex vivo and suggest that 
this particular cytokine combination induced proliferation of a primitive cell. 
In the absence of a fully formed stromal layer, despite the regular addition of 
positively acting growth factors, these cultures eventually showed depletion 
of amplification ability. It is possible that some stromal elements formed in 
these cultures although this would have been disrupted with every medium 
change. This was not specifically looked at in these experiements.
The results for parallel cultures supplemented with M IP-la in addition to SCF 
and IL-11 are shown in Figure 3.7. The cell count reached a maximum of 
1014 (+ 734) fold over baseline by day 32 and was falling by day 39. CFU-
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Figure 3.6 The amplification of murine bone marrow progenitors in
culture with SCF and IL-11
Unfractionated murine bone marrow cells were cultured for 39 days in tissue 
culture flasks as described in materials and methods. SCF and IL-11 were 
added at the start of culture and again with fresh medium at each time point. 
The amplification factors (logarithmic scale) for cell number, CFU-GM and 
CFU-A are shown against days in culture to day 39. Results represent the 
mean (± SEM) for three replicate experiments.
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Figure 3.7 The amplification of murine bone marrow progenitors in
culture with SCF, IL-11 and MIP-la
Unfractionated murine bone marrow cells were cultured for 39 days in tissue 
culture flasks as described in materials and methods. SCF and IL-11 were 
added at the start of culture and again with fresh medium at each time point. 
M IP-la was added every 48 hours. The amplification factors (logarithmic 
scale) for cell number, CFU-GM and CFU-A are shown against days in 
culture to day 39. Results represent the mean (± SEM) for three replicate 
experiments.
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GM peaked at 4261 (+ 3867) by day 25, and then began to decline and CFU-A 
reached a maximum of only 270 (+ 102) fold over baseline.
The reduced expansion potential in the presence of MIP-la, compared with 
SCF and IL-11 alone, may be explained by the fact that one of the three 
replicate experiments showed extremely poor expansion from day 12 of 
culture. The inclusion of results from this experiment resulted in a lower mean 
amplification for the three replicate experiments and a much wider SEM for 
the later time points. In the early part of these parallel expansion cultures no 
difference could be detected in terms of progenitor expansion between 
cultures supplemented with only SCF and IL-11 and those with SCF, IL-11 
and MIP-la. Thereafter, there was no evidence that MDP-la was stimulatory 
for progenitor output. Whether the MIP-la cultures genuinely showed a 
decline in progenitor output earlier than the cultures without M IP-la is 
unlikely since two of three MIP-la supplemented cultures continued to show 
progenitor expansion at least to day 32.
Accessory cells in unfractionated bone marrow may either secrete growth 
factors independently, or may be induced to produce growth factors or 
inhibitory factrs by cytokines which are known to be present (i.e. an indirect 
effect). Both IL-ip and TNF-a appear to work indirectly by inducing cytokine 
production by accessory cells. MDP-la has a role in the inflammatory process 
and as such could be anticipated to induce either growth factor or inhibitor 
secretion by accessory cells. One way to reduce the possible effects of 
accessory cells present in bone marrow is to purify stem and progenitor cells. 
An additional advantage of stem cell purification would be that if the activity 
of M IP-la was directed at a primitive target cell then the effect on progenitor 
expansion may become more obvious in experiments with a relatively pure 
population of primitive cells. Day 2 post 5-FU bone marrow from a pool of
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Expansion conditions Experiment 1 
(% blasts)
Experiment 2 
{% blasts)
Mean
(% blasts ±SD)
SCF/IL-11 22.7 37.1 30.0 ± 10
SCF/IL-11 /MIP-la 54.7 60.4 58.0 ± 4
Results based on 500 cell differential counts
s c p / i l - \ y
twenty mice was used to prepare a lineage negative fraction as described in 
materials and methods. This fraction is depleted of B cells, T cells, mature 
myeloid cells, monocytes and macrophages. The lineage negative cells were 
then established in expansion culture with SCF and IL-11 +/- MIP-la. The 
cells were incubated for 6 days as before. As shown in Figure 3.8, whereas, 
for unfractionated bone marrow, cell number increase was in the range of only 
2-3 fold, lineage negative cells expanded dramatically in culture to around 200 
fold by day 6. This increase in cell number reflects both the enrichment by 
using post 5-FU bone marrow and the depletion of mature cells. It is also 
likely that inhibitory proteins are produced in unfractionated cultures which 
would be absent or present at only low levels in more purified populations 
(e.g. TGF-P). CFU-A progenitors amplified to 400 fold over baseline by day 6 
but no effect on CFU-A expansion was observed when M IP-la was added to 
the combination of SCF and IL-11. The morphology of the starting lineage 
negative fraction was predominantly blast cells (>95%). At the end of 6 days 
expansion, lineage negative cells amplified in the presence of SCF and IL-11 
showed differentiation down the myeloid lineage with some blast cells 
remaining, but also promyelocytes and more mature cells including 
neutrophils appearing. The addition of M IP-la produced a striking change in 
morphology compared with SCF and IL-11 alone. The majority of the cells 
were still blast cells with some promyelocytes, but with far fewer mature cells
i
such as neutrophils. I
(see page facing)
To further investigate this finding, it was decided to further purify the lineage 
negative fraction by FACS for Sca+ cells. As shown in Table 3.1, lineage 
negative cells prepared from post 5-FU bone marrow were enriched for the 
Sca+ lineage negative fraction. This separation was performed on 4 separate 
occasions. Although the cloning efficiency of the final cell product was 
greatly enhanced over baseline (204-4456 fold), recovery of Sca+ cells was
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Figure 3.8 Amplification of murine lineage negative bone marrow cells
Lineage negative, post-5 fluorouracil, murine bone marrow cells were 
prepared as described in materials and methods. These cells were cultured for 
6 days in 24 well plates at a cell concentration of 0.1 x lOfyml as described in 
materials and methods. SCF and IL-11 were added at the start of culture only. 
M IP-la was added every 48 hours from the start of culture. Amplification 
factors (± SD) are show for cell count and CFU-A progenitors. Results 
represent a single experiment.
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Table 3.1 Purification of a Sca+ lineage negative population from 2 day 
post 5-Fluorouracil murine bone marrow
2 days prior to investigation mice received 150mg/kg 5-FU intravenously. Bone 
marrow cells were enriched firstly for lineage negative cells by immunomagnetic 
depletion as described in materials and methods. The lineage negative population 
was then further purified by FACS for Sca+ progenitors. The results compare 
starting post 5-FU bone marrow with Sca+ lineage negative progenitors for CFU- 
A cloning efficiency, and show the recovery of CFU-A progenitors in the 
enriched fraction. Results represent four consecutive experiments.
Table 3.1
Experiment
code
Cell type CFU-A 
per 10*
Total cell 
number (10^)
Recovery
( % )
Cloning 
efficiency (%)
Enrichment 
(fold over baseline'
1. 2dpost-5FU 57 2830 100 0.057 1
Sca+ lin- 11600 0.7 5 11.6 204
2. 2d post-5FU 3.7 4440 100 0.0037 1
Sca+ lin- 16500 0.45 45 16.5 4456
3. 2d post-5FU 5 4600 100 0.005 1
Sca+ lin- 5500 0.82 19.6 5.5 1100
4. 2d post-5FU 15.3 4586 100 0.0153 1
Sca+ lin- 15500 0.06 1.3 15.5 1013
very poor and the number of cells available for investigation was limited. The 
Sca+ lineage negative cells purified in these four experiments were 
established in expansion culture with SCF and IL-11 +/- MIP-la. One set of 
cultures showed bacterial contamination from the start of culture which 
probably occurred during the purification process which includes a great deal 
of cell manipulation. One set of cultures showed no expansion although there 
was no clear evidence of contamination. A third set amplified slightly but less 
than for lineage negative cells not further enriched for Sca+. The results 
shown in Figure 3.9 are for the final set of expansion cultures which showed 
excellent in vitro growth. Cell numbers increased 360 fold with SCF and IL- 
11 and 443 fold with SCF, IL-11 and MIP-la. CFU-A amplified 520 (± 130) 
fold without MIP-la and 750 (± 77) fold with MIP-la. Once again 
morphology showed that there was less terminal myeloid differentiation in the 
presence of MIP-la. In view of the low cell recoveries and the fact that, for 
technical reasons, only one of four experiments was successful, no further 
Sca+ lineage negative cells were purified.
The standard stem cell purification process described above was simplified to 
try to make it more applicable for regular use. A lineage negative fraction was 
prepared from normal mice (no 5-FU) and FACS for Sea was not performed. 
The consistent differences in morphology between MIP-la supplemented and 
standard SCF / IL-11 cultures were of great interest. It appeared that MIP-a, 
by an, as yet, unknown mechanism, blocked differentiation of primitive cells. 
At this stage in my studies, the only formal ’’read-out1 for the expanded 
populations had been cell number, CFU-A and CFU-GM. It could be reasoned 
that the target cell for M IP-la in these culture conditions could represent a 
small proportion of the total progenitor population previously measured. 
Therefore, lineage negative cells were established in expansion culture as 
described in the protocol in Figure 3.10. Initial "read out" was for cell number,
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Figure 3.9 Amplification of murine Sca+ lineage negative bone marrow
cells
Sca+ lineage negative, post-5 fluorouracil, murine bone marrow cells were 
prepared as described in materials and methods. These cells were cultured for 
6 days in 24 well plates at a cell concentration of 0.05 x 10^/ml as described 
in materials and methods. SCF and IL-11 were added at the start of culture 
only. M IP-la was added every 48 hours from the start of culture. 
Amplification factors (± SD) are shown for cell count and CFU-A 
progenitors. Results represent a single experiment.
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Figure 3.10 Protocol for amplification of murine lineage negative bone
marrow cells
Lineage negative cells were first enriched from normal bone marrow by 
immunomagnetic depletion as described in materials and methods. Read-out 
was performed for cell number, CFU-A, CFU-GM, percentage Sca+ and 
Rhodaminedull (flow cytometry) and percentage blasts cells (by morphology). 
The cells were then incubated for 7 days in tissue culture flasks in medium 
supplemented with SCF and IL-11 or SCF, IL-11 and MIP-la. SCF and IL-11 
were added at the start of culture only. M IP-la was added at the start of 
culture and every 48 hours. Following 7 days culture, the cells were harvested, 
washed and again enriched for lineage negative cells. Read-out was performed 
on the starting lineage negative fraction, on the day 7 total cell population and 
on the day 7 lineage negative reselected fraction.
Figure 3.10
SCF/IL-n±MIP-a
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Read-out
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CFU-GM and CFU-A as before, but in addition for percentage Sca+ and 
Rhodaminedull cells and percentage of cells of blast morphology. An example 
of baseline lineage negative cells labelled with the negative control antibody 
and with Sea is shown in Figure 3.11. Approximately 10% of the starting 
lineage negative fraction was Sea positive. The cells were then cultured for 7 
days in either SCF and IL-11, or SCF, IL-11 and MIP-la. At the end of 
incubation "read out" was performed for cell number, CFU-GM, CFU-A, 
percentage of Sca+, Rhodamine^u^ and blast cells. To ascertain whether 
fewer cells had differentiated and become lineage positive in the presence of 
MIP-la, the two expanded populations were once again depleted of lineage 
positive cells and "read out" was repeated. Two examples of the reselected 
lineage negative populations labelled with Sea are shown in Figure 3.12. It is 
clear that the proportion of cells which were Sca+ following expansion in the 
presence of MIP-la was greater than without MIP-la. In addition the total 
number of lineage negative cells was consistently greater in the presence of 
MIP-la. Figure 3.13 shows an example of a reselected population stained 
with Rhodamine. On this occasion the percentage of cells which failed to 
retain Rhodamine ( R h o d a m i n e d u l l )  was roughly equivalent in the presence or 
absence of MIP-la, however, since the number of cells recovered in the 
lineage negative fraction was around two fold higher in the presence of MIP- 
la , the absolute number of lineage negative Sca+ cells was still greater. To 
allow for unavoidable cell losses during the lineage positive depletion step, 
"read out" for all parameters was performed on both the total expanded 
population and the reselected lineage negative fraction. As shown in Figures 
3.14 a-g, this experiment was repeated in full on three occasions. The degree 
of amplification achieved in each experiment was highly variable, resulting in 
large SEM between the three experiments, however in each experiment the 
difference between adding MIP-la and no MIP-la was similar. The cell 
number increase was consistently slightly greater in the presence of M IP-la
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Figure 3.11 Flow cytometric analysis: example for baseline lineage
negative cells
The percentage of cells expressing Sea was determined by flow cytometry as 
described in materials and methods. The top panel is the negative control 
using an irrelevant IgG antibody. The lower panel demonstrates that 
approximately 10% of the starting lineage negative cells expressed Sea.
FL1, on the X axis, represents fluorescence intensity for FlTC-conjugated 
antibodies, in this case either the isotype control or anti-Sca. The Y axis 
represents relative frequency of events.
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Figure 3.12 Flow cytometric analysis: 2 examples of Sea labelling for the
reselected lineage negative population at day 7
Following 7 days ex vivo expansion culture, the cells were harvested, 
reselected for lineage negative cells and labelled for flow cytometry. The top 
panel is the negative control. The middle panel shows expression of Sea in 
cells expanded with SCF and IL-11 alone. The lower panel shows expression 
of Sea in cells expanded with SCF, IL-11 and MIP-la. The percentage of 
positive cells in this example was 10.3% for SCF and IL-11 and 31.2% for 
SCF, IL-11 and MIP-la.
In the second example, from a separate experiment, 19.2% of cells were 
positive for Sea after expansion with SCF and IL-11 and reselection for 
lineage negative cells. 28.2% were sca+ after expansion with SCF, IL-11 and 
MIP-la.
FL1, on the X axis, represents fluorescence intensity for FITC-conjugated 
antibodies, in this case either the isotype control or anti-Sca. The Y axis 
represents relative frequency of events.
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In the second example, from a separate experiment, 19.2% of cells were 
positive for Sea after expansion with SCF and IL-11 and reselection for 
lineage negative cells. 28.2% were sca+ after expansion with SCF, IL-11 and 
MIP-la.
FL1, on the X axis, represents fluorescence intensity for FITC-conjugated 
antibodies, in this case either the isotype control or anti-Sca. The Y axis 
represents relative frequency of events.
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Figure 3.13 Flow cytometric analysis: example for Rhodamine for the
reselected lineage negative population at day 7
This figure shows a representative example of Rhodamine staining for cells 
expanded for 7 days, then reselected for lineage negative cells. The top panel 
shows the negative control. The middle panel shows Rhodamine staining for 
cells expanded with SCF and IL-11, then reselected for lineage negative cells. 
The lower panel shows cells expanded with SCF, IL-11 and MIP-la, and them 
reselected for lineage negative cells. In this example, the percentage of 
R h o d a m i n e d u l l  cells was 24.9% in the presence of SCF and EL-11 and 26.3% 
for SCF, IL-11 and MIP-la.
FL1 represents fluorescence for rhodamine and the vertical markers divide the 
population into cells with low, intermediate and high fluorescence, working 
from left to right.
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Figure 3.14 a-g Amplification of lineage negative bone marrow cells
Normal murine bone marrow cells were enriched for lineage negative 
progenitors by immunomagnetic depletion as described in materials and 
methods. Lineage negative cells were then established in culture as shown in 
the protocol above. Results represent the mean (± SEM) for three consecutive 
experiments. The shaded columns represent results for culture with SCF, IL- 
11 and M IP-la. The open columns are for SCF and IL-11.
Figure 3.14a
Increase over baseline for cell number
0 7
Days in ex p a n s io n  cu l ture
To
ta
l 
N
um
be
r 
of 
C
FU
-G
M
Figure 3.14b
CFU-A increase over baseline
500000
Days In e x p a n s io n  cu l tu re
Figure 3.14c
CFU-GM increase over baseline
2e+6 -
1e+6 -
0e+0
0 7
Days in expansion culture
To
ta
l 
nu
m
be
r 
of
 
Rh
o 
du
ll
 
ce
ll
s
Figure 3.14d
Increase over baseline for Rhodamine dull cells
0 7
D a y s  in e x p a n s i o n  c u l t u r e
oQ.
(0o</>
4)
-O
E3
Figure 3.14e
Increase over baseline for Sea positive cells
0 7
Days in expansion culture
«
■Q
E3
C
OI-
Figure 3.14f
Increase over baseline for blast cells
0 7
D a y s  in e x p a n s i o n  c u l t u r e
Figure 3.14g
Increase over baseline for lineage 
negative cells
0 7
Days in expansion culture
(paired, 2-tailed t-test, p=0.03). There was no apparent difference in CFU-A or 
CFU-GM amplification under the two culture conditions tested (p=0.93 &
0.55 respectively). However, the four parameters used to detect more 
primitive progenitors (i.e. Rhodaminedull, Sca+, blast morphology and 
lineage negative) consistently showed greater amplification (not always 
statistically significant) in the presence of M IP-la (p=0.1,0.09,0.04, 0.1). As 
discussed there was marked variation between experiments. For example, 
having started with the same input number, the absolute number of lineage 
negative cells at the end of culture in the absence of M IP-la was 3.58,1.18 
and 10.5 x 10^ for the three replicate experiments and 8.46, 3.57 and 20.4 x 
10^ in the presence of MIP-la for parallel cultures. Such variation makes it 
most unlikely that a statistical method based on these absolute numbers in 
such a small sample (i.e. only 3 sets of data) would prove to be statistically 
significant. What is of interest is the trend for greater recovery of more 
primitive progenitors in the presence of MIP-la which was seen in every 
experiment.
The mechanisms of cytokine signal transduction for the three growth factors 
used in these studies are very different. SCF is the ligand for the c-kit 
receptor, a cell surface receptor with protein-tyrosine kinase activity. This 
receptor is similar to the receptors for M-CSF and PDGF. Receptors for IL-11, 
IL-6 and LIF share the signal transducing protein gpl30 and IL-6 and G-CSF 
show structural homology. Members of the chemokine family including MIP- 
la , MCP-1, RANTES and IL-8 are all thought to signal via seven membrane 
spanning receptors. In an attempt to determine if the amplification of CFU-A 
and CFU-GM achieved with the combination of SCF, IL-11 and M IP-la was 
specific for these cytokines, or, perhaps, reflected simultaneous signalling via 
three very different receptors on stem and progenitor cells, cytokines which 
signal via similar receptors were exchanged for the standard combination.
8 6
Unfractionated bone marrow was expanded under standard culture conditions 
for 6 days. PDGF and M-CSF were exchanged for SCF; LIF, G-CSF and IL-6 
were exchanged for IL-11; and MCP-1, RANTES and EL-8 were exchanged 
for MIP-la. As shown in Figure 3.15, the addition of M IP-la to SCF and IL- 
11 produced only slightly increased amplification of CFU-A and no 
enhancement of CFU-GM expansion compared with SCF and IL-11. 
Exchanging MCP-1, RANTES or IL-8 for MIP-la neither increased nor 
decreased the observed progenitor expansion. LIF, G-CSF and IL-6 were 
equivalent to IL-11 in terms of CFU-A and CFU-GM expansion. SCF, 
however, appeared to be essential in this combination and could neither be 
substituted by PDGF nor M-CSF. These findings suggest that substituting 
cytokines with similar signal transduction pathways is not sufficient for 
progenitor amplification and that SCF is unique in its ability to synergise with 
the other cytokines present to induce progenitor proliferation.
M IP-la is considered to reversibly inhibit stem cell proliferation by 
preventing entry into the S phase of the cell cycle (Dunlop et al., 1992). CFU- 
A and CFU-S day 12 appear to be within that part of the stem cell 
compartment which is a target for the actions of MIP-la. In resting bone 
marrow the CFU-A compartment is generally quiescent ( < 20% in S phase), 
but may easily be triggered to proliferate by a variety of positive stimuli. It 
was, therefore, of interest to determine the effect of M IP-la on CFU-A 
progenitors prepared from normal marrow and the change in cycle status 
obtained when M IP-la was combined with SCF and IL-11. Normal bone 
marrow cells were prepared in the usual manner and were cultured for 4 or 24 
hours either in medium alone, or supplemented with M IP-la . Following 
incubation, an Ara-C suicide assay was performed to determine the percentage 
of progenitors in active cell cycle. Figure 3.16 shows the results for CFU-A 
progenitors. After only 4 hours incubation in medium alone, the % of CFU-A
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Figure 3.15 Effect of growth factor exchange
Unfractionated murine bone marrow cells were cultured for 6 days in 24 well 
plates as described in materials and methods. SCF, IL-11, G-CSF (20ng/ml), 
PDGF (lOng/ml), M-CSF (6ng/ml), IL-6 (20ng/ml), LIF (lOng/ml), IL-8 
(lOOng/ml), Rantes (lOOng/ml) and MCP-1 (lOOng/ml) were added at the start 
of culture only. M IP-la was added every 48 hours from the start of culture. 
Amplification factors (+ SEM) are shown for CFU-A and CFU-GM 
progenitors. Results represent the mean of three replicate experiments.
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Figure 3.16 Effect of MIP-la on cycle status of CFU-A progenitors
Unfractionated murine bone marrow cells were incubated for 4 and 24 hours 
at 37°C in Fischer's medium supplemented with DHS (10%) with and 
without MIP-la. Following incubation, the cells were washed once and used 
in an Ara-C suicide assay, as described in Materials and Methods. After 
washing three times, the cells were plated into the CFU-A assay. The mean 
percentage of CFU-A in S-phase for four replicate experiments is shown (± 
SEM).
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in S phase was approximately 50%. There are two possible explanations for 
this effect. The first is that factors present in DHS (which is selected for 
optimal growth in the CFU-A assay) may be sufficient to trigger cycling of 
CFU-A. The second is that, at the time this series of experiments was 
performed, the baseline cycle status of CFU-A for the particular batch of 
animals in use was greater than usual (around 20-30% in S phase), perhaps 
due to undetected infection. The percentage of CFU-A in active cell cycle was 
much less when MIP-la was included in the medium throughout the period of 
incubation. Similar, but even greater inhibition was seen after a 24 hour 
culture period. These results suggest that in the absence of stimulatory 
cytokines, MIP-la's effects are those of a classical inhibitor of stem cell 
proliferation.
In the next experiment, CFU-A cycle status was assessed at baseline, prior to 
either serum or growth factor exposure. The cells were then incubated in 
serum supplemented medium for 4 hours either in the presence of SCF and IL- 
11, or SCF, IL-11 and MIP-la. Following incubation, cycle status was 
determined by Ara-C suicide assay. The results for three such replicate 
experiments are shown in Figure 3.17. For this series of experiments <15% of 
CFU-A progenitors were in S phase prior to growth factor stimulation. The 
percentage in cell cycle rose significantly following culture in the presence of 
SCF and IL-11 to > 30%. The addition of MIP-la was able to prevent CFU-A 
entry into S phase, even in the presence of SCF and IL-11, at least over a 4 
hour period.
This experiment was extended to time points at 24 hours, 3,7,10 and 14 days 
as shown in Table 3.2. The inhibitory effect of MIP-la, though maintained in 
the face of growth factor stimulation for 4 hours, was no longer detectable by
8 8
Figure 3.17 The effect of MIP-la on entry of CFU-A progenitor cells into 
cell cycle in response to growth factors
Unfractionated murine bone marrow cells were divided into three aliquots. 
The first was immediately used for an Ara-C suicide assay to determine the 
percentage of CFU-A progenitors in S-phase at baseline. The second was 
incubated for 4 hours in Fischer's medium supplemented with DHS (10%), 
SCF and IL-11. For the third, M IP-la was added in addition to SCF and IL- 
11. Following 4 hours incubation, the cells were washed and then used in a 
suicide assay. The mean percentage of CFU-A progenitors in S-phase for the 
three test conditions is shown (± SEM) and represents the mean of three 
replicate experiments. The difference between the baseline cycle status and 
the response to SCF and IL-11 was statistically significant (p=0.03, Student's 
t-test, paired & 2-tailed) as was the difference between the response to SCF 
and IL-11 and that to SCF, IL-11 and M IP-la (p=0.05).
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Table 3.2 A comparison of CFU-A cycle status for bone marrow cells 
expanded ex vivo with SCF/IL-11 or SCF/IL-ll/MIP-la
Unfractionated murine bone marrow cells were cultured for 14 days in 24 well 
plates as described in materials and methods. Baseline CFU-A cycle status 
was assessed by Ara-C suicide assay prior to the start of incubation. Cells 
were then established in cultures supplemented with either SCF and IL-11 or 
SCF, IL-11 and MIP-la. SCF and IL-11 were added at the start of culture and 
again at the time of medium change at day 7. M IP-la was added at the start of 
culture and every 48 hours. Replicate cultures were harvested and assessed by 
Ara-C suicide assay at 4 and 24 hours, days 3, 7, 10 and 14. Results represent 
the mean (+ SEM) for 3 replicate experiments.
Table 3.2
Growth Factors Baseline 4 hours 24 hours 3 days 7 days 10 days 14 days
SCF/IL-11 13 ±  5.4 31 ±  3.1 62 ±  6.8 61 ± 3 38 ± 2 .5 55 ± 4 56 ± 3
S C F /IL -ll/M IP -la 13 ±  5.4 13 ±  2.5 54 ±  3.8 59 ± 6 27 ±  3.5 59 ±  5.5 60 ± 3
24 hours. Thereafter there was no difference in cycle status for cultures 
supplemented with SCF and IL-11, or SCF, IL-11 and MIP-la.
Discussion
In the first experiment described in this chapter, SCF was found to promote 
CFU-A expansion during a 6 day incubation in serum containing medium. 
There has been some controversy over the ability of SCF, as a single factor, to 
stimulate colony formation in semi-solid agar or progenitor expansion in 
suspension culture. Zsebo et al showed that SCF alone promoted colony 
formation from total bone marrow or post 5-FU bone marrow, but not from 
enriched lineage negative bone marrow and concluded, therefore, that SCF did 
not act directly on colony forming cells (Zsebo et al., 1990b). Hey worth et al 
investigated the role of SCF on highly purified GM-CFC, both in the presence 
and absence of serum, and found that SCF's effects were both direct and 
independent of the requirement for serum (Heyworth et al., 1992). Lowry et al 
found that SCF used alone had negligible clonogenic capacity on 2 day post 5- 
FU bone marrow enriched to the level of Sca+ lineage negative progenitor 
cells (Lowry et al., 1992). Metcalf and Nicola investigated the effects of SCF 
on unfractionated and on Sca+ lineage negative murine bone marrow cells. 
Their data strongly suggested that SCF was able to promote colony formation 
directly, although the effects were much less for purified cells than for 
unfractionated marrow (Metcalf & Nicola, 1991). De Vries et al, demonstrated 
direct effects for SCF on highly purified murine haemopoietic progenitor cells 
(de Vries et al., 1991), however, Migliaccio failed to show colony formation 
using similarly enriched populations (Migliaccio etal., 1991). Taken together, 
these studies suggest that the proliferative effect of SCF on highly purified 
progenitor cells, in the absence of serum is small, but increased levels of 
proliferation may be seen for unpurified cells in the presence or absence of 
serum. To fully clarify this issue, highly purified single cells should be
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cultured under serum free conditions in the presence of SCF alone. Under 
such conditions, Xiao et al showed that SCF alone was unable to induce 
colony formation from highly purified human progenitor cells (Xiao et al., 
1992). In view of the above data, it is not surprising that in the experiments 
described above, SCF alone promoted CFU-A and CFU-GM amplification in 
cultures of unfractionated bone marrow in the presence of serum.
The synergistic effect of SCF and IL-11 in inducing proliferation of 
multipotent progenitor cells has been recognised by several investigators 
(Musashi et al., 1991; Quesniaux etal., 1992; Tsuji etal., 1992). Both SCF 
and IL-11 are stromal cell derived cytokines which appear to have a central 
role in regulating haemopoiesis. SCF and IL-11, along with G-CSF and IL-6, 
appear to induce the entry of dormant murine haemopoietic progenitor cells 
into cell cycle by shortening the Go period (Musashi et al., 1991). In addition, 
IL-11 appears to control later stages of development, promoting macrophage 
proliferation, megakaryocyte and erythroid colony formation (Quesniaux et 
al., 1992). The cytokine combination of SCF and IL-11 was selected for 
further study firstly, because it was demonstrated to induce proliferation of 
CFU-A and CFU-GM progenitors cells at least as well as any other two 
cytokine combination and secondly, since both cytokines are stromal cell 
derived they are likely to have a pivotal role in the regulation of the early 
stages of haemopoiesis in vivo and may therefore be expected to interact 
synergistically in vitro in a similar manner.
In the culture conditions employed in these experiments, IL-3, either 
alone or in combination with other cytokines, was unable to promote 
progenitor expansion and even reduced the degree of expansion induced by 
other combinations. Morphological analysis suggested that the concentration 
of IL-3 used promoted terminal differentiation of progenitor cells. In view of 
the large number of macrophages present at the end of culture it is possible 
that IL-3 may, in addition, have been toxic to progenitor cells. The effect of
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IL-3 appears to be highly dependent on both the concentration of IL-3 used 
and the presence or absence of serum in the culture medium. Ploemacher et al 
observed that the addition of IL-3 in high concentration to the combination of 
SCF and IL-11 acted in a counterproductive manner with respect to the 
number of colony forming cells generated and their proliferative ability 
(ability to produce secondary colonies) (Ploemacher etal., 1993a). Since the 
IL-3 message is low or absent in the stromal environment under steady state 
conditions it is likely that IL-3 does not play a primary role in the regulation 
of proliferation of primitive progenitor cells. In a small number of 
experiments performed in our own laboratory, by titrating the concentration of 
IL-3, in cultures expanded with SCF and IL-11, from 50ng/ml to 0.05ng/ml, 
very low concentration IL-3 (0.05ng/ml) synergised with SCF and IL-11 to 
promote further amplification of CFU-A and CFU-GM progenitors. This 
effect was only reproducible under serum free conditions and in the presence 
of serum even 0.05ng/ml of IL-3 abolished the progenitor expansion seen with 
SCF and IL-11 (Holyoake et al., 1994).
Although M IP-la has been shown to have both inhibitory and 
stimulatory effects depending on the maturational stage of the target 
population, the results observed with this chemokine are somewhat surprising 
and difficult to interpret. It appears that when MIP-la is added to the 
combination of SCF and IL-11, during the early hours of culture, progenitor 
proliferation (determined by Ara-C suicide assay) is inhibited, but this 
inhibition is overcome within 24 hours with no differences in cycle status 
detectable at and beyond that point If inhibition of cell cycling were the only 
difference detectable, one would expect fewer cells at the end of culture in the 
presence of MIP-la. However, by day 7 of culture there were consistently 
more cells present with a greater proportion of more primitive progenitors in 
the presence of MIP-la. The likely explanation is that M IP-la does indeed 
"hold up" progenitor proliferation, but at the point when this inhibition is
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overcome, proliferation proceeds with less associated differentiation, 
accounting for both the increase in total cell number (by self-renewal) and in 
primitive subsets. The most convincing work demonstrating a role for M IP-la 
in the maintenance of primitive progenitor cells during ex vivo culture has 
been performed by Verfaillie et al using human cells. In the long term culture 
conditions described, primitive human progenitor cells were cultured 
separated from a stromal layer by a microporous membrane. Without 
exogenous growth factor addition LTCIC, (the most primitive human 
progenitor cell detected by in vitro assay) fell to 50% of input numbers by 
week five of culture. The addition of MIP-la alone had no effect on LTCIC 
maintenance. The addition of IL-3 alone resulted in exhaustion of LTCIC by 
week five, however, the addition of both IL-3 and M IP-la produced full 
maintenance of LTCIC at input numbers for at least eight weeks (Verfaillie et 
al., 1993). These data strongly suggest that the effect of M IP-la observed in 
our own experiments is a genuine effect and as such requires further 
investigation.
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RESULTS II
Chapter 4 Short term engraftment studies
The in vitro data described in chapter 3 demonstrate that SCF and IL-11 +/- 
M IP-la may amplify CFU-A and CFU-GM progenitors in unfractionated 
bone marrow approximately 50 and 100 fold respectively. There are two 
possible mechanisms by which stem and progenitor cells expanded ex vivo 
may produce more rapid in vivo haematological recovery upon 
transplantation. The progenitors considered to be important for the early but 
"transient" engraftment following BMT include both CFU-A (equivalent to 
CFU-S) and probably CFU-GM (Jones et al., 1990). By greatly increasing the 
number of these progenitors by ex vivo culture it was hoped that, following 
transplantation into a suitable model, early engraftment would be faster. 
Furthermore, it would be of potential clinical value if the number of cells 
required for rescue following myeloablation could be reduced by expanding a 
smaller number of "input" cells prior to transplantation. The second 
mechanism by which ex vivo culture of the cells to be transfused may 
accelerate haemopoietic recovery following BMT involves exposure to 
cytokines ex vivo without necessarily attempting to increase stem and 
progenitor cell numbers. Short term exposure (2 hours) of bone marrow cells 
to cytokines has been shown to modulate cell surface molecules including 
adhesion molecules and this may affect the rate and degree of progenitor 
homing to the bone marrow following transplantation (Tavassoli & Hardy, 
1990; Tavassoli et al., 1991; Zanjani etal., 1992). This mechanism has 
recently been contradicted by Van der Loo et al (van der Loo & Ploemacher, 
1995) and was not studied in the work described here.
To assess the engraftment potential of bone marrow cells expanded ex vivo, a 
murine bone marrow transplantation model was developed. Syngeneic female
93
recipient mice were given a potentially lethal dose of radiation and were then 
rescued using test cells from male donors which had been manipulated ex 
vivo. The dose of radiation used was sufficient to produce death from bone 
marrow failure if a bone marrow transplant was not performed. A single dose 
of radiation was tested in preliminary experiments but was shown to produce 
excessive non-haemopoietic toxicity. Fractionated radiation, with a minimum 
delay of three hours between two fractions, has been shown in previous 
studies to allow some repair of rapidly proliferating tissues such as the 
gastrointestinal tract and lung and so prevent deaths from non-haematological 
toxicity therefore this approach was investigated (Spangrude & Scollay,
1990).
As shown in Figure 4.1, to establish the ideal dose of radiation, a dose titration 
was performed in the absence of transplantation. Deaths prior to day 7 are 
likely to be due to non-haematological toxicity with deaths from bone marrow 
failure occurring between day 7 and 18 post radiation. None of the doses used 
in the first titration were sufficient to cause 100% mortality by day 30. In both 
the first and second titration a dose of 1 lGy was lethal to 50% of animals. 
Above 1 lGy the doses were lethal to 100% of animals by day 20, but 
occasional deaths were observed prior to day 7 and, were therefore, possibly 
due to non-haematological toxicity. These results, however, suggested the 
possibility of a good model for the intended experiments and were far more 
promising than with single dose radiation. The radiation dose for all the 
experiments described in this chapter was 12Gy, administered as 2 equal 
fractions exactly 3 hours apart.
The primary aim of these initial in vivo experiments was to assess the transient 
engrafting potential of stem and progenitor cells expanded ex vivo and to 
compare this with unmanipulated bone marrow cells. To allow assessment of
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Figure 4.1 First titration of fractionated radiation in B6D2F1 mice
To establish the dose of fractionated radiation required to induce bone marrow 
aplasia in 100% of animals, a dose titration was carried out. Groups of 10 
mice received increasing doses of radiation from 9.5 to 11 Gy in two equal 
fractions, three hours apart. Mice were then observed for survival to day 30 
following radiation. Results are shown for percentage survival against time.
Second titration of fractionated radiation in B6D2F1 mice
Since none of the radiation doses used in the first titration was lethal to 100% 
of animals, a second dose titration was carried out. Groups of 10 mice 
received increasing doses of radiation from 11 to 12.5Gy in two equal 
fractions, three hours apart. Mice were then observed for survival to day 30 
following radiation. Results are shown for percentage survival against time.
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the contribution of donor cells to engraftment either soon after BMT, or much 
later, donor cells were taken from male animals with females as recipients.
The method used to detect male donor cells was Southern blotting using the Y 
chromosome specific probe pY353/B (Bishop et al., 1985). Figure 4.2 shows 
the typical pattern obtained by Southern blotting of Eco R1 digested genomic 
DNA from male and female animals using this probe. Female DNA shows no 
hybridisation, however male DNA shows hybridisation with a consistent band 
of 1.5kb. Although several bands of higher molecular weight are seen, these 
are weaker and therefore less reliable for assessment of donor engraftment. 
The 1.5kb band was routinely used to look for evidence of donor cells post 
BMT.
Each time samples were tested for evidence of donor cells, a standard titration 
of male DNA diluted into female DNA was included in the gel. This was to 
allow an approximate quantification of the percentage of male cells present. 
Following hybridisation with probe pY353/B, blots were stripped and re­
hybridised with a probe for GAPDH, which is not male specific and therefore 
could be used to assess how much DNA was loaded into each well and 
transferred successfully to the membrane. Figure 4.3 shows an example of the 
standard titration of male DNA from 100% to 0%, hybridised first with the Y 
specific probe and then with the GAPDH probe. The GAPDH hybridisation 
(showing almost equal hybridisation in every lane) confirms that for lanes in 
which the male signal was low, this was genuinely due to a low percentage of 
male donor cells on a background of female recipient cells rather than because 
less DNA than intended was loaded into the well or because of poor transfer 
to the membrane.
In Figure 4.4, the results of densitometry performed on X-rays derived from 
the titration described in Figure 4.3 are shown in a plot of optical density
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Figure 4.2 Southern hybridisation of Eco R1 digested genomic blots with 
pY353/B
In this blot, the first two lanes show undigested male genomic DNA 
(10(ig/lane) hybridising to the Y chromosome specific probe. The third and 
sixth lanes were empty. The fourth and fifth lanes were loaded with Eco R1 
digested female genomic DNA which does not hybridise with the probe. The 
seventh and eighth lanes were loaded with Eco R1 digested male genomic 
DNA (1 Ojj,g) which binds to the probe in a specific manner. The 1.5kb band 
was found to be the most reliable for assessment of male donor engraftment.
undig. male digested female digested male
<—  1.5kb
Figure 4.3 Titration curve of male DNA
Male DNA was diluted with female DNA to produce a standard titration (100, 
50, 25, 12.5, 6.25, 3.125, 0% male). lOpg of DNA was loaded per well. 
Following Southern blotting, hybridisation to the Y specific probe and X-ray 
exposure, the blots were stripped and re-hybridised with the GAPDH probe. 
The upper panel shows the titration of male DNA hybridised with the Y 
probe. The lower panel shows the same blot after hybridisation with GAPDH. 
This titration was included with all test samples to allow an estimate of the 
percentage donor haemopoiesis. The GAPDH hybridisation was performed to 
assess DNA loading from well to well (i.e. both male and female DNA would 
hybridise with GAPDH).
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Figure 4.4 Correlation of the quantity of male DNA loaded per well with 
optical density by densitometry
The known quantity of male DNA loaded per well was plotted against optical 
density (contour OD x mm^) measured by densitometry. As shown, the data 
points fell very close to a straight line with a correlation of R=0.993.
Figure 4.4
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against the quantity of male DNA thought to have been loaded in each well. In 
this example, the correlation of optical density with quantity of DNA is 
excellent. The data points fall close to a straight line with a correlation 
coefficient of R=0.993.
The next series of experiments were designed to compare the short term (to 
day 30) engraftment potential of progenitor cells expanded with SCF and IL- 
11 +/- MIP-la with that of unmanipulated cells. In preliminary experiments it 
was determined that a dose of 10^ unmanipulated bone marrow cells per 
mouse was required to ensure survival of close to 100% of lethally irradiated 
animals (data not shown). In the experiments described in Figure 4.5, the cell 
dose per mouse was titrated from 2 x 10^ to 10^. Control BMT was with fresh 
unmanipulated bone marrow cells harvested on the day of BMT. For 
expanded populations, ex vivo cultures were established 6 days prior to BMT. 
The number of expanded cells transplanted per mouse was calculated based on 
the number established in culture 6 days prior to BMT rather than on the 
number in culture after expansion had taken place. These experiments were 
performed on several occasions and each time 10 animals were included in 
each experimental group. The percentage of animals surviving to day 30 post 
BMT was significantly greater, at each cell dose, following BMT with 
expanded compared with unmanipulated bone marrow cells. There was no 
difference in survival following BMT with cells cultured with SCF and IL-11 
compared with SCF, IL-11 and MIP-la. Percentage survival appeared similar 
following BMT with either 10,000 unmanipulated cells or only 1,000 
expanded cells. This suggests that, at least for short term engraftment, 
approximately 10 fold fewer bone marrow cells are required for rescue 
following lethal irradiation if these cells are expanded with growth factors 
prior to infusion. All the animals surviving to day 30 post BMT in these 
experiments were observed for one year. There were no deaths later than day
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Figure 4.5 Short term survival after bone marrow transplantation
Female B6D2F1 mice received fractionated radiation as detailed in materials 
and methods prior to tail vein injection of either medium alone (control), 2 x 
104 / 104/5 x 103 or 1()3 unmanipulated fresh bone marrow cells or cells 
following 6 days expansion in either SCF and IL-11 or SCF, IL-11 and MIP- 
la . The number of expanded cells per mouse was based on the number 
established in culture at day -6. Results are for survival to day 30 following 
BMT for 3-6 replicate experiments. In each replicate experiment there were 
10 mice per experimental group.
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Figure 4.6 Assessment of donor engraftment one year after BMT
One year following transplantation of either unmanipulated or expanded bone 
marrow cells, surviving animals were randomly selected from the above 
experiments and Southern blots were performed to assess the presence of 
donor (male) cells in bone marrow according to the techniques described in 
materials and methods. The top and third panel represent results of 
hybridisation with the Y chromosome specific probe, the second and fourth 
panels results for GAPDH. In the top panel the first 6 lanes represent a 
titration of male DNA. The remainder of the lanes in the top panel and all of 
the third panel represent individual test animals. The number of cells 
transplanted per mouse is shown and whether the transplant was with 
unmanipulated bone marrow (UM), SCF and IL-11 expanded marrow 
(SCF/11) or SCF, IL-11 and MIP-la expanded marrow (SCF/11/MIP) is 
indicated. The second and fourth panels show the results of rehybridising the 
blots with a probe for GAPDH which binds to both male and female DNA 
and, therefore, was used as a loading control.
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Figure 4.7 Peripheral blood indices after bone marrow transplantation
Female B6D2F1 mice received fractionated lethal irradiation followed by tail 
vein injection of 5 x 10^ fresh unmanipulated bone marrow cells, 5x10^ 
unfractionated bone marrow cells following 6 days ex vivo expansion with 
SCF and IL-11 or 5 x 10^ unfractionated bone marrow cells following 6 days 
ex vivo expansion with SCF, EL-11 and MIP-la (lOOng/ml added every 48 
hours). At each time point, 6 animals were sacrificed from each treatment 
group (ie. a total of 18 animals). To enable full analysis, blood was pooled 
from two animals for each FBC result. Each data point therefore represents 
the mean for three blood samples, each of which was performed on blood 
pooled from two animals (Sysmex NE 8000). Results (mean SEM) are shown 
for a. haemoglobin, b. platelets, c. neutrophils and d. total WBC.
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unmanipulated bone marrow cells or cells expanded with SCF and IL-11, or 
SCF, IL-11 and MIP-la. Non-transplanted, but irradiated, mice became 
profoundly pancytopenic and all died prior to day 18 (data not shown). The 
haemoglobin level from animals transplanted with either of the two expanded 
populations was showing signs of recovery as early as day 7 post BMT, 
however, for unmanipulated cells the haemoglobin level was still falling on 
day 7, reached a plateau and remained stable on days 9 and 11, before starting 
to rise (Figure 4.7a). The platelet counts fell in all experimental groups to a 
nadir on day 9 following transplantation. This nadir was significantly less 
severe for mice transplanted with cells expanded ex vivo with SCF and IL-11 
than for unmanipulated cells (pcO.OOl). Thereafter, platelet recovery was 
more rapid for animals which received expanded bone marrow, although, 
because of the variability in platelet counts full statistical analysis was only 
performed for results to day 11 after BMT (Figure 4.7b, pcO.OOl on day 11). 
The neutrophil count fell to zero by day 3 under all experimental conditions 
(Figure 4.7c). On day 5 following radiation, the mean neutrophil count was 
significantly higher in mice transplanted with bone marrow cells expanded ex 
vivo with SCF and IL-11 than for mice transplanted with unmanipulated bone 
marrow cells (P=0.002). Thereafter, from day 5 to day 11, the differences in 
neutrophil counts between animals transplanted with expanded versus 
unmanipulated bone marrow were highly significant and in favour of ex vivo 
expansion (Figure 4.7c, p<0.001 on days 7, 9 and 11). By day 14, the 
neutrophil counts were still higher for animals transplanted with expanded 
cells but this difference was no longer of statistical significance (p=0.029). For 
the above results, analysis of variance techniques (Armitage & Berry, 1987) 
were used to examine platelet and neutrophil counts. In each case residuals 
were plotted in various ways to determine a transformation which resulted in 
variance homogeneity and approximate normality. These plots indicated a 
logarithmic transformation for neutrophil counts and a square root
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transformation for platelets. The transformed group means were compared at 
each day using the error estimate from the analysis of variance table. The p- 
values were adjusted using the Bonferroni method (Johnson & Wichem, 1988) 
to allow for multiple comparisons. In the case of the platelet counts the data 
for days 14 and 18 appeared markedly more variable than at other time points 
and these observations have not been included in the main analysis. This 
statistical analysis was kindly performed by Mr Jim Paul (Department of 
Medical Oncology, Western Infirmary, Glasgow).
It has been shown previously that for unmanipulated bone marrow there is a 
threshold cell and progenitor dose above which engrafment may not be further 
accelerated (Jones et al., 1990). In the experiments described above, total cell 
number did not increase over two fold during ex vivo expansion culture and 
for transplantation, cell doses 10 fold over the known engraftment threshold 
were used. Therefore, the observed effects on both neutrophil and platelet 
recovery suggest that ex vivo culture of bone marrow cells with this cytokine 
combination mediated a qualitative influence on engraftment and did not 
reflect the small increase in the number of cells transplanted for animals given 
expanded cells.
Discussion
These experiments have demonstrated important advantages for the 
transplantation of expanded cells compared with unmanipulated cells. Since 
cell numbers increase only 1-2 fold over the 6 day culture period, the observed 
marked improvement in survival as a function of the number of cells 
transplanted cannot be due only to an increase in the total number of cells 
transplanted but must relate either to the increased concentration of CFU-A 
progenitors (50 fold increase over 6 days) and / or to effects on progenitor 
"homing". This result has important potential implications for clinical
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transplantation, since, especially for autologous transplantation, there are often 
situations when the threshold cell number for BMT cannot be harvested either 
from bone marrow or by leukapheresis. In addition, if one could use only one 
tenth or less of a standard transplant cell dose, then the risk of tumour cell 
contamination would be reduced by at least one log. The first clinical study 
using progenitor cells expanded ex vivo has now been reported in which 
Brugger et al expanded one tenth of a standard peripheral blood progenitor 
cell (PBPC) product prior to infusion. The first four cases received a standard 
transplant dose of CD34 positive cells plus an aliquot of progenitor cells 
generated ex vivo. The following six cases received only expanded cells. All 
patients treated in this way experienced rapid and durable engraftment 
following high dose chemotherapy (Brugger et al., 1995).
Following transplantation with cell doses in excess of the threshold for 
engraftment (i.e. optimised to ensure as rapid recovery as possible), SCF/IL- 
11 expanded bone marrow gave rise to significantly more rapid 
haematological recovery in terms of haemoglobin, platelets and neutrophils 
compared with unmanipulated BMT. This has previously been shown by 
Muench et al, using post 5-FU bone marrow and the combination of SCF and 
IL-ip, and, therefore, is not specific to the growth factor combination used in 
this work (Muench et al., 1993). Previously it has been shown that 
transplantation with cell doses well in excess of the threshold for 
haemopoietic rescue cannot further hasten haematological recovery (Jones et 
al., 1987). Therefore, it appears that cytokine exposure in some way reduces 
the time required for progenitors to home to the bone marrow and / or spleen 
and to produce functionally mature blood cells.
In these two series of experiments, we have demonstrated 
convincingly that transient engrafting stem cells can be expanded in vitro and 
that following their transplantation in vivo may favourably influence the
1 0 0
kinetics of engraftment. Clearly, if these results can be extended to the human 
system, they would have exciting clinical relevance.
1 0 1
RESULTS III
Chanter 5 Long Term Reconstitution
A fundamental question in haemopoiesis is whether expansion of stem and 
progenitor cells ex vivo can occur without reducing the proliferative capacity 
of the stem cell compartment. Although BMT with progenitor cells expanded 
ex vivo produced both more rapid haematological recovery following lethal 
doses of radiation and improved survival as a function of transplanted cell 
dose, no measure of long term engraftment had been undertaken. The capacity 
of stem cells to proliferate and self-renew can be studied using serial BMT. 
Serially transplanted bone marrow eventually fails to reconstitute lethally 
irradiated mice (Harrison et al., 1978; Harrison & Astle, 1982; Jones et al., 
1989). This has been shown to be due, not to a decrease in the number of 
CFU-GM or CFU-S (committed progenitors and transiently engrafting stem 
cells), but to loss of pluripotent stem cells responsible for long term 
reconstitution (Jones et al., 1989). The number of successful serial transplants 
is dependent upon both the cell dose transplanted and the interval between cell 
transfers, such that fewer cell passages are possible if the interval between 
transplants is short. This is thought to be due to dilution of LTRC by more 
committed progenitors early after BMT with re-establishment of the normal 
ratio over time. In order to obtain unambiguous results, cells of donor and 
recipient origin must be distinguishable.
A serial BMT experiment was therefore devised to try to repetitively stress the 
transplanted stem cell population and to compare unmanipulated bone marrow 
with SCF/IL-11 and SCF/IL-11/MIP-la expanded bone marrow for their 
ability to sustain serial BMT. Serial transplantation is not a quantitative assay 
but could nevertheless be regarded as an indirect qualitative measurement of 
the most primitive stem cell. Therefore, any augmentation or reduction in the
1 0 2
ability of expanded marrow to sustain serial BMT compared with 
unmanipulated marrow would be interpreted as an indirect measure of the 
LTRC content of the different primary cell inoculations.
Prior to commencing the serial BMT experiment, a fractionated radiation dose 
titration, in the absence of BMT, was repeated to reassess the radiation 
sensitivity of the current animal batch. This confirmed that the dose required 
to cause bone marrow failure which was lethal in 100% of animals was 
>12.125Gy (Figure 5.1). For animals receiving the slightly higher dose 
(12.5Gy), there was mortality as early as day 7 which may have been caused 
by non-haematological toxicity. For this reason, the dose of 12.125Gy was 
chosen for all subsequent experiments.
The basic protocol for serial BMT is shown in Figure 5.2. Three experimental 
conditions were tested; unmanipulated BMT, SCF/IL-11 expanded BMT and 
SCF/IL-11/MIP-la expanded BMT. In addition a group of 10 animals did not 
receive a cell infusion and were included as radiation only controls. The 
primary (1°) animals were each transplanted with 5 x 10^ cells (based on the 
number of cells used to establish expansion culture). Following 1° BMT, three 
time points were selected for analysis. Since short term engraftment had been 
shown to occur significantly faster in recipients of expanded versus 
unmanipulated bone marrow, an early time point of one month (1/12) post 
BMT was first selected. At this time point the ratio of LTRC to committed 
progenitors might still be deranged and therefore influence the results of serial 
BMT. The second time point selected was at three months (3/12) following 1° 
BMT. This should be sufficiently late post BMT for the normal balance 
between short and long term reconstituting stem cells to have been re­
established (Jones et al., 1989) and, therefore, for a true comparison between 
the long term reconstitution potential of unmanipulated and expanded bone
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Figure 5.1 Third titration of fractionated radiation in B6D2F1 mice
Prior to commencing a serial BMT experiment the radiation dose titration was 
repeated. Groups of 10 mice received increasing doses of radiation from 11.75 
to 12.5Gy in two equal fractions, three hours apart. Mice were then observed 
for survival to day 30 following radiation. Results are shown for percentage 
survival against time.
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Figure 5.2 The basic scheme for serial BMT
Serial BMT was performed as described in materials and methods. Three 
experimental groups were established. These groups each consisted of 40 
mice, transplanted with either unmanipulated bone marrow cells, bone 
marrow cells expanded with SCF and IL-11 or with SCF, IL-11 and MIP-la. 
These mice were designated the primary (1°) BMT recipients. Following 1° 
BMT there were three time points for analysis; at one month (1/12), three 
months (3/12) and nine months (9/12) after BMT. At each time point 10 
animals were sacrificed from the original group of 40 and used for analysis 
including testing the ability of pooled cells from each group to sustain serial 
BMT into new groups (20 mice per group) of lethally irradiated animals. 
These were designated as secondary (2°) BMT recipients. Following 2° BMT 
there were two time points for analysis; at two months (2/12) and six months 
(6/12) after BMT. At these time points 10 animals were sacrificed, analysed 
and marrow pooled for tertiary (3°) BMT. Following 3° BMT there was a 
single time point at three months (3/12).
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marrow to be made. Finally, a late time point at nine months (9/12) post 1° 
BMT was selected to ensure that donor engraftment was durable with no cases 
of either host reconstitution or late bone marrow failure. As shown in Figure 
5.2, there were two time points following 2° BMT at two and six months, and 
one time point following 3° BMT at three months. All secondary and 
subsequent BMT recipients each received 5 x 10^ cells for transplantation.
The full experimental design, including group identification, is shown in 
Figure 5.3. As a result of the large number of derivative groups of animals in 
this single experiment a rather cumbersome coding system was developed and 
adhered to throughout the study period. The initial test groups were numbered 
1-4 and derivative groups were given a letter starting with A and proceeding 
with every alternate letter in the alphabet (e.g. A, C, E, G, I etc.) until the 
tertiary BMTs were completed. For quaternary BMT the groups were labelled 
R, S, T, U, V and W according to the chronological order of the transplant 
procedures. Group 1 was the radiation controls and these are not included in 
the Figure. Although there were three original groups, unmanipulated BMT 
(group 2), SCF/IL-11 expanded BMT (group 3) and SCF/IL-ll/MIP-la 
expanded BMT (group 4), there were three time points following 1° BMT, 
creating nine groups (2A, 2C, 2E, 3A, 3C, 3E, 4A, 4C, 4E), and two time 
points following 2° BMT, creating 18 groups (2G, 21, 2K, 2M, 20, 2Q, 3G,
31, 3K, 3M, 30, 3Q, 4G, 41,4K, 4M, 4 0 ,4Q). At each time point analyses 
were performed for FBC and number of CFU-A per femur, Southern blotting 
was performed to assess the contribution of donor cells and the ability to 
reconstitute a further batch of lethally irradiated animals (i.e. serial BMT) was 
tested.
Figure 5.4 shows the number of CFU-A per femur in the 1° BMT recipients at 
the three time points chosen for analysis. At each time point three normal
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Figure 5.3 The detailed scheme for serial BMT
Group 1 represented radiation only controls which did not receive a transplant. 
For simplicity this group has not been included in the figure. Group 2 
represents animals transplanted with fresh unmanipulated bone marrow cells 
as a primary transplant. Group 3 represents animals transplanted with SCF and 
IL-11 expanded bone marrow cells. Group 4 represents animals transplanted 
with SCF, IL-11 and MUM a  expanded bone marrow cells. Thereafter, each 
individual group was given an identifying letter e.g. 2A, 2C, 2E. Individual 
mice from each group were further identified by an additional number e.g.
2A1, 2A2 etc. to 2A10. If tissues were removed for analysis these were 
designated S for spleen, T for tibia and F for femur e.g. 2A1S, 2A1T, 2A1F 
etc.
Abbreviations: 1/12, one month etc. 1°, primary BMT etc.
Figure 5.3
1° 2 ° 3 ° 4 °
2
3
Figure 5.4 Femur CFU-A content in primary (1°) BMT recipients
In the first stage of serial transplantation, three groups of lethally irradiated 
mice were transplanted with either unmanipulated bone marrow cells (Group 
2, UM BMT), SCF and IL-11 expanded cells (Group 3, SCF/11 BMT) or 
SCF, IL-11 and M IP-la expanded cells (Group 4, SCF/11/M BMT). There 
were three time points after 1° BMT, at 1/12, 3/12 and 9/12. At these times 10 
animals were sacrificed from each group and analyses were performed to 
measure the total CFU-A number per femur. Results represent the mean (± 
SEM) CFU-A content per femur for 10 animals. Control animals were 
normal, having received neither radiation nor BMT.
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control mice were analysed for FBC and CFU-A number per femur. The 
results of all control mice were then pooled. The mean result of CFU-A for all 
such control animals is included for each Figure. Results (except for controls) 
represent the mean (+ SEM) for 10 animals. As shown, CFU-A numbers were 
reduced to approximately 50% of control numbers in 1° BMT recipients at 
one and nine months following BMT. At these time points there was no 
difference between the three experimental groups. At the three month time 
point, CFU-A numbers were significantly higher for animals in either the 
unmanipulated BMT or SCF/IL-ll/MIP-la expanded BMT groups than for 
SCF/IL-11 expanded BMT (p<0.001, paired, 2-tailed t-test). Although this 
result was highly statistically significant and found both in the number of cells 
and the number of CFU-A per femur, the reason for this difference is difficult 
to determine. The initial tentative interpretation was that two stimulatory 
cytokines (i.e. SCF & IL-11) had induced differentiation of stem cells in 
culture, resulting in a reduction of CFU-A per femur compared with 
unmanipulated BMT, and that this differentiation had been prevented by the 
inclusion of MIP-la such that CFU-A numbers were equivalent for either 
SCF/IL-11/MIP-la expanded BMT or unmanipulated BMT. If this were the 
case, however, these changes would likely have persisted at the nine month 
time point (which they did not) and the ability of SCF/IL-11 expanded bone 
marrow to serially transplant would have been reduced compared with the 
other experimental groups. This was not seen at later time points. The 
alternative explanation is that, during recovery post BMT, CFU-A numbers 
may "over-shoot" before reaching stable numbers (Lorimore et al., 1990). 
From the short term engraftment kinetics described in chapter 4 (Figure 4.7), 
this "over-shoot" would be expected to occur earliest for SCF/IL-11 expanded 
BMT, then SCF/IL-11/MIP-la expanded BMT and finally for unmanipulated 
BMT. The three month time point may have been after the "over-shoot" had 
occurred and CFU-A numbers had stabilised, for SCF/IL-11 expanded BMT,
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but during the "over-shoot" in the other two groups. This would explain why 
CFU-A numbers were still only 50% of controls at nine months following 
BMT, and no different in the three experimental groups.
Following 2° BMT, the nine groups of experimental animals (i.e. 2A, 3A, 4A 
(1/12 post 10 BMT); 2C, 3C, 4C (3/12 post 1° BMT); 2E, 3E, 4E (9/12 post 
1° BMT)) were analysed for femur CFU-A content at two and six months 
following BMT. As shown in Figure 5.5, CFU-A were reduced compared with 
control animals in all experimental groups, both at two and six months post 
BMT and no differences were seen between the three experimental conditions 
(i.e. unmanipulated, SCF/IL-11 expanded and SCF/IL-ll/MIP-la expanded 
BMT). This suggests that, using the radiation dose described, and 
transplanting cell doses well in excess of threshold, CFU-A progenitors 
numbers did not return to control numbers even as late as six months 
following BMT. This has been shown previously in a serial transfer 
experiment performed by Jones et al (1989).
Haemopoiesis will be exclusively donor soon after lethal dose irradiation and 
BMT, however, unless the radiation dose is sufficient to fully ablate host bone 
marrow, there may be a contribution (small or large) from host marrow at later 
time points following BMT, especially if there are insufficient LTRC in donor 
marrow to maintain engraftment long term (Jones et al., 1989). It was 
therefore important to assess the contribution by donor marrow, at both early 
and later time points following BMT, especially for 2° and subsequent 
recipients of serially transplanted bone marrow. Figure 5.6 shows the results 
of Southern blotting for both the Y specific probe, to detect the presence of 
male donor cells, and GAPDH, as a loading control, for secondary recipients 
of unmanipulated (group 2) versus expanded (groups 3 & 4) bone marrow 
analysed at two months after BMT. In all lanes with adequate DNA loading
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Figure 5.5 Femur CFU-A content in secondary (2°) BMT recipients
Pooled bone marrow, derived from 1° BMT recipients was used to transplant 
lethally irradiated 2° animals. These 2° BMT recipients were designated A 
(derived from the 1/12 time point following 1° BMT), C (3/12) and E (9/12). 
10 animals from groups A, C and E were sacrificed at two separate time 
points following 2° BMT, at 2/12 and 6/12. At these times analyses were 
performed to measure the total CFU-A number per femur. Results represent 
the mean (+ SEM) CFU-A content per femur for 10 animals. Control animals 
were normal, having received neither radiation nor BMT. Figure a. represents 
the 2/12 time point and b. the 6/12 time point.
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Figure 5.6 Assessment of donor engraftment in group E animals at two
months following 2° BMT
Genomic DNA was extracted from five randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The left hand 
panels represent Southern blots hybridised with the Y chromosome specific 
probe, the right hand panels the GAPDH loading controls.
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(all except 4E2 lanes 1 & 3) hybridisation to the Y probe produced a very 
strong 1.5kb band suggesting that haemopoiesis was predominantly donor in 
origin. A similar pattern, with evidence of donor haemopoiesis for all samples 
adequately loaded, is seen for groups A, C and E at 6 months following 2° 
BMT in Figures 5.7-5.9. These results suggest that bone marrow cells 
expanded ex vivo still contain sufficient stem cells for a proportion of 
haemopoiesis to be of donor origin up to six months following a second serial 
transplant.
Results for CFU-A per femur for 12 of the 18 groups which received BMT 
with marrow transplanted for a third time (i.e. 3° BMT) are shown in Figure 
5.10. Please refer back to Figure 5.3 (detailed scheme for serial BMT) to 
clarify nomenclature. All these analyses were performed at approximately 
three months after 3° BMT (group G closer to 6 months). At the time of 
writing, groups O and Q had not been analysed. CFU-A numbers were greatly 
reduced compared with controls for all experimental groups, however, there 
appeared to be, in addition, some important differences between the groups. 
When the intervals between serial cell transfers were relatively short (i.e. 1/12 
then 2/12 for G; 3/12 then 2/12 for K) CFU-A were almost non-existent in the 
femurs of mice transplanted with unmanipulated bone marrow. CFU-A 
numbers were greater for the groups transplanted with expanded cells. This 
may reflect the faster kinetics of engraftment in animals transplanted with 
expanded cells which allowed the ratio of committed progenitors: LTRC to 
return to normal earlier after BMT than for unmanipulated BMT. If this 
marrow was then used at an early time point for serial transplantation, stem 
cell numbers would be greater for expanded compared with unmanipulated 
marrow. When the intervals were prolonged (1/12 then 6/12 for I; 3/12 then 
6/12 for M) CFU-A numbers for animals transplanted with unmanipulated 
bone marrow were back to the level seen for recipients of expanded BMT in
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Figure 5.7 Assessment of donor engraftment in group A animals at six
months following 2° BMT
Genomic DNA was extracted from randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The top, third 
and fifth panels represent Southern blots hybridised with the Y chromosome 
specific probe, the second, fourth and sixth panels the GAPDH loading 
controls.
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Figure 5.8 Assessment of donor engraftment in group C animals at six
months following 2° BMT
Genomic DNA was extracted from randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). Results 
represent hybridisation with the Y chromosome specific probe.
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Figure 5.9 Assessment of donor engraftment in group E animals at six
months following 2° BMT
Genomic DNA was extracted from randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The top panel 
shows a standard titration of male DNA. The left hand panels represent 
Southern blots hybridised with the Y chromosome specific probe, the right 
hand panels the GAPDH loading controls.
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Figure 5.10 Femur CFU-A content in tertiary (3°) BMT recipients
Pooled bone marrow, derived from 2° BMT recipients was used to transplant 
lethally irradiated 3° animals. These 3° BMT recipients were designated G 
(derived from the 1/12 time point following 1° BMT, and the 2/12 time point 
following 2° BMT), K (3/12, 2/12), O (9/12, 2/12), I (1/12, 6/12), M (3/12, 
6/12) and Q (9/12, 6/12). Groups O and Q had not been analysed at the time 
of writing. 10 animals from each of the groups available were sacrificed at a 
single time point following 3° BMT, at 3/12. At this time analyses were 
performed to measure the total CFU-A number per femur. Results represent 
the mean (+ SEM) CFU-A content per femur for 10 animals. Control animals 
were normal, having received neither radiation nor BMT.
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groups G and K. These changes were reflected in the survival of tertiary BMT 
recipients shown later in this chapter. In this case, the CFU-A numbers for 
recipients of expanded marrow were low (groups I and M) and, as discussed 
later, this may have been due to the development of leukaemia in these 
animals.
The results of Southern blotting to assess the contribution of male donor 
haemopoiesis is shown for 3° BMT recipients in Figures 5.11-5.14 (groups 
G, K, I, M). For group G, although the contribution of donor cells differs for 
individual animals, there is clear evidence that donor cells were present in 
every animal. Even animals in group 2G (in whom CFU-A numbers were 
greatly reduced) showed evidence of residual donor haemopoiesis. 
Approximately 3 months following 3° BMT, animals transplanted with 
serially passaged unmanipulated bone marrow started to die of bone marrow 
failure (group 2K). In Figure 5.12, animals from group 2K (in whom CFU-A 
numbers were also severely depleted) showed little or no evidence of residual 
donor haemopoiesis on Southern blotting. This blot was repeated on three 
occasions to confirm the result and the GAPDH hybridisation confirmed 
adequate DNA loading. Since these animals were dying of bone marrow 
failure it appears that the radiation protocol used in this study was sufficiently 
myeloablative to prevent early return of host haemopoiesis in the face of a 
failing bone marrow graft of donor cells. Both groups 3K and 4K, transplanted 
with expanded bone marrow, showed clear evidence of donor haemopoiesis. 
There were no deaths from bone marrow failure in either of these groups. For 
groups I and M, all animals tested showed residual donor haemopoiesis which 
was easily detectable by Southern blotting.
To summarise, CFU-A numbers were reduced in all recipients of 3° BMT 
when compared with normal controls. For serial BMT with relatively short
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Figure 5.11 Assessment of donor engraftment in group G animals at three
months following 3° BMT
Genomic DNA was extracted from ten randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The top and 
third panels represent Southern blots hybridised with the Y chromosome 
specific probe, the second and fourth panels the GAPDH loading control.
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Figure 5.12 Assessment of donor engraftment in group K animals at three
months following 3° BMT
Genomic DNA was extracted from randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/EL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The top panel 
shows a titration of male DNA followed by 9 individual test samples from 
group 2K. The arrows indicate hybridisation to the Y chromosome specific 
probe at a very low level. The third panel shows results with the Y specific 
probe for groups 3 and 4K. The second and fourth panels represent the 
GAPDH loading control.
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Figure 5.13 Assessment of donor engraftment in group I animals at three
months following 3° BMT
Genomic DNA was extracted from randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/EL-11 
expanded BMT; group 4, SCF/EL-11/MIP-la expanded BMT). The top panel 
shows the titration of male DNA. The left hand panels represent results for the 
Y specific probe, the right hand panels results for GAPDH.
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Figure 5.14 Assessment of donor engraftment in group M animals at
three months following 3° BMT
Genomic DNA was extracted from five randomly selected animals from each 
experimental group (i.e. group 2, unmanipulated BMT; group 3, SCF/IL-11 
expanded BMT; group 4, SCF/IL-11/MIP-la expanded BMT). The top panels 
show the titration of male DNA and GAPDH loading control. The second 
panel shows results for test DNA hybridised to the Y specific probe and the 
third panel the corresponding GAPDH controls.
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intervals between cell transfers, recipients of unmanipulated BMT showed 
lower CFU-A numbers compared with recipients of either SCF/IL-11 or 
SCF/DL-11/MIP-1 a  expanded BMT. With longer intervals between cell 
transfer, unmanipulated BMT appeared to regain the ability to sustain serial 
BMT and CFU-A numbers were improved for groups 21 and 2M. Except for 
recipients of unmanipulated bone marrow after short cell transfer intervals (i.e. 
2K) there were no deaths from bone marrow failure and there was evidence of 
persistent donor engraftment by Southern blotting.
At each of the time points following 1°, 2° and 3° BMT, peripheral blood was 
analysed for FBC. As shown in Figure 5.15 a-d, the haemoglobin level of 1° 
BMT recipients was close to that of normal controls at each of the time points, 
with no differences seen between the three experimental groups. The platelet 
counts appeared to continue to increase towards those of normal controls, 
even up to nine months following BMT (Figure 5.15 b). Compared with 
normal controls, the total WBC (also reflected in the neutrophil count) was 
higher at three months following 1° BMT in all three experimental groups.
As was discussed regarding CFU-A numbers at three months (Figure 5.4), this 
difference may reflect an "over-shoot" produced during marrow regeneration 
following the insult of BMT. For 2° BMT recipients, peripheral counts at 
either the two or six month time points, showed no differences between the 
three experimental groups (Figure 5.16). Haemoglobin, platelets and WBC 
were close to normal for all the analyses.
Peripheral blood counts are shown for 3° BMT recipients in Figure 5.17 a-d. 
In all four groups analysed (G, K, I, M) mean haemoglobin levels were 
slightly lower for the animals transplanted with SCF/IL-11/MIP-la expanded 
marrow than for the other two experimental groups (unmanipulated and 
SCF/EL-11 expanded BMT). In Figure 5.17 b, the mean platelet counts were
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Figure 5.15 Peripheral blood values in primary (1°) BMT recipients
At one month (1/12), 3/12 and 9/12 following 1° BMT, 10 animals were 
sacrificed from each of the three experimental groups (UM BMT, SCF/11 
BMT and SCF/11/M BMT). Analyses were performed on each individual 
animal for full blood count (FBC). Results therefore represent the mean (± 
SEM) for 10 animals. Figure a. haemoglobin, b. platelets, c. white blood count 
(WBC) and d. neutrophils.
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Figure 5.16 Peripheral blood values in secondary (2°) BMT recipients
At 2/12 and 6/12 following 2° BMT, 10 animals were sacrificed from groups 
2A, 3A, 4A, 2C, 3C, 4C and 2E, 3E, 4E (derived at 1/12, 3/12 and 9/12 
respectively following 1° BMT). FBC was performed on each individual 
animal. Results represent the mean (± SEM) for 10 animals. Figure a. 
haemoglobin, b. platelets, c. WBC and d. neutrophils.
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Figure 5.17 Peripheral blood values in tertiary (3°) BMT recipients
At 3/12 following 3° BMT, 10 animals were sacrificed from groups 2G, 3G, 
4G, 2K, 3K, 4K, 21, 31, 41 and 2M, 3M, 4M. FBC was performed on each 
individual animal. Results represent the mean (+ SEM) for 10 animals. Figure 
a. haemoglobin, b. platelets, c. WBC and d. neutrophils.
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far lower for the SCF/IL-11/MIP-la BMT groups than for SCF/IL-11. The 
mean platelet count was also lower for the remaining 9/20 animals in group 
2K (unmanipulated BMT) compared with controls. Since 11/20 animals died 
in group 2K prior to this analysis, it is likely that, if analysed, those animals 
would have had even lower platelet counts. It has already been shown that 
CFU-A numbers were very low in this group (Figure 5.10). The WBCs shown 
in Figure 5.17 c reveal a very important development in this study. Whereas 
the mean WBC for groups G, K and I appeared normal, the mean WBC for 
group 4M (SCF/EL-11/MIP-la expanded BMT) was elevated to 
approximately 6 times control. The individual indices for animals in group 4M 
are shown in Table 5.1. At least 8 of 12 animals appeared to have developed a 
form of leukaemia (see chapter 6 for elaboration).
To summarise the results described so far in this chapter, it appears that 
unmanipulated cells used for rescue following lethal irradiation either take 
longer to re-establish a normal complement of LTRC compared with 
expanded marrow, or contain fewer LTRC than expanded marrow, because of 
an increase in absolute LTRC numbers during ex vivo expansion. When the 
interval between cell transfers was relatively short, unmanipulated marrow 
was less able to sustain serial BMT compared with expanded marrow. When 
the interval was increased, the ability of unmanipulated marrow to sustain 
serial BMT increased. This serial BMT approach, with varying time intervals 
between cell transfers and proceeding to quaternary BMT has been very 
informative and extends similar work performed by other investigators, in 
particular that of Muench et al (1993). Whether the abilities of unmanipulated 
and expanded marrow to sustain serial BMT were comparable after a longer 
interval was impossible to determine in these experiments, because animals 
transplanted with expanded marrow started to die with raised WBC, 
suggestive of the development of leukaemia.
1 1 0
Table 5.1 Peripheral blood counts of quaternary BMT recipients (Group 
4M)
Full blood count results are shown individually for group 4M (SCF/IL- 
11/MIP-la BMT). For the results for 2M and 3M refer to the previously 
presented histogram showing mean (± SEM) for all three groups.
Table 5.1
Individual
identification
Total WBC 
(x 109/L)
Platelets 
(x 109/L)
Haemoglobin
(g/dl)
4M1 38.8 52 9.5
4M2 20.1 222 10.5
4M3 3.5 725 11.9
4M4 27.6 398 11.5
4M5 16.3 143 5.6
4M6 150.0 50 7.3
4M7 24.7 272 10.8
4M8 3.2 398 10.3
4M9 6.0 547 12.1
4M10 7.3 167 11.4
4M11 164.0 160 6.0
4M12 61.5 94 9.0
The following series of survival curves, individual FBC indices and Southern 
blots relate to groups of animals already described above (i.e. 3° BMT) and to 
4° BMT recipients. The only group in which bone marrow was not pooled to 
assess its ability to sustain a fourth serial transplant was group 2K. This was 
because 11/20 animals in this group died of bone marrow failure and it was 
reasoned that a fourth serial transplant would be unsuccessful. For groups 3K 
and 4K, and 2G, 3G, 4G a fourth serial BMT was performed. In groups I and 
M, although deaths were seen in the SCF/IL-11/MIP-la groups, these 
appeared to be due to leukaemia and it was, therefore, of interest to perform a 
fourth serial transplant to determine whether the leukaemia was transplantable.
The survival of recipients of bone marrow (3°BMT) derived at time points of 
one month post 1° BMT, and two months post 2° BMT (i.e. group G) is 
shown in Figure 5.18. Deaths early after BMT were presumed to be related to 
radiation toxicity, but no formal analyses were performed on these animals. 
One animal was killed on day 100 post BMT in the SCF/IL-11 expanded 
BMT group because it had developed a skin tumour. This animal was 
otherwise healthy. There were several deaths between days 75 and 100 in the 
SCF/IL-11/MIP-la group. At the time of these deaths occurring they were 
presumed to be due to late bone marrow failure and no further analyses were 
therefore performed (see below). All three groups were sacrificed at 182 days 
after 3° BMT. The marrow of 10 animals from each group was pooled and 
used to transplant a further three groups of lethally irradiated animals (20 mice 
per group). The survival of these groups (2R, 3R & 4R) is shown in Figure 
5.18. Mice transplanted with 5 x 10^ serially transplanted unmanipulated bone 
marrow cells all died by day 25 post BMT. This timing strongly suggested 
that these animals were indeed dying of bone marrow failure because they 
were transplanted with an inadequate number of both short and LTR stem and
1 1 1
Figure 5.18 Survival curve of recipients of 3° BMT (Group G)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/IL-11 BMT and SCF/IL-11/MIP BMT) in Group G 
(derived from the time points at 1/12 post 1° and 2/12 post 2° BMT). There 
were twenty animals in each group.
Survival curve of recipients of 4° BMT (Group R)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/11 BMT and SCF/11/MIP BMT) in Group R (derived 
from the time points at 1/12 post 1°, 2/12 post 2° and 6/12 post 3° BMT). 
There were twenty animals in each group.
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Figure 5.18
Survival analysis of recipients of serially 
transplanted marrow: tertiary BMT (Group G)
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progenitor cells. In view of the very low CFU-A content of group G marrow 
(Figure 5.10) this result was not surprising. Mice transplanted with SCF/IL- 
11/MIP-la expanded marrow became unwell around 75 days post BMT. This 
timing was identical to that for animals transplanted with SCF/IL-11/MIP-la 
BMT in group G (see above), although in group G there were only a small 
number of deaths. This timing was very different to that of unmanipulated 
BMT where all the deaths occurred before day 25. Because of these 
interesting differences in the time after BMT until signs of malaise developed, 
8/20 animals from group 4R were sacrificed and analyses performed for FBC, 
donor haemopoiesis and pathology. All these 8 animals were unwell at the 
time of sacrifice and the remaining 12/20 died. All but one animal in the 
SCF/IL-11 BMT group survived until 140 days after BMT when 10 of the 20 
were sacrificed and analyses performed for FBC, donor haemopoiesis and 
immunophenotyping (see later). Table 5.2 shows the FBC results for 11 
animals in group 3R (SCF/IL-11 BMT), sacrificed on days 137 (number 
3R11) and 140 (3R1-10) post BMT, and 8 animals in group 4R (SCF/IL- 
11/MIP-la BMT), sacrificed between days 75 and 100 post BMT. In group 
3R, one animal (3R11) appeared unwell on day 137 post BMT. FBC revealed 
leucocytosis, thrombocytopenia and anaemia, highly suggestive of a 
leukaemic process. The remaining 19 animals appeared healthy at the time of 
analysis (day 140). The 10 animals sacrificed all had a normal FBC with no 
suggestion of either bone marrow failure or leukaemia. The remaining 9 
animals were observed for survival. There were no further deaths in this group 
to day 218 post BMT. On the other hand, all 8 animals in group 4R (SCF/IL- 
11/MIP-la BMT) had leucocytosis, thrombocytosis and anaemia. The 
remaining 12 had already died, presumably of leukaemia. The southern blot 
results in Figure 5.19 confirm that all the animals assessed in group 3R 
(SCF/IL-11 BMT) showed clear evidence of donor derived haemopoiesis. The 
pattern seen for group 4R suggests minimal binding of the Y specific probe to
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Table 5.2 Peripheral blood counts of quaternary BMT recipients (Groups 3R 
and 4R)
Full blood count results are shown for groups 3R (SCF/IL-11 BMT) and 4R 
(SCF/IL-11/MIP-la BMT). (Group 2R perished soon after BMT and no 
analyses were performed).
Table 5.2
Individual
identification
Total WBC 
(x 109/L)
Platelet count 
(x 109/L)
Haemoglobin
(g/dl)
3R1 6.2 809 12.6
3R2 3.2 787 12.3
3R3 7.1 486 12.0
3R4 8.3 833 12.6
3R5 3.8 831 13.1
3R6 3.8 871 12.7
3R7 3.9 915 13.0
3R8 2.3 67 10.5
3R9 5.5 878 12.9
3R10 5.0 693 12.1
3R11 53.7 212 8.6
4R1 86.9 64 9.8
4R2 134.5 162 10.4
4R3 31.6 192 8.6
4R4 37.7 99 8.1
4R5 19.7 85 3.5
4R6 28.9 149 7.2
4R7 70.3 243 9.5
4R8 158.0 170 5.0
Figure 5.19 Assessment of donor engraftment in group R animals
following 4° BMT
Genomic DNA was extracted from randomly selected animals from each 
remaining experimental group (i.e. group 3, SCF/IL-11 BMT; group 4, 
SCF/IL-11/MIP BMT). Group 2R perished soon after 4° BMT and was 
followed for survival only (i.e. no other analyses were performed). The top 
panels show the titration of male DNA and GAPDH loading control. The left 
hand panels represent results for the Y specific probe, the right hand panels 
results for GAPDH.
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digested DNA which had been partially degraded at the time of analysis, 
hence the smear, rather than clear bands. Unfortunately, all the DNA from this 
group was of similar quality. Referring back to the FBC results in Table 5.1 it 
is clear that group 4M had also developed leukaemia. In light of these results, 
it is likely that the small number of deaths in group 4G (SCF/IL-11/MIP-la 
BMT) was also due to leukaemia rather than to bone marrow failure (see 
Figure 5.18).
The survival of recipients of bone marrow (3°BMT) derived at time points of 
three months post 1° BMT, and two months post 2° BMT (i.e. group K) is 
shown in Figure 5.20. Apart from a few early deaths, probably related to 
radiation toxicity, all three groups of animals survived until > day 75. At that 
point, animals in group 2K (unmanipulated BMT) began to die. The animals 
analysed for FBC, donor haemopoiesis and pathology, were the remaining 9 
live animals. These nine animals, at the time of analysis, appeared healthy 
and, therefore, may not have been representative of the animals which died. 
These animals had normal WBC, near normal haemoglobin and reduced 
platelet counts. These nine animals showed no evidence (FBC & pathology) 
of leukaemia. It may be presumed, therefore, that the deaths seen in group 2K 
were due to late bone marrow failure and not to leukaemia. On day 100 post 
BMT, bone marrow was pooled from groups 3K (SCF/IL-11) and 4K 
(SCF/IL-11/MIP-la) and used to transplant two groups of lethally irradiated 
animals (20 mice per group). Group 2K was not used in a fourth serial 
transplant because only nine animals were available which had low femur 
counts and therefore insufficient cells to transplant a further 20 animals. In 
any case since group 2K appeared to be dying of bone marrow failure a fourth 
transplant from this group was not likely to be successful. The survival of the 
recipients of marrow from groups 3K and 4K is shown in Figure 5.20 (groups 
3S and 4S). Animals transplanted with SCF/IL-11/MIP-la (group 4S)
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Figure 5.20 Survival curve of recipients of 3° BMT (Group K)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/11 BMT and SCF/11/MIP BMT) in Group K 
(derived from the time points at 3/12 post 1° and 2/12 post 2° BMT). There 
were twenty animals in each group.
Survival curve of recipients of 4° BMT (Group S)
The survival curves following BMT are shown for the two experimental 
groups (SCF/11 BMT and SCF/11/MIP BMT) in Group S (derived from the 
time points at 3/12 post 1°, 2/12 post 2° and 3/12 post 3° BMT). There were 
twenty animals in each group. Since only 9 remaining animals were analysed 
from the UM BMT group in group K, there were insufficient cells to test 
ability to sustain a fourth serial BMT in this cohort.
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Figure 5.20
Survival analysis of recipients of serially 
transplanted marrow: tertiary BMT (group K)
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expanded marrow began to die around day 40 post BMT. Since animals in 
group 4R had all died from leukaemia or showed evidence of leukaemia at the 
time of analysis, it was presumed that animals in group 4S were also dying of 
leukaemia, but no analyses were performed. 10 animals from Group 3S were 
sacrificed for analysis at day 152 post BMT. These animals all appeared 
healthy at that time. The FBC results for these 10 animals are shown in Table 
5.3. One animal had a slightly raised WBC (number 3S2) however, both the 
platelet count and haemoglobin were fully normal and this may have been due 
to intercurrent infection. Pathology revealed no evidence of leukaemia in these 
animals and as shown in figure 5.21, haemopoiesis was at least partially donor 
derived. The remaining animals in this group were alive and well at 232 days 
post BMT. To conclude, although full analyses were not performed on every 
group or on every animal within a group, it appears that animals in groups 4G, 
4R and 4 S (all SCF/IL-11/MIP-la BMT) developed leukaemia. In addition at 
least one animal in group 3R (SCF/IL-11 BMT) also developed leukaemia. 
There was no evidence of leukaemia in animals transplanted with 
unmanipulated BMT.
The survival of recipients of bone marrow (3°BMT) derived at time points of 
one month post 1° BMT and six months post 2° BMT (i.e. group I) is shown 
in Figure 5.22. Once again deaths were observed in the SCF/IL-11/MIP-la 
group (41) from around 90 days post BMT. When only 6/20 animals in this 
group remained alive all three groups were analysed for FBC, donor 
haemopoiesis, pathology and ability to sustain a fourth serial BMT. FBC was 
also performed for three additional animals in group 41 prior to this time point. 
As can be seen by referring back to Figure 5.17, the FBCs were normal for 
groups 21 and 31 which all appeared healthy. However, the FBCs were all 
abnormal for group 41. Three animals showed mild leucocytosis, all had a 
reduced platelet count and all were anaemic. The spleens of these animals
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Table 5.3 Peripheral blood counts of quaternary BMT recipients (Group 3S)
Full blood count results are shown for group 3S (SCF/IL-11 BMT). Since 
group 2K was not used for a quaternary BMT there is no group 2S (UM 
BMT). Group 4S (SCF/IL-11/MIP-la BMT) perished soon after BMT and no 
analyses were performed.
Table 5.3
Individual
identification
Total WBC 
(x 109/L)
Platelets 
(x 109/L)
Haemoglobin
(g/dl)
3S1 5.8 665 12.8
3S2 17.7 836 13.3
3S3 5.6 794 12.4
3S4 4.4 814 12.1
3S5 4.4 742 12.3
3S6 3.7 952 12.2
3S7 12.3 854 12.9
3S8 9.1 634 12.2
3S9 7.7 718 13.0
3S10 7.5 680 12.5
Figure 5.21 Assessment of donor engraftment in group S animals
following 4° BMT
Genomic DNA was extracted from five randomly selected animals from group 
3S (SCF/IL-11 BMT). Since some animals in group 2K perished during 3° 
BMT this group was not used in a 4° transplant, therefore there was no group 
2S. Group 4S (SCF/IL-11/MIP-la BMT) perished after 4° BMT and was 
followed for survival only (no other analyses were performed). The top panels 
show the titration of male DNA and GAPDH loading control. The second 
panel shows results for group 3S for hybridisation with the Y probe and with 
GAPDH.
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Figure 5.22 Survival curve of recipients of 3° BMT (Group I)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/11 BMT and SCF/11/MIP BMT) in Group I (derived 
from the time points at 1/12 post 1° and 6/12 post 2° BMT). There were 
twenty animals in each group.
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were grossly enlarged, as was the liver. At the time of writing, the animals 
transplanted with the pooled marrow from these three groups (4°BMT, groups 
2U, 3U, 4U) were alive and well (day 40 post BMT).
The final survival curves (Figure 5.23) are for recipients of bone marrow 
(3°BMT and 4°BMT) derived at time points of three months post 1° BMT, 
six months post 2° BMT (i.e. group M) and three months post 3°BMT (i.e. 
group V). Ten animals from groups 2M (UM BMT) and 3M (SCF/IL-11 
BMT) and all remaining animals in group 4M (SCF/IL-11/MIP-la BMT), 
were sacrificed for analysis 102 days post BMT. By then, 9/20 in group 4M 
had died of leukaemia. 12/20 had FBC performed and the majority showed 
abnormalities consistent with leukaemia (Table 5.1). All showed enlargement 
of spleen and liver. Group 2M (UM BMT) all appeared healthy at the time of 
analysis, and all their FBCs were within normal limits. 8/20 in this group 
remained alive and well 178 days post BMT. Although group 3M (SCF/IL-11 
BMT) appeared healthy at the time of analysis, one (3M7) had a very 
abnormal FBC (WBC 24.8 x 109/1, Hb. 8.4g/dl, platelets 106 x 109/1) and 
several showed a degree of pancytopenia. The remaining 8/20 animals left 
after the time point for analysis have since died. At the time of analysis, all 
three groups showed evidence of donor derived haemopoiesis in bone marrow, 
whether leukaemic or not (Figure 5.13). Pooled marrow from groups 2M, 3M 
and 4M was used to serially transplant further batches of lethally irradiated 
mice (15 per group). The survival curve of these animals is also seen in Figure 
5.23. Since group 4M showed clear evidence of leukaemia (see FBC Table
5.1) at the time of analysis, the deaths (100% by day 20 post BMT) in group 
4Y were presumed to be due to leukaemia and no further analyses were 
performed in this group. Group 2V remained alive and well at 76 days post 
BMT. Group 3V began to show signs of malaise by 25 days post BMT. On 
day 36 post BMT the 5/15 remaining alive were sacrificed and analysed for
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Figure 5.23 Survival curve of recipients of 3° BMT (Group M)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/11 BMT and SCF/11/MIP BMT) in Group M 
(derived from the time points at 3/12 post 1° and 6/12 post 2° BMT). There 
were twenty animals in each group.
Survival curve of recipients of 4° BMT (Group V)
The survival curves following BMT are shown for the three experimental 
groups (UM BMT, SCF/11 BMT and SCF/11/MIP BMT) in Group Y (derived 
from the time points at 3/12 post 1°, 6/12 post 2° and 3/12 post 3° BMT). 
There were twenty animals in each group.
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FBC and pathology. The five individual FBCs are shown in Table 5.4. At least 
three animals showed significant leucocytosis, all were anaemic and severely 
thrombocytopenic. This result confirms that the leukaemia process seen in all 
groups transplanted with SCF/IL-11/MIP-la expanded marrow also 
developed later in animals transplanted with SCF/IL-11 expanded marrow. 
During prolonged follow-up one animal from the unmanipulated BMT group 
(2111) became unwell and was found to have developed leukaemia. This was 
the only animal transplanted with unmanipulated marrow in which this 
occurred.
Discussion
The results described in this chapter are fascinating but difficult to interpret 
For serial transplantation with unmanipulated cells it seems clear that if the 
interval between transplants is short (groups G and K) then the ability to 
sustain serial BMT is less than if the interval is longer (groups I and M). This 
feature has previously been described by Jones et al and was interpreted as 
evidence that soon after BMT, LTRC are diluted out by committed 
progenitors, but by six months after BMT, the normal ratio is regained 
allowing further successful serial BMT (Jones et al., 1989).
If this hypothesis were correct it would explain one possible 
mechanism underlying the improved ability of expanded bone marrow to 
sustain serial BMT even with short intervals between transplants. As 
described in Chapter 4, expanded bone marrow, used for rescue following 
lethal dose radiation, produced more rapid haematological recovery compared 
with unmanipulated cells. We can assume, therefore, that expanded marrow 
may also allow more rapid recovery of the ratio of LTRC to committed 
progenitors compared with unmanipulated material. This would explain the 
augmentation of the ability to serially transplant marrow seen for expanded 
marrow at the early time points. The ability of unmanipulated bone marrow to
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Table 5.4 Peripheral blood counts of quaternary BMT recipients (Group 
3V)
Full blood count results are shown for the 5 out of 15 animals in group 3 V 
(SCF/IL-11 BMT) remaining alive at day 36 post BMT.
Table 5.4
Code Total WBC 
(x 109/1)
Platelets 
(x 109/I)
Haemoglobin
(g/dl)
3V1 23.8 10 3.3
3V2 5.8 17 6.2
3V3 111.2 57 7.9
3V4 3.8 27 10.7
3V5 25.7 25 9.0
Group 3, SCF/IL-11 BMT
V = 40 BMT from Group M (3/12 after 1<>, 6/12 after 2°, 3/12 after 3° BMT)
sustain a 3° and 4° BMT was regained when the duration between the 2° and 
3° BMT was increased from two months to six months (groups I and M) again 
in agreement with the work by Jones et al.
However, the development of leukaemia, almost exclusively in the 
expanded groups, suggests that the more rapid return of the normal LTRC: 
committed progenitor ratio post BMT cannot be the only mechanism 
underlying the differences between unmanipulated and expanded BMT and 
suggests an effect of growth factor exposure at the level of a primitive stem 
cell. The alternative explanation for the improved ability of expanded marrow 
to sustain serial BMT is that LTRC were actually increased in number during 
ex vivo expansion. If this were the case, then expanded marrow would be 
expected to show an improved ability to sustain serial BMT whether the 
interval between transplants was short or long. It was, however, impossible to 
compare the ability of expanded marrow to sustain serial BMT at these later 
time points because of the development of leukaemia. In the absence of 
quantitative stem cell assays (e.g. cobblestone area forming cell assay (in 
vitro) Ploemacher et al., 1991) or competitive repopulation assay (in vivo) 
(Harrison, et al., 1993), no conclusions can be made regarding the number of 
LTRC used for the 1° BMT. These experiments are now in progress, but were 
not completed at the time of writing.
The conclusions which can be made, with the information available, 
are firstly that growth factor exposure of bone marrow cells prior to 
transplantation appears to augment the ability to sustain serial BMT if the 
interval between transplants is short. Secondly, that growth factor exposure 
appears, in some way, to trigger the development of a leukaemia in recipient 
animals. This leukaemia may develop following serial BMT with 
unmanipulated marrow but this appears to be a very rare event (one case 
only). Growth factor exposure, however, appears to increase the incidence of 
leukaemia and the addition of MIP-la to SCF and IL-11 appears to further
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increase the incidence and reduce the latency of leukaemogenesis. The 
mechanism underlying the development of this leukaemia is not yet known, 
but is likely to relate both to the primary ex vivo culture and to the requirement 
to repopulate lethally irradiated host animals in vivo.
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RESULTS IV
Chapter 6 Characterisation of the Leukaemia observed in 
Recipients of Bone MarrowTransplantation
Murine leukaemias, either arising spontaneously or induced by radiation or 
drugs, have been described previously and may be strain or age dependent. 
New Zealand Black mice spontaneously develop a B-cell lymphoproliferative 
disorder as they age and have been used as a murine model of B-cell chronic 
lymphocytic leukaemia (B-CLL) (Okada et al., 1991; Marti et al., 1995). In 
these mice, spleen weight, peritoneal cell counts, and absolute lymphocyte 
counts are elevated in old (>18 months) compared with young (2 months) 
animals. They develop lymphocytic infiltrates in the lacrymal glands, kidneys, 
liver and lung. There is an age dependent increase in CD5 positive B cells in 
blood and spleen which show oligoclonal and even clonal expansion, 
eventually giving rise to B-CLL (Okada et al., 1991; Marti et al., 1995). To 
our knowledge, leukaemia of this type has not been described as occurring 
spontaneously in the B6D2F1 strain.
Leukaemias induced by radiation are usually of the myeloid lineage 
and originate in the host stem cells which have themselves been exposed to 
radiation damage (Fennelly et al., 1995). They are often associated with 
chromosomal changes. The leukaemia observed in this study did not occur in 
all groups of animals (given an identical radiation schedule), and occurred 
only in the later part of the serial transplantation experiment, therefore, it is 
most unlikely to have been related to radiation exposure. In addition, as 
discussed below, the leukaemia was found to be lymphoid rather than 
myeloid.
The leukaemia occurred almost exclusively in animals transplanted 
with expanded cells. This suggested that the ex vivo culture, by an unknown 
mechanism, was the initiating factor in leukaemogenesis. A range of
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investigations were planned to determine if the disorder seen was truly 
leukaemia and if so what type of leukaemia it was. Detailed pathology was 
performed on normal control animals, and animals from all three experimental 
groups, whether the animals appeared healthy or not. Southern blotting, to 
detect male or female haemopoiesis, was performed as already described. 
Immunophenotyping was performed for both myeloid antigens (Gr-1 and c- 
kit) and markers typically positive in B-CLL (CD5 and surface IgM). Pooled 
marrow from some experimental groups was used to transplant 
(intraperitoneal) sub-lethally irradiated mice to determine whether the disorder 
was transplantable and therefore leukaemic. These mice were given only 2Gy 
irradiation to ensure that any deaths observed were due to leukaemia and not 
to bone marrow suppression. Finally, FISH studies using a Y specific marker, 
and cytogenetic analyses were performed.
The results of pathology from both normal and leukaemic animals are shown 
in Figures 6.1-9. In normal mouse peripheral blood, compared with red cells, 
white cells are infrequent and platelets plentiful (Figure 6.1). There are 
approximately equal numbers of lymphocytes and neutrophils. Eosinophils 
and monocytes are rarely seen and basophils are even less common. The 
normal neutrophils lack granulation and have a segmented nucleus (Figure
6.1). Normal lymphocytes are slightly smaller than neutrophils, with a round 
nucleus, little cytoplasm, no granules and no nucleoli. In the leukaemic 
animals, the leucocytosis consisted of a lymphocytosis. In some cases the 
lymphocytes appeared relatively mature, however when the disease was more 
advanced the cells looked more primitive. Two high power views of blood 
films from leukaemic animals are shown in Figure 6.2. The lymphoid cells 
are larger than normal with less cytoplasm. They are best described as "blast" 
cells.
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Figure 6.1 Normal mouse blood film
High power view of a normal mouse blood film. A normal lymphocyte and 
neutrophil are shown. Platelets appear plentiful.
Figure 6.2 Blood films from animals with leukaemia at high power
Two high power views of the blood films from animals with 
lymphoproliferation. Platelets appear significantly reduced.
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In the leukaemic animals, the spleens and livers were gready enlarged.
Macro scopically the spleens often appeared haemorrhagic and showed paler 
"follicular" areas. An example of spleen size and morphology from leukaemic 
mice is shown in Figure 6.3. The normal splenic architecture is completely 
effaced, with patchy areas of lymphoid infiltrate separated by haemorrhage. At 
high power, the infiltrate consists of a fairly homogeneous population of large, 
nucleolated lymphoid blast cells. The presence of haemorrhage is obvious. For 
comparison, the gross appearance of a normal sized spleen, next to two 
leukaemic spleens is shown.
Many of the mice examined, whether leukaemic or not, showed evidence of 
extramedullary haemopoiesis. This is likely to occur following lethal 
irradiation, with transplanted cells proliferating both in the bone marrow and 
in the spleen. The example shown in Figure 6.4 shows evidence of 
lymphoproliferation and, in addition, extramedullary haemopoiesis. The 
megakaryocytes are seen very clearly.
Normal bone marrow is shown in Figure 6.5. Cellularity tends to be greater in 
the shaft of the femur with an increase in the fat spaces towards the end as 
shown in this example. Bone trabeculae are seen and lymphoid cells are 
infrequent In the following example (Figure 6.6), from a leukaemic animal, 
the bone marrow is completely infiltrated by tumour. There is little residual 
normal haemopoiesis although occasional megakaryocytes are present. The 
normal architecture, including bone trabeculae and fat spaces, has been 
destroyed. In some animals, intermediate stages of the disease were seen. 
These animals appeared healthy at the time of analysis however their bone 
marrow showed early infiltration with lymphoid cells and peripheral blood 
indices showed pancytopenia.
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Figure 6.3 Splenic infiltration by leukaemia
Low power view of a spleen from an animal with lymphoproliferation. In this 
example the normal splenic architecture is completely destroyed. The spleen 
has been invaded by a lymphoid infiltrate and extensive haemorrhage is 
visible.
At high power the lymphoid cells appear rather pleomorphic and the 
haemorrhage is striking. Many of the lymphoid cells are nucleolated.
The final figure shows the gross appearances of a normal spleen next to two 
leukaemic spleens.

Figure 6.4 Extramedullary haemopoiesis
This example from an animal with lymphoproliferation shows evidence of 
extramedullary haemopoiesis. Note the presence of megakaryocytes.
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Figure 6.5 Normal bone marrow
Low power view of a normal femur. Cellularity appears normal with ample fat 
spaces. Bone trabeculae are present.
Figure 6.6 Bone marrow infiltration by leukaemia
Low power view of a femur from an animal with lymphoproliferation. 
Cellularity is greatly increased with few fat spaces. Bone trabeculae are 
reduced in number.
In some cases with splenomegaly, the spleens were cut in half and the cut 
surface was touched onto a slide (spleen dabs). One such preparation is shown 
from a leukaemic animal in Figure 6.7. In this example, the lymphoid cells are 
large and primitive. Many appear as smudge cells, typically seen in CLL. In 
intact cells there is little cytoplasm. In animals with very advanced disease, 
there was macroscopic evidence of infiltration of spleen, liver, lymph nodes 
and kidney. In Figure 6.8 a sample from an enlarged kidney is shown. In the 
upper part of the low power view some glomeruli remain, however, extensive 
tumour infiltration is shown in the lower part of the field. At high power the 
infiltrate is seen to consist of large lymphoid cells, similar to those seen in 
spleen (Figure 6.3). Finally, Figure 6.9 shows a high power view of an area 
found to be infiltrated by lymphoid tissue in the intestinal wall of a leukaemic 
mouse. This particular field shows the heterogeneous nature of the lymphoid 
infiltrate. There are cells of varying sizes and morphology, from small 
relatively mature lymphocytes, to large, nucleolated cells. Debris from dead 
and dying cells is also seen, re-emphasising the rapid turnover of the tumour.
As shown previously (chapter 5), in 3° BMT recipients which developed 
leukaemia (groups 4M and 41), evidence of residual male donor cells persisted 
in the bone marrow at the time of analysis. The result of Southern blotting for 
group M is repeated in Figure 6.10. The WBC was elevated in 8 of 12 animals 
in the SCF/IL-11/MIP-la group (4M), but was still normal in the SCF/IL-11 
(3M) and unmanipulated BMT (2M) groups. As shown in Figure 6.10, 
hybridisation to the Y specific probe was clearly demonstrated for 5 animals 
from group 4M confirming the persistence of male donor cells in bone 
marrow. It was, however, impossible to state with certainty, in these animals, 
whether the persistent male signal was from residual normal haemopoiesis or 
from leukaemic cells. Transplantation from these groups (i.e. 4M and 41) 
(which were obviously leukaemic) into sublethally irradiated female animals,
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Figure 6.7 Spleen dab from an animal with leukaemia
High power views of a spleen dab from an animal with lymphoproliferation. 
In this preparation cellularity is greatly increased.
The majority of the cells are lymphoid blast cells with many smudge cells.
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Figure 6.8 Kidney infiltration by leukaemia
Low power view of kidney from an animal with lymphoproliferation. In the 
upper part of the field a few remaining normal glomeruli can be seen, 
however, in the lower part there is evidence of lymphoid infiltration.
At high power the lymphoid cells appear pleomorphic with both small mature 
lymphocytes and more primitive "blasts" with nucleoli.
Figure 6.9 Infiltration of the intestinal wall by leukaemia
High power view of an area of lymphoproliferation in the intestine. The 
lymphoid cells are pleomorphic showing small mature lymphocytes and large 
immature lymphoblasts which are nucleolated.
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Figure 6.10 Assessment of donor engraftment in group M animals at
three months following 3° BMT
Genomic DNA was extracted from five randomly selected animals from each 
experimental group (i.e. group 2, UM BMT; group 3, SCF/IL-11 BMT; group 
4, SCF/IL-11/MIP BMT). The top panels show the titration of male DNA and 
GAPDH loading control. The second panel shows results for test DNA 
hybridised to the Y specific probe and the third panel the corresponding 
GAPDH controls.
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with Southern blotting and / or FISH, both for a Y specific probe, performed 
when possible on both marrow and spleen, was therefore required, to prove 
whether the leukaemia had arisen in cells of male or female origin. If 
sublethally irradiated female recipients developed a leukaemia, then the 
presence of only a female signal would confirm that the leukaemia was 
female, whereas the presence of a male signal in the majority of cells would 
confirm that the leukaemia was male (see later for results of these 
experiments). The reason for looking both at marrow and spleen is that, in 
mice, CD5 positive CLL usually progresses from a clonal proliferation 
localised in peritoneum, to the lymph nodes, spleen and finally marrow. In 
these animals we had already seen evidence of extramedullary haemopoiesis 
in the spleen, therefore it was possible that circulating peripheral leukaemic 
cells were coming from spleen rather than bone marrow.
Pathology of the leukaemic animals suggested that this was a lymphoid 
malignancy. The disease appeared to become more aggressive as it advanced, 
in keeping with CLL. The widespread infiltration of a variety of tissues was 
also suggestive of CLL. To confirm that the leukaemia was indeed CLL, 
immunophenotyping was performed.
CD5 positive B cells are implicated in the pathogenesis of CLL. In addition to 
expressing CD5, these cells express low amounts of surface immunoglobulin 
(IgM) (Burrows et al.> 1993). For this reason, immunophenotyping was 
performed using two markers for B cells, CD5 and IgM, to confirm that the 
disease was originating from CD5 positive B cells and therefore was likely to 
be CLL. Cells which showed double labelling for these two markers would be 
typical of B-cell CLL (i.e. CD5+/sIgM+). For completeness cells were also 
labelled for two myeloid antigens, Gr-1 and c-kit. Gr-1 is present on mature
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myeloid cells of the granulocytic lineage, whereas c-kit is present on more 
immature myeloid stem cells.
Figures 6. 11 and 6.12 show the results of immunophenotyping for the 
markers mentioned above. Population R1 was gated to represent lymphocytes 
whereas R2 represented larger more granular cells. In Figure 6.11 the cells 
were taken from the spleen of a normal control animal. The top line of dot 
plots is for population Rl, the lower line for population R2. In the first panel 
the cells are stained with an irrelevant control antibody to allow the gates to be 
set accurately. The second panel shows cells labelled with both PE-CD5 and 
FITC-IgM. In the lymphocyte population two clear populations are seen, those 
which stain with CD5, which are likely to represent normal T cells and cells 
which stain with IgM, which are likely to represent normal B cells. Few cells 
show double marking for both CD5 and IgM. There is little marking for either 
Gr-1 or c-kit. Figure 6.12 a-c shows results for 3 animals which were 
developing leukaemia. In these cases, although leukaemia was definitely 
present, it was not at an advanced stage. For all three cases, the dot plots show 
a significant proportion of cells in the lymphocyte window which show double 
marking for both CD5 and IgM, confirming the presence of CD5+ B cells, 
typical of the cell type in B-cell CLL. The dot plots are very similar for all 
three animals presented here and have been identical in analysis of other 
groups with leukaemia, confirming that there was only one form of leukaemia 
arising under the experimental conditions used in this study.
In the previous chapter, results were presented which showed that when 
tertiary BMT recipients showed evidence of leukaemia, then, if their bone 
marrow was pooled and used to transplant further lethally irradiated animals, 
these would develop leukaemia and die soon after BMT (Figure 5.23). Since a 
radiation dose of 12.125Gy may cause death from the effects of radiation on
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Figure 6.11 Flow cytometric analysis to detect CD5/IgM positive B cells
Any animals which showed serious signs of malaise were sacrificed. If either 
the FBC revealed abnormalities suggestive of lymphoproliferation or the 
spleen was found to be enlarged, the spleen was removed, half was processed 
for pathology and the remainder was used for antibody labelling. Cells were 
double labelled for CD5 and IgM and for Gr-1 and c-kit. In the top panel R1 
represents the "lymphocyte population" and R2 the "granulocyte population". 
In the lower panel the top row is for population R1 and the lower row for 
population R2. The left hand results are for an irrelevant IgG antibody, the 
middle for CDS and IgM and the right for Gr-1 and c-kit. In this example for a 
normal animal there are few if any cells which double label for CD5 and IgM.
FL1 represents fluorescence for FITC-conjugated antibodies, either IgM or c- 
kit whilst FL2 represents fluorescence for PE-conjugated antibodies, either 
CD5 or Gr-1.
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Figure 6.12 Flow cytometric analysis to detect CD5/IgM positive B cells
At the time of analysis this animal (group 41) was found to have a greatly 
enlarged spleen, an elevated WBC and reduced Hb and Platelets. As shown in 
the figure a significant proportion of the spleen cells showed double labelling 
for CD5 and IgM. In this case the primary transplant was with cells expanded 
with SCF, IL-11 and MIP-la.
The following two figures show results for a further two animals which showed 
signs of lymphoproliferation at the time of analysis. Both these cases were from 
group 41.
FL1 represents fluorescence for FTTC-conjugated antibodies, either IgM or c- 
kit whilst FL2 represents fluorescence for PE-conjugated antibodies, either 
CD5 or Gr-1.
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non-haemopoietic tissues or from myelosuppression it was necessary to prove 
that in these animals the leukaemia had been the direct cause of death. Further 
transplantation experiments were therefore carried out to determine whether 
the leukaemia was transplantable following sublethal doses of radiation. The 
bone marrow cells were pooled from tertiary BMT recipients from group M 
and I. Mice were given only 2Gy of radiation and were then injected 
intraperitoneally with 10^ cells per mouse. There were 5 animals in each 
group (i.e. 2MIP1-5, 3MIP1-5, 4MIP1-5 and 2IIP1-5, 3IIP1-5, 4IIP1-5, 
IP=intraperitoneal). Table 6.1 shows the survival of these groups of animals to 
15 weeks following transplantation. The group of animals transplanted with 
cells pooled from group 4M (SCF/IL-11/MIP-la expanded BMT) became 
unwell and 4/5 died within 4 weeks of transplantation. Since these animals 
received only 2Gy radiation, these deaths must have been due to the 
transplantation of leukaemic cells. To confirm that this was indeed the case, 
the remaining animal in this group, which still appeared healthy, was 
sacrificed and analyses were performed for pathology, FBC, FISH and 
immunophenotyping. These confirmed that this animal had developed B-cell 
CLL. At 15 weeks following transplantation, one animal in group 3MIP 
looked unwell and was therefore sacrificed and analyses performed for FBC, 
immunophenotyping, FISH, cytogenetics and Southern blotting. All remaining 
animals in this experiment (i.e. group 2MIP and 3MIP) were alive and well at 
15 weeks after transplantation. The animals transplanted IP with pooled cells 
from groups 21, 31 and 41 were well until week 15. This probably reflected the 
fact that the leukaemia was less advanced in groups 31 and 41 at the time of 
the transplant, therefore it had taken longer to appear in recipient animals. 
However, by 15 weeks post transplantation, 2 animals in group 41 showed 
obvious splenomegaly. These were sacrificed and analyses performed for FBC 
and Southern blotting.
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Table 6.1 Demonstration that the lymphoproliferative condition was 
transplantable
Bone marrow was pooled from groups 2M, 3M, 4M, 21, 31, 41 at the time of 
analysis and used to inject groups of 5 animals by intraperitoneal injection. The 
mice were given only low dose irradiation (2Gy) to facilitate engraftment but 
without causing bone marrow suppression. The results show survival at 4, 10 and 
15 weeks following transplantation.
Table 6.1
Code Survival at 
4 weeks (%)
Survival at 
10 weeks (%)
Survival at 
15 weeks (%)
2MIP (n=5) 100 100 100
3MIP (n=5) 100 100 80**
4MIP (n=5) 20* 0 0
2IIP (n=5) 100 100 100
3nP  (n=5) 100 100 100
4IIP (n=5) 100 100
* At 4 weeks the remaining animal in group 4MIP showed signs of 
malaise and was sacrificied.
**At 15 weeks one animal in group 3MIP appeared unwell and was 
sacrificed
*** At 15 weeks 2 animals in group 4IIP showed signs of splenomegaly 
and were therefore sacrificed.
*FBC- WBC 22.1 x lO^/L, haemoglobin 13.0 g/dl, platelets 552 x 10 /^1; 
**WBC 18.4, haemoglobin 10.6, platelets 239;
***WBC 57, haemoglobin 8.2, platelets 388,
WBC 11.9, haemoglobin 5.5, platelets 331 
Abbreviation: IP, intraperitoneal
A number of samples from the above experiments were analysed in 
collaboration with the MRC Radiobiology Unit in Oxon, UK., to establish 
whether the leukaemia was male, therefore derived from the original cell 
innoculum, or female, derived from earlier BMT recipients.
Southern blotting results were available for 7 individual animals from group 
4U (4° serial BMT, 12.125Gy, from group 41), one animal which developed 
leukaemia in group 3MIP at 15 weeks of follow-up, (2Gy radiation and IP 
transplant of pooled marrow from group 3M) and 2 animals from group 4IIP 
again at 15 weeks of follow-up. These results are shown for hybridisation to 
the Y specific probe, together with GAPDH loading control, in Figure 6.13.
As demonstrated, haemopoiesis was either fully female or <5% male, 
confirming that the leukaemia, after serial passage, was female, and had, 
therefore, arisen in an earlier female recipient.
The animals chosen for these definitive experiments were selected because the 
donor animals were already showing evidence of advanced leukaemia and 
therefore, when transplanted into either lethally irradiated or sublethally 
irradiated female animals, would clearly demonstrate whether leukaemia, 
when it arose in recipients was male or female derived.
Results of FISH, performed by Katherine Harper (MRC, Oxon), using a Y 
chromosome specific probe, are shown in Table 6.2 and Figure 6.14. In these 
animals with advanced leukaemia, FISH confirmed that haemopoiesis was 
predominantly, or exclusively female. Gwyneth Watson (MRC, Oxon) kindly 
agreed to perform cytogenetic analyses on some representative samples from 
leukaemic animals. These are shown in Table 6.3 and Figure 6.15. These 
confirmed, firstly, the presence of 2 marker chromosomes which were
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Figure 6.13 Assessment of donor engraftment in 7 selected quaternary
BMT recipients (group 4U) and 3 animals transplanted with leukaemic
cells following 2Gy irradiation
Genomic DNA was extracted from the bone marrow and / or spleen of 
selected animals (4U1-5, 12 and 13,4IIP1 & 2 and 3MIP1). The top panel 
show the titration of male DNA and hybridisation of all the samples with the 
Y specific probe. The second panel shows results for the corresponding 
GAPDH loading controls.
Y titration
g *O O
* #
$  ^  ^  r  $ in cm i- o o 4U1-5
lL C/)
L L C / ) L L C / ) L J _ C / ) I L C / ) t- ^ -
C M C M C O C O T - r - C M C M Q . I L
t - t - t - t - Q _ Q _ Q . Q _  —  — ;
D D D D = = = = 2 5
t
Y titration
Table 6.2 FISH results for quaternary BMT recipients and for sublethally
irradiated BMT recipients
The Y chromosome paint JB16/3 and the female specific probe DXWas70 
were used to label interphase or metaphase preparations as described in 
materials and methods. The results show the percentage of male cells scored 
for the Y paint, or the percentage of female cells in which 2 X chromosomes 
were definitely present for the female probe.
Table 6.2
Code FISH % of cells with Y 
chromosome
FISH % of cells with 2X 
chromosomes
2V1F >90 not done
3MIPS 0 95
4U1F 0 92
4U2F 0 not done
4U3F 0 not done
4U4F 1 83
4U5F 3 86
F=femur, S=s ?leen
Figure 6.14 FISH results for control male cells and for selected animals 
with and without leukaemia
A. This represents FISH performed with the Y specific JB16/3 paint on a 
metaphase preparation from a normal control male B6D2F1 mouse. A single 
Y chromosome is clearly seen.
B. This represents FISH performed with JB16/3 on an interphase preparation 
from a non-leukaemic animal from group 31. The majority of cells are male.
C. This represents FISH performed with JB16/3 on a metaphase preparation 
from a leukaemic animal. Although 40 chromosomes are present there is no Y 
chromosome confirming that the leukaemia must be female.
D. This represents FISH performed with the female probe DXWas70 on a 
metaphase preparation from a non-leukaemic animal. There is only a single X 
chromosome present confirming that the cell is male.
E. This represents FISH performed with DXWas70 on a metaphase 
preparation from a leukaemic animal. There are 2X chromosomes present, 
confirming that the leukaemia was female.

Table 6.3 Cytogenetic analysis for quaternary BMT recipients and for
sublethally irradiated BMT recipients
The results shown are those for a non-leukaemic animal (2V1), an animal 
given 2Gy irradiation prior to intraperitoneal injection of cells pooled from 
group 3M and 5 animals from group 4U. The 3MIP1 animal and all 5 from 
group 4U showed evidence of leukaemia at the time of analysis. Results show 
the total number of cells scored, the number with a Y chromosome or with no 
Y but with either a single or 2 marker chromosomes.
Table 6.3
Code Cells
scored
Cells with Y 
chromosome
Cells with 1 marker 
chromosome & no Y
Cells with 2 marker 
chromosomes & no Y
2V1F 10 10 0 0
3MIPS 10 3 2 0
4U1F 60 1 2 41
4U2F 13 0 0 13
4U3F 15 0 0 15
4U4F 5 0 0 5
4U5F 7 0 2 5
F=femur, S=spleen
Figure 6.15 Examples of metaphase spreads showing the presence of 
marker chromosomes
Top: This represents a metaphase spread from a non-leukaemic animal from 
group 2V (2V1). There is a single Y chromosome (arrowed), showing that the 
cell is male, but no marker chromosomes.
Bottom: This represents a metaphase spread from a leukaemic animal (4U3). 
There is no Y chromosome, showing that the cell is female, but 2 marker 
chromosomes are present (arrowed).
/
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identical in all animals examined and, secondly, the absence of Y 
chromosomes in the majority of samples examined.
These results, taken together, confirm that the leukaemia observed was CLL, 
arising in CD5 positive, surface IgM positive, B cells. The leukaemic cells 
tested were female and, therefore, the leukaemia must have arisen, at some 
point, in host B cells in recipient animals, rather than in the cells cultured ex 
vivo. In all animals for which full data were available, the same type of 
leukaemia was observed with the same type of marker chromosomes. Without 
clonality studies, however, it is impossible to show how many single 
leukaemias occurred in this study.
Discussion
In the adult mouse normal B cell populations include conventional B cells (B2 
cells) and CD5 (ly-1) positive B cells (reviewed by Burrows et al., 1993).
CD5 positive B cells show a distinctive tissue distribution in adult mice and 
are most commonly found in the peritoneal cavity. Only small numbers are 
present in spleen and very few in lymph nodes. Progenitors of CD5 positive B 
cells may be found in relative abundance in fetal liver and spleen but are 
virtually absent from adult bone marrow. In addition, the CD5 positive B cell 
subset has been shown to contain cells at different stages of activation and 
maturation. These observations prompted speculation that CD5 positive B 
cells belong to a different subset of the B cell lineage than conventional B 
cells.
Work performed by Hayakawa et al, in 1985, supported this 
hypothesis (Hayakawa et al., 1985). This group compared cell populations 
from various donor organs, from newborn and adult mice, for their ability to 
reconstitute particular B cell subsets when transplanted into lethally irradiated 
recipients. These experiments showed, that, whereas progenitor cells present
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in newborn liver and spleen and bone marrow from all age groups, were able 
to reconstitute conventional B cells, adult bone marrow and spleen lacked the 
ability to reconstitute CD5 positive B cells. These cells were readily 
reconstituted if the transplant was with either newborn liver or cells from adult 
peritoneum (Hayakawa et al., 1985). These findings were interpreted to 
suggest that B lineage progenitor cells present in adult bone marrow may give 
rise to conventional B cells, but not to CD5 positive B cells, and that separate 
progenitor cells responsible for the generation of CD5 positive B cells must be 
transplanted to reconstitute that lineage.
There are several other examples inconsistent with the view that a 
single HSC is the progenitor of all cells in the haemopoietic system relating to 
both erythroid differentiation, expression of fetal versus adult haemoglobin 
(Fantoni et al., 1967) and to T cell development (Ikuta & Weissman, 1991).
Since the initial report (Hayakawa et al., 1985), further studies now 
suggest the presence of three B cell lineages, B-la cells (CD5 positive B 
cells), B-lb cells and conventional B cells (Kantor et al. , 1992b; Kantor & 
Herzenberg, 1993). According to this work, conventional B cells develop late 
in ontogeny and appear to be replenished from progenitors present in adult 
bone marrow by differentiation of non-rearranged progenitor cells; B-la cells 
develop early in ontogeny and appear to maintain their numbers by self­
replenishment (i.e. by division of fully mature B-l cells); and B-lb cells, 
which share the property of self-replenishment with B-la cells, may also 
develop from progenitors in adult bone marrow. Conventional B cells may be 
distinguished from B-l cells by their anatomical localisation, functional 
characteristics and cell surface markers. B-la and B-lb cells appear to be 
similar to each other, except that only B-la cells express CD5. Within the 
limits of the experiments performed, it appeared that each of the B-l cell 
populations could replenish itself but not the other (Kantor et al., 1992b; 
Kantor & Herzenberg, 1993).
128
Recent cell transfer studies confirm the finding by Hayakawa that 
adult bone marrow contains very little progenitor activity for B-la cells, but 
they do suggest that reconstitution of B-la cells by transplanting adult bone 
marrow is possible, at least at a low level, (Lalor et al.y 1989; Stall et al.,
1992; Kantor et al. , 1992a; Kantor et al., 1992b; Kantor & Herzenberg,
1993).
Considering my own data, if we assume that under normal 
circumstances CD5 positive B cells are present at very low frequencies in 
adult bone marrow, then following single and serial transfers of 
unmanipulated bone marrow cells, whether donor or recipient derived, this 
population would be under strong proliferative stress to replenish normal 
numbers. Under these circumstances it is likely that the resulting CD5 positive 
population is donor derived. However, for bone marrow cells cultured ex vivo, 
the number of CD5 positive B cells remaining viable following expansion 
with a cytokine combination chosen for its effects on myeloid progenitors, 
might be low or even non-existent, such that the host CD5 positive progenitor 
cells, already exposed to radiation, would receive an even greater stimulus to 
regenerate. These suggestions are, of course, hypothetical, but might explain 
the increased incidence of CD5 malignancy seen in the groups of mice 
transplanted with stem cells cultured ex vivo.
It is well recognised that B cell CLL originates from the CD5 positive 
B-la population. In the vast majority of mouse strains, clonal populations of 
B-la, CD5 positive B cells can be detected as the animals age (Stall et al., 
1988; Tarlinton et al., 1988). Young mice generally show polyclonal 
populations but in older mice the number of clones decreases to one or two. In 
certain strains, however, these clones may be detected even in neonates (e.g. 
New Zealand Blacks) (Kantor & Herzenberg, 1993). CD5 positive B cells are 
responsible for production of autoantibodies and certain mouse strains are 
particularly susceptible to autoimmune disease. It is these strains which
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develop clonal populations at the earliest age. These clones do not appear to 
occur at random, since there is repetitive usage of the same Vh and D 
elements within the clones of an individual animal (Rajewsky et al., 1987; 
Tarlinton et al., 1988). This suggests a selective force, perhaps related to 
antigenic stimulation. In the autoimmune models, therefore, perhaps an 
endogenous antigen stimulates clonal proliferation of CD5 positive, 
autoantibody producing, B cells.
In all mouse strains certain clones of CD5 positive B cells predominate 
with ageing. As such clones expand, the possibility of neoplastic 
transformation presumably increases. This has been demonstrated in a number 
of studies: Stall et al (Stall et al., 1988) have shown that young New Zealand 
Black mice and old normal mice have detectable clones of CD5 positive B 
cells which may be detected by either Southern blotting or FACS analysis and 
tend to develop and grow rapidly upon transfer into irradiated or non­
irradiated hosts. This rapid clonal proliferation may explain why serial transfer 
increased the incidence and aggressiveness of the leukaemia in our study. The 
cells invade in a characteristic pattern: peritoneum then spleen, lymph nodes 
and finally bone marrow. Both phenotype and growth pattern are very similar 
to human B cell CLL (Stall et al., 1988). A further study by Fowlis et al 
(Fowlis et al., 1989), demonstrated imbalance of CD5 positive B cell 
populations as early as one year of age in mice bred to be informative for two 
donor cell populations. Such populations occasionally produced transplantable 
leukaemia, shown to be CLL. The incidence of these leukaemias and the level 
of aggressiveness of the leukaemias were increased by serial BMT. Although 
the majority of the leukaemias were monoclonal there were instances of at 
least two clones coexisting for many months, or of a latent donor cell 
producing a distinct leukaemia after several serial transfers of the original 
tumour. Leukaemia was frequently observed if spleen cells from old, but
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apparently healthy, donors were used for transplantation in young recipients 
(Fowlis etal.t 1989).
Clearly the B cell leukaemias observed in our own work were similar, 
if not identical, to those described above but occurred in a strain which is not 
know to be susceptible to B cell leukaemia. In mice transplanted with cultured 
cells, the possible absence of CD5 positive B cells in the donor innoculum, 
may have provided a stimulus for regeneration of this population in the female 
recipients. Since CD5 positive B cells are already more at risk of malignant 
transformation than conventional B cells, presumably because of the need for 
long lived self-replenishment, this may have been sufficient to induce 
leukaemia in relatively young animals. Having developed in one, or several, 
early recipient(s), the disease was then serially transplanted in pooled bone 
marrow, both increasing the incidence and the level of aggressiveness of the 
tumour until it eventually became detectable in the majority of animals 
transplanted with cultured cells. Alternatively, serial transfer of clonal 
populations of recipient CD5 positive B cells may have been sufficient, alone, 
to induce a transplantable leukaemia in 2 of the 3 experimental groups (i.e. 
SCF/IL-11 expanded BMT and SCF/IL-ll/MIP-la expanded BMT). Since 
pooling of bone marrow prior to each serial transfer would be likely to 
increase the incidence of leukaemia, eventually effecting all animals within 
the group, only 2 separate cases of leukaemia would be necessary to produce 
the findings observed. If this were the case, it is conceivable that the 
leukaemias in the two expanded groups occurred by chance and, therefore, 
that the ex vivo expansion, per se, had no influence on the generation of 
leukaemia.
Clearly the work presented in this chapter raises a number of important 
questions. It will be of interest to determine clonality of the B-cell leukaemia 
and to search for cytogenetic abnormalities in this leukaemia at different 
stages of development. It is likely that this leukaemia becomes more
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aggressive as it progresses. This progression could be hastened by 
manipulating the experimental conditions used to produce a very useful 
laboratory model of leukaemogenesis. These results have important 
implications in a number of areas, both experimental and clinical. Stem cell 
expansion is regarded as having great clinical potential, both for 
transplantation studies and for gene transduction. If the generation of the 
leukaemia seen in these studies reflects an effect of stem cell expansion then 
this will have to be addressed.
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DISCUSSION
In vitro assessment of the culture conditions required to promote CFU-A 
proliferation and expansion ex vivo
The early experimental work presented in this thesis was planned to 
investigate growth factor combinations which would induce expansion, in 
vitro, of multipotential progenitor cells. The availability of the CFU-A assay 
"in house" greatly facilitated these studies. Previous studies, performed by 
Pragnell and co-workers, had demonstrated that murine CFU-A progenitors 
were comparable to CFU-S day 12 in terms of their position within the stem 
cell hierarchy (Pragnell et al., 1988). This in vitro assay, which is relatively 
simple to perform, was therefore used to measure stem and progenitor cells 
rather than the in vivo CFU-S assay, which is more cumbersome and 
expensive in terms of animal use.
The CFU-A assay was selected as the primary "read-out" for 
progenitor expansion because several workers had shown that CFU-S 
(therefore presumably CFU-A) were separable from HSC and appeared to be 
responsible for the early phase of haemopoietic engraftment following BMT 
(Jones et al., 1990; Ploemacher & Brons, 1989). The experiments were 
planned to specifically target these "transient engrafting stem cells" to try to 
increase their numbers in vitro, and thereby to influence the kinetics of 
haemopoietic recovery when these expanded populations were used for 
transplantation.
A number of cytokines were selected for investigation. SCF had been 
identified only a short time before this project was initiated and the available 
information suggested that it was a potent physiological regulator of stem cell 
proliferation. Its unique ability to synergise with a range of other cytokines, in 
vitro, suggested that it would prove useful as one component for ex vivo 
expansion of stem cells. IL-11, which was cloned in 1990, was selected for
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study because it appeared to have major effects on megakaryopoiesis in 
addition to erythropoiesis and granulopoiesis. This property was felt to be of 
crucial importance since an in vitro amplification of megakaryocytic 
precursors might be expected to influence platelet recovery following 
transplantation of the expanded cells.
In our hands, cytokine combinations involving SCF and either IL-11, 
IL-1|3, G-CSF or IL-6, stimulated CFU-A amplification (Holyoake et al., 
1996). IL-lp was not selected for further study because its effects had been 
shown to be indirect by elaboration of other cytokines including IL-6 and G- 
CSF (Leary et al., 1988). IL-11 was chosen, rather than either G-CSF or IL-6, 
both because CFU-A expansion appeared to be consistently slightly greater 
with IL-11 and because of its known effects on megakaryopoiesis. Over recent 
years, a number of investigators, including ourselves, have clearly 
demonstrated that CFU-S (or in our hands CFU-A) may be expanded ex vivo 
using SCF containing cytokine combinations. The choice of the second 
cytokine has proven to be less critical and a number of cytokines appear active 
in this respect including IL-11, IL-6, IL-1 a, G-CSF and IL-1 (3 (Neben et al., 
1994; Luskey et al., 1992; de Vries et al., 1991; Muench et al., 1993).
Over a six day incubation period the combination of SCF and IL-11 
stimulated an approximate 50 fold CFU-A amplification in cultures of 
unfractionated bone marrow. Even in the absence of cytokines, input CFU-A 
numbers were maintained over the six day culture period. The cultures were 
supplemented with DHS (25% v/v) which had been pre-tested to promote 
maximum colony growth in the CFU-A assay and may have contained low 
concentrations of cytokines sufficient to allow stem cell survival. Such 
maintenance of input CFU-A in the absence of cytokines was neither seen for 
cultures of highly purified Sca+ lineage negative cells in the presence of DHS 
nor for unfractionated bone marrow cultured under serum free conditions. 
These results would suggest that the combination of DHS and supporting
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accessory cells was sufficient to allow survival of CFU-A progenitor cells. 
Whether these conditions also allowed survival of LTRC was never formally 
tested.
On the basis of a single experiment, the degree of CFU-A 
amplification was unaffected by stem cell purification. In this experiment day 
2 post 5-FU bone marrow had a cloning efficiency in the CFU-A assay of 4% 
and amplified approximately 800 fold over 6 days in the presence of SCF and 
IL-11. The equivalent values for unfractionated bone marrow would be 0.2% 
and 50 fold. Therefore the level of enrichment for CFU-A was 20 fold and the 
increase in amplification potential 16 fold. This suggests firstly that the 
presence of accessory cells is not necessary for CFU-A amplification and 
secondly that accessory cells present in unfractionated bone marrow do not 
elaborate sufficient levels of inhibitory cytokines to prevent amplification.
Is there a role for MIP-la?
We decided to investigate how negative regulators of stem cell proliferation 
might interact with stimulatory cytokines for three reasons. Firstly, there was 
evidence that both TGF-(3 and MIP-la might act in an inhibitory or 
stimulatory manner depending on the culture conditions employed (Keller et 
al., 1994; Broxmeyer et al., 1990). Secondly, studies by Bodine et al 
suggested that although several cytokine combinations induced expansion of 
CFU-S in expansion cultures, in some instances this would occur at the 
expense of LTRC (Bodine et al., 1991). In our studies we primarily wished to 
expand CFU-A in order to improve early engraftment post transplant and if 
possible we wished to achieve this aim whilst, at the same time, maintaining 
LTRC. If this were possible then clinical cases in whom an insufficient 
numbers of stem cells could be harvested might benefit from ex vivo 
expansion of their stem cells prior to transplantation. In the study by Bodine et 
al either IL-3 /  G-CSF or IL-3 / IL-6 increased the number of both CFU-S and
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LTRC over IL-3 alone. However, when all three cytokines were combined, 
although CFU-S expansion increased, the number of LTRC fell significantly, 
suggesting too great a differentiative stimulus (Bodine et al., 1991). In the 
same report, MIP-la, used alone, was ineffective in promoting CFU-S 
survival and did not alter CFU-S survival when added to IL-3 supplemented 
cultures. However, when MIP-la was added to the combination of IL-3 /  IL- 
6, CFU-S expansion fell significantly. The effect of M IP-la was not tested 
with IL-3 / IL-6 / G-CSF, which had been shown to increase CFU-S but at the 
expense of LTRC, nor was it tested, in any combination, for effects on LTRC. 
In these studies cytokine combinations containing SCF were not explored and 
the possible role of MIP-la was not fully elucidated. It therefore seemed 
logical to assess whether negative regulators, when combined with a cytokine 
combination known to be active in increasing CFU-A / CFU-S would affect 
CFU-A proliferation or the survival / expansion of LTRC. Finally, these 
negative regulators were selected for further study because of our group's long 
term interest in the control of stem cell proliferation and in MDP-la in 
particular.
TGF-p and MIP-la were assessed alone and in combination with SCF 
and IL-11, for effects on progenitor proliferation over 6 days expansion 
culture. TGF-p's effects were consistently inhibitory from the start of culture 
and this inhibitory effect predominated even for cultures supplemented with 
the stimulatory cytokines SCF and IL-11. The addition of M IP-la alone had 
no effect on either cell numbers or progenitor numbers compared with 
medium control cultures. When added to cultures supplemented with SCF and 
IL-11, M IP-la did not significantly inhibit or stimulate either the number of 
cells or progenitors present after six days. If any pattern was observed, the 
effect of M IP-la was to increase, rather than decrease the number of 
progenitors present.
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At the time these experiments were performed there were two factors 
which prompted us to continue to investigate M IP-la in conjunction with 
SCF and IL-11. The first was that the cell population present at the end of 
culture appeared less differentiated (by morphological criteria only) in the 
presence of MIP-la. The second was work presented in abstract form by 
Catherine Verfaillie in 1993 (Verfaillie et al., 1993).
The culture system employed by Verfaillie et al differed in many ways 
from our own (Verfaillie et al., 1993). The starting cells were from human 
bone marrow and were enriched to the level of CD34+ HLA-DR- (0.1-0.4% 
of bone marrow). These were cultured in the presence and absence of either a 
stromal layer or stromal derived conditioned medium. The cells were either 
plated in direct contact with, or separated from, the stromal layer (by a 
transwell insert). The cells were cultured in the absence of cytokines or in the 
presence of one or more stimulatory or inhibitory cytokines (e.g. IL-3, MIP- 
la , TGF-p) or a combination of stimulatory and inhibitory cytokines (e.g. IL- 
3 and MIP-la). The cells were cultured for 5-8 weeks before quantification of 
CFC and LTCIC. The main conclusion from this work was that LTCIC 
maintenance for 5-8 weeks required the presence of both IL-3 and M IP-la 
and in addition the presence of either stroma or stroma conditioned medium 
(SCM). As in our own studies, TGF-p was consistently inhibitory in these 
experiments (Verfaillie et al., 1993; Verfaillie etal., 1994).
Although, as stated, these experiments differed greatly from our own, 
they suggested that the possible MIP-la effect seen in our own in vitro 
experiments might be a real effect.
We next performed three consecutive experiments in which 
unfractionated bone marrow was cultured in the presence of SCF / IL-11 +/- 
M IP-la for up to 39 days. There was no suggestion that CFC output was 
improved by the addition of MIP-la or that MIP-la prevented the cultures 
exhausting around day 35-40. If anything, the M IP-la supplemented cultures
137
appeared less productive than the cultures without M IP-la although this may 
have been because one culture of three supplemented with M IP-la showed 
poor expansion from day 12 onwards.
Our next approach was to enrich day 2 post 5FU murine bone marrow 
for Sca+ lineage negative cells. This was performed on four occasions. These 
experiments proved to be expensive in terms of time and animal requirements, 
and produced variable levels of stem cell enrichment (204-4456 fold) and 
recovery (1.3-45%). This may have been the result of our inexperience in this 
technique. Unfortunately, although the purified Sca+ lineage negative 
populations were set up in expansion culture on four occasions, progenitor 
expansion was satisfactory in only one experiment. On this occasion, CFU-A 
expansion was 520 (+ 130) fold in the absence of M IP-la and 750 (± 77) fold 
in the presence of MIP-la. Clearly no conclusion may be drawn from a single 
result. Because of our technical difficulties in purifying Sca+ lineage negative 
cells, no further similar experiments were performed.
Stem cell purification may have reduced our chances of demonstrating 
an effect of MIP-la. Taking Verfaillie et al's finding, that stroma (or SCM) 
was essential for maintenance of LTCIC, into account, it is possible that by 
purifying stem cells we may have decreased the effect of M IP-la in stroma 
free cultures, i.e. that the presence of stroma derived cells in our 
unfractionated bone marrow cultures may have functioned similarly, though 
perhaps less efficiently, to a fully formed stromal layer.
In the next series of experiments the stem cell purification strategy was 
simplified. A lineage negative fraction was prepared, in a single step, from 
normal bone marrow. It was hoped that by using this method the level of stem 
cell enrichment and recovery might be more reproducible than for day 2 post 
5-FU marrow which was both depleted of lineage negative cells and then flow 
sorted. These lineage negative populations were expanded in three consecutive 
experiments. We reasoned that the effect of MIP-la, if present at all, may
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target only a small subset of the stem cell compartment, and therefore may be 
difficult to demonstrate. "Read-out" was therefore performed for cell and 
CFU-A /  CFU-GM numbers as before, but in addition the starting cells were 
examined morphologically, scored for percentage of blasts and were analysed 
by flow cytometry for percentage of Sca+ and of Rhodaminedull cells. 
Following a seven day incubation, "read-out" was repeated for the same 
parameters and the expanded population was again enriched for lineage 
negative cells. In all three experiments total cell number and the number of 
lineage negative cells recovered by the second purification step were greater 
in the presence of MIP-la. In addition the expanded populations contained a 
greater proportion and, therefore, a greater total number of Sca+ and 
r h o d a m i n e d u l l  cells of blast morphology. In these experiments neither CFU-A 
nor CFU-GM expansion was increased in the presence of MIP-la. This 
finding is difficult to explain but may suggest that M IP-la’s effect is directed 
at an earlier precursor that CFU-A. If this were the case CFU-A and CFU-GM 
would have been increased in the presence of MIP-la, if the cultures were 
maintained for long enough. This had not been observed in the cultures 
established with unfractionated bone marrow maintained for up to 39 days 
(discussed above).
We therefore found it impossible to develop a simple in vitro assay 
which would demonstrate conclusively that MIP-la was affecting progenitor 
expansion. However, in view of our own data, and that of Verfaillie et al, 
MIP-la supplemented cultures were pursued for in vivo experiments.
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Assessment of the short term engrafting potential of expanded 
populations: Comparison with unmanipulated bone marrow
In parallel with in vitro experiments, an in vivo murine model was developed 
to test the short term engrafting ability of expanded cells. Two forms of "read­
out" were used; survival to day 30 following lethal dose radiation and rate of 
recovery of peripheral blood counts. It was hoped that by expanding the 
number of CFU-A progenitors available for transplantation, fewer starting 
cells would be required to rescue animals following a standard radiation 
protocol. This type of approach would be applicable clinically since, for a 
significant proportion of patients for whom autologous BMT is indicated, 
insufficient stem and progenitor cells can be harvested to reach the threshold 
which ensures rapid recovery following transplantation.
The experiments described in chapter 4 demonstrated that it was 
indeed possible to reduce the number of cells required for short term 
engraftment by a factor of 10-20 fold. Since CFU-A increased approximately 
50 fold but cell number could only be reduced about 10 fold, it seemed likely 
that a threshold number of CFU-A progenitors was not the only requirement 
for transient engraftment. The CFU-A compartment is likely to be 
heterogeneous, comprised of both primitive and more mature multipotential 
progenitor cells. The expansion of CFU-A seen in these studies was probably 
accompanied by maturation such that the ratio of primitive to more mature 
cells was shifted towards more committed progenitors. If this were indeed the 
case these results suggested that more primitive CFU-A progenitors were also 
required for transient engraftment, explaining why the cell number 
transplanted could not be reduced by 50 fold. The number of cells required for 
rescue was not further reduced by the addition of M IP-la to the combination 
of SCF and IL-11 suggesting that MIP-la did not exert potent effects on 
maintaining the CFU-A compartment in a less differentiated state during 
expansion.
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Similar data on short term recovery have been published by Muench et 
al (Muench et al., 1993) and by Serrano et al (Serrano et al., 1994). In the 
study by Muench et al SCF and IL-lp stimulated expansion of 1,000 fold for 
LPP-CFC, over 100 fold for HPP-CFC and 100 fold for CFU-S starting with 
post 5-FU bone marrow. The number of cells required for rescue from lethal 
dose irradiation could be reduced by 200 fold. The difference in both the 
degree of progenitor expansion achieved and the ability to reduce the cell 
number required for rescue to such a degree, compared with our own data is 
most likely to be the result of pre-enrichment for stem cells by treatment of 
the animals with 5-FU prior to harvesting. In the study by Serrano et al day 4 
post 5-FU bone marrow was expanded for 3 days with IL-3 and IL-6. 
Following transplantation of 5 x 10^ cells per mouse, survival to day 30 post 
radiation was 68% for expanded BMT versus only 27% for non-expanded 
BMT.
The first clinical study to report the transplantation of progenitor cells 
generated ex vivo was reported very recently by Brugger et al (Brugger et al., 
1995) who applied CD34 selection to standard leukapheresis products. 
Following CD34 selection approximately one tenth (11 x 10^ CD34 cells 
total) of a leukapheresis product was expanded ex vivo with a cytokine 
combination comprising SCF, IL-lp, IL-3, IL-6 and erythropoietin. CFU-GM 
progenitor cells were expanded approximately 50 fold and the few patients 
transplanted with expanded cells recovered peripheral blood counts as rapidly 
as historical controls treated with the same chemotherapy regimen. This study 
provided evidence that those cells responsible for transient engraftment may 
indeed be expanded ex vivo on a clinically relevant scale. One of the important 
applications of this type of cell manipulation would be to reduce the size of 
the transplant and thereby reduce the potential number of contaminating 
tumour cells present. The crucial question which this study did not address 
regarded the fate of LTRC during ex vivo expansion. The patients were treated
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with high dose, but non-myeloablative chemotherapy and, therefore, would 
recover endogenous haemopoiesis within a few weeks of transplantation. In 
this setting there was no requirement for LTRC in the transplanted material. 
Whether one tenth of a leukapheresis would contain sufficient LTRC to secure 
long term reconstitution following myeloablative therapy is not known. The 
fate of LTRC in such expansion cultures cannot be addressed clinically until 
patients are transplanted with cells expanded ex vivo following truly 
myeloablative therapy (see later).
The next important question to address with our experiments was 
whether the kinetics of neutrophil and platelet recovery could be influenced by 
using expanded populations for rescue following radiation. For these 
experiments all mice were transplanted with ten fold more cells (5 x 
lO^/mouse) than the minimum number required for rescue (5 x lO^/mouse). 
The reason for this was based on evidence reported by Jones that the rate of 
engraftment correlated with the cell number transplanted until a threshold cell 
number was exceeded. Thereafter, further increasing the cell dose would not 
further hasten haemopoietic recovery (Jones et al., 1987). If these data were 
correct then animals transplanted with expanded cells should show accelerated 
recovery compared with animals transplanted with a large number of 
unmanipulated bone marrow cells. We could then conclude that this 
observation was not solely due to transplanting approximately two fold more 
cells (total cell number increased approximately two fold over a 6 day 
expansion), but reflected either the progenitor content of the graft or an 
undetermined effect on progenitor seeding or homing.
The results of this experiment confirmed that neutrophils, platelets and 
haemoglobin recovered more rapidly following transplantation with expanded 
populations than for unmanipulated bone marrow. This difference was 
statistically highly significant and suggested that if a similar result could be 
obtained in clinical studies it would be clinically relevant. There was at least a
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seven day difference in the time taken for recovery to a neutrophil count of 0.5 
x lO^/L. This occurred by day seven for mice transplanted with SCF / IL-11 
expanded marrow but not until day 18 for unmanipulated cells. A similar, but 
less dramatic effect on neutrophil recovery was also shown by Muench et al 
(Muench et al., 1993) and Serrano et al (Serrano et al., 1994), confirming our 
results.
Our findings showing that transplants with expanded cells reduced the 
number of cells required for short term recovery following myelosuppressive 
therapy and that neutrophil recovery was significantly accelerated are both 
interesting and of potential clinical importance. However, results obtained 
with animal models do not necessarily mean that similar results may be 
possible for humans. Clinical studies are underway but to date no acceleration 
of neutrophil recovery has been demonstrated.
The results discussed in the preceding sections have established that 
those cells responsible for short term engraftment following BMT could be 
effectively expanded ex vivo. However, for a number of potential clinical 
applications it was also important to assess the effect that cytokine driven 
proliferation, in the absence of stroma, had on LTRC present in the cultures.
In order to safely reduce the number of cells required for stem cell rescue 
following myeloablative therapy the LTRC pool would have to be expanded, 
or at least maintained during expansion culture, otherwise patients would be 
likely to experience bone marrow failure late after BMT. For gene therapy 
applications, it is necessary to stimulate LTRC to divide but remain 
pluripotent (i.e. self-renewal) to ensure efficient and long-lived gene 
expression.
There are a number of assays which are thought to measure LTRC. Of 
the available in vitro assay systems, the CAFC assay is likely to be the most 
informative since several stem cell subsets may be assessed simultaneously. 
Although our group did not have experience with this assay at the time of
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these experiments being performed, the assay is now established “in house” 
and experiments are currently underway to quantify the number of stem cells 
in different subsets which remain after expansion either in the absence of 
cytokines (medium control), in the presence of SCF and IL-11, or SCF, IL-11 
and MIP-la. These experiments should provide some quantitative information 
regarding the maintenance of CAFC under the different culture conditions and 
may be sufficient to demonstrate whether M IP-la has any effect on the 
maintenance of early progenitor cells under the experimental conditions used.
Assessment of the ability of expanded populations to sustain serial BMT: 
Comparison with unmanipulated bone marrow
The most quantitative means of measuring stem cell numbers in vivo is by 
competitive repopulation (CRA assay). This enables an accurate comparison 
of the long term reconstituting ability of different cell populations. In our 
experiments this could have been applied to unmanipulated cells and to cells 
expanded with SCF and IL-11 versus SCF, IL-11 and MIP-la. The 
availability of mice which differ at the Ly-5 locus will facilitate the use of 
CRA in future studies.
For our studies serial BMT was selected to compare the long term 
reconstituting ability of three cells populations: unmanipulated, SCF / IL-11 
expanded and SCF / IL-11 / MIP-la expanded bone marrow. For serial BMT 
the donor and recipient cells must differ to allow detection of donor derived 
haemopoiesis at different time points following BMT. The system chosen for 
our studies employed male donors and female recipients. A Y chromosome 
specific probe was then use to perform Southern blotting on DNA samples 
derived from recipient animals.
Why should serial BMT be used to assess the repopulating ability of 
stem cell populations? Under normal circumstances bone marrow stem cells 
have a high proliferative capacity which may be increased by at least 10 fold
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under situations requiring marrow regeneration. However, this proliferative 
capacity is significantly challenged when donor bone marrow cells are 
required to fully regenerate haemopoiesis following myeloablative doses of 
radiation administered to host animals (i.e. the procedure of BMT). When 
serial BMT is performed, the recipient animals receive a lethal dose of 
irradiation. At a chosen time point following the primary transplant, bone 
marrow cells from the primary recipient (s) are transferred to a second lethally 
irradiated recipient. This is then repeated until the required endpoint is 
reached. The reason that serial BMT may be used to compare the 
reconstituting ability of different cell populations is that the ability of serially 
transplanted marrow to repopulate irradiated hosts is limited and therefore cell 
populations of unknown stem cells content (expanded populations) may be 
compared in parallel with normal marrow. Haemopoietic cells transplanted at 
short intervals (8-10 weeks) have been shown, in a number of studies , to 
develop a progressively impaired ability to repopulate irradiated hosts 
(Siminovitch et al., 1964; Cudkowicz etal., 1964). By lengthening the 
interval between transfers the repopulating ability may be improved, but even 
with very long (6-12 months) intervals, serial transfers cannot be continued 
for more than 5 generations (Cudkowicz et al., 1964; Harrison et al., 1978; 
Ogden & Micklem, 1976; Siminovitch et al., 1964). The exact mechanism 
underlying these findings is not clear. For example, the change in quality of 
stem cells during serial transfer could indicate that the stem cells have aged 
because of the number of divisions required for regeneration of haemopoiesis 
on multiple occasions. This would suggest that the number of divisions a stem 
cell can go through is limited and that the regenerative capacity of the stem 
cell pool is exhaustible. This limitation may however never be seen under 
normal circumstances since stem cell reserve in mice seems to be ample to 
maintain haemopoiesis throughout life. In a serial BMT experiment, as the 
donor cells are serially passaged, competition will arise between the fraction
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of host stem cells which have survived radiation and the less competent donor 
stem cells, which is why markers are required to indicate the continuing 
presence of donor cells. The ability of the host marrow to compete will 
depend on the level of myeloablation caused by the radiation protocol and the 
quality of remaining donor cells. Eventually there will be so few stem cells 
remaining in the donor marrow that recipient animals will die from bone 
marrow failure soon after cell transfer and before host marrow is able to 
regenerate to any significant degree.
The use of serial transfer as a means of measuring the proliferative 
capacity of cell populations is, at best, inexact. It is a useful functional test of 
the ability of cells to reconstitute under circumstances requiring enormous 
stem cell reserve, but it cannot measure the number of reconstituting cells 
present. Although the assumption is generally made that serial transfer 
eventually fails because stem cells have a finite capacity for self-renewal there 
are a number of other possible explanations for this observation. For example, 
the homing behaviour of bone marrow cells which have been serially 
transplanted may be abnormal or stem cells which have been transplanted may 
never regain their normal quiescent characteristics because of changes in the 
microenvironment induced by radiation. Also, the signals to regenerate 
following BMT may shift the stem cells into differentiative rather that self­
renewal divisions. If the interval between transfers is lengthened then the stem 
cells have more time to return to a quiescent state. The fact that leaving 
intervals of one year between transfers is insufficient to allow more than 5 
transfers suggests that the changes to the stem cell compartment induced by 
BMT are in part irreversible.
In the serial transfer experiment, cell populations expanded ex vivo 
were compared with unmanipulated bone marrow. It was already realised that 
expanded populations had an advantage in terms of transient engrafting 
potential and that the ability to serially transfer was critically dependent on the
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interval between transfers. I, therefore performed the second cell transfers at 
one, three and nine months following primary BMT to gain as much 
information from the experiment as possible. The interval between the second 
and third transplant was set at two and six months (short and long). Thereafter 
an interval of three months was left between transfers.
The results showed that expanded marrow had a definite advantage 
over fresh marrow in terms of its capacity for serial BMT, but only when the 
interval between transfers was short. Since the assay systems employed were 
not quantitative, this may have been related to a more rapid return to steady- 
state haemopoiesis for expanded BMT compared with unmanipulated BMT 
and need not imply that there were more LTRC present in the expanded 
transplant. Although short term haemopoietic recovery was more rapid for 
expanded than for unmanipulated BMT it was not clear whether this was due 
to an increased CFU-A concentration, to effects of growth factor exposure on 
progenitor homing, or to a mixture of both. Therefore, when these cells were 
then serially transplanted (short interval) their observed advantage in terms of 
ability to serially transfer may have been related to qualitative changes in 
transplantation ability rather than to an increase in the number of stem cells 
induced by the ex vivo expansion. For serial transfers performed after longer 
intervals, unmanipulated marrow regained the ability to serially transplant and 
at least 4 serial transfers were possible instead of 2. It would be interesting to 
compare unmanipulated marrow and expanded marrow for their ability to 
sustain serial BMT after a longer interval (i.e. 9 months). By 9 months post 
transplant all three experimental groups would be expected to have returned to 
steady state haemopoiesis. Any differences detected in the ability to serially 
transfer or in the proportion of donor cells at this time point would be more 
likely to reflect the quality of the stem cells in the original cell innoculum (i.e. 
fresh versus expanded). If by nine months the donor marrow had failed 
(related to the ex vivo culture) then Southern blotting would have confirmed
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loss of male cells. Unfortunately I was unable to obtain data from the two 
experimental groups transplanted with expanded cells at the later time point 
because a proportion of these animals developed leukaemia.
Possible mechanisms underlying the generation of CD5 B cell leukaemia 
in BMT recipients
As discussed in detail at the end of chapter 6, CD5 positive B cells appear to 
represent an individual B cell lineage which develops and matures during 
ontogeny but in adult life is sustained by "self-replenishment" of mature cells. 
Although this is likely to be the case during steady state haemopoiesis, it is 
possible that, following transplantation with adult bone marrow, CD5 positive 
cells may be reconstituted in a limited fashion, either by differentiation of 
HSC, or by proliferation of the few CD5 positive cells present in the donor 
marrow. These possibilities have been investigated in studies using FACS 
sorted candidate stem cells (reviewed by Kantor & Herzenberg, 1993). In 
these studies, adult mouse bone marrow enriched by FACS-sorting for Thy- 
ll°/Lin- cells was transferred into SCID mice. Conventional B cells were fully 
reconstituted, but in addition a small number of CD5 positive cells were also 
derived from the donor cells. Since the enriched population should have 
contained no CD5 positive B cells (B220 positive cells were <1% of the total) 
it seems likely that, in this instance, low numbers of CD5 positive B cells 
developed by differentiation of pluripotent HSC. This finding would account 
for the more recent data obtained from cell transfer studies which suggest that 
CD5 positive B cells may indeed be reconstituted to a low level from adult 
bone marrow (reviewed by Kantor & Herzenberg, 1993; Stall et al., 1992; 
Lalor et al., 1989; Kantor et al., 1992b).
The CD5 positive B cell population, perhaps because of the 
requirement for "self-replenishment", appears to be at greater risk, compared 
with conventional B cells, of neoplastic transformation. As normal mice age
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there is a tendency for clones of CD5 B cells to develop (Stall et al.t 1988). 
These clonal populations may spontaneously progress to an invasive 
leukaemia, but this process is accelerated by serial transfer of bone marrow 
populations into irradiated recipients (Fowlis et al., 1989).
In our study bone marrow populations (either unmanipulated or 
expanded) from male mice were transplanted into lethally irradiated female 
recipients. After serial transfer of pooled marrow from these primary 
recipients a female, CD5 positive, B cell CLL developed, firstly in recipients 
of marrow derived from primary recipients of SCF/IL-11/MIP-la expanded 
marrow, but later in recipients of SCF/IL-11 expanded marrow. In these 
groups, with time, eventually almost all animals developed leukaemia. In the 
unmanipulated BMT group only one case of CD5 positive B cell CLL 
occurred. Cases of advanced leukaemia were transplantable into animals 
treated with only 2Gy of radiation and were rapidly lethal. The mechanism 
underlying these observations is not clear but three hypotheses are likely.
There is substantial evidence that CD5 positive B cells are susceptible 
to leukaemogenesis, even before manipulation, and that these cells are present 
at very low numbers in normal adult bone marrow. For the first hypothesis it 
must be assumed that CD5 B cells may only develop by "self-replenishment", 
and not by differentiation of HSC. It is suggested that following 
transplantation with unmanipulated bone marrow, the small number of CD5 B 
cells present in the marrow innoculum was sufficient to regenerate the CD5 
positive B cell population (albeit at a low level). Since reconstitution was only 
likely to be 10-20% of normal (according to previous studies) then serial 
transfer would further increase the number of cell divisions required (by self­
replenishment) by a cell population already susceptible to leukaemogenesis. 
One might, therefore, expect occasional examples of leukaemia to occur (only 
one case in our study). Why then was the incidence of leukaemia much greater 
for expanded BMT? It is possible that the few CD5 positive B cells present in
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adult bone marrow did not survive the ex vivo culture. Upon transfer then, 
there would be no source of replenishing CD5 positive B cells. Under these 
circumstances perhaps host (female) CD5 B cells would have to proliferate to 
replenish the CDS B cell population. These cells would have been exposed to 
radiation thereby increasing further the chance of leukaemogenesis.
Alternatively, if we assume that CD5 positive B cells may be 
reconstituted from HSC rather than by self-replenishment, then for 
unmanipulated BMT, HSC present in the donor innoculum would be 
responsible for the low level regeneration of CD5 positive B cells following 
BMT. However for expanded BMT, perhaps the exposure to a combination of 
cytokines chosen to stimulate myelopoiesis, resulted in the HSC being 
triggered towards myeloid, rather than lymphoid commitment. If this were 
true then the donor marrow would be insufficient for reconstitution of CD5 B 
cells and once again the host CD5 B cells would have to proliferate and by so 
doing become leukaemic.
Finally, it is possible that the donor bone marrow contained 
insufficient CD5 B cells to regenerate the CD5 B cell population whether 
expanded or not. If this were so, then the host CD5 B cells would have to 
proliferate equally in all three experimental groups in order to replenish the 
population regardless of the make up of the donor cell innoculum. Although 
clonal populations may have been present in many or all animals due to the 
stress of proliferation and serial transfer, only two animals may have actually 
developed leukaemia (by chance in the expanded groups). When the cells 
were pooled and serially transplanted, eventually all animals in those two 
groups developed leukaemia. The reason that the SCF/IL-11/MIP-la group 
developed leukaemia earlier than the SCF/IL-11 group may be simply that the 
animal in that group which developed the primary tumour did so at an earlier 
time point than in the SCF/IL-11 group (i.e. by chance).
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The development of leukaemia in this study has generated a number of 
important questions. For example, does unmanipulated bone marrow or 
expanded bone marrow contain detectable CD5 positive B cells? This may be 
a difficult question to answer. Since, if present at all, these cells are likely to 
occur at a very low frequency they would be difficult to detect by flow 
cytometry. Practically, this would be complicated by CD5 expression by 
normal T cells. If a B cell population was first selected on the basis of B220 
and IgM expression this could then be labelled for CD5. Even so, these cells 
may be too infrequent to be readily identified. Since T cells express CD5 it 
may be difficult to separate a "clean" enough population of B cells to perform 
RT-PCR for CD5. The chances of detecting a signal from small numbers of 
contaminating T cells must be high.
A further question is whether CD5 B cell reconstitution following 
BMT is of donor or host origin. This could be simply determined by using 
donor and recipient mice with a detectable marker (e.g. Ly-5.1/5.2, male / 
female). Following BMT, recipient spleen, peritoneal fluid, lymph nodes and 
bone marrow could be harvested, flow sorted for CD5 positive B cells and 
then examined for the relevant markers.
The next question would be, if the CD5 B cell population following 
BMT is donor derived does it develop by "self-replenishment" of CD5 B cells 
or by differentiation of HSC? This could be addressed by transplanting highly 
purified cells which were completely depleted in CD5 B cells and looking for 
donor markers in the recipients post BMT. If both total bone marrow and 
highly purified marrow were able to reconstitute donor derived CD5 B cells 
this would suggest differentiation from HSC, whereas, if only total bone 
marrow reconstituted CD5 B cells, then "self-replenishment" would be the 
more likely explanation.
A crucial question however, is whether this type of experiment can be 
repeated with the same result. In a repeat experiment it would be useful to
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reduce the interval between transfers (to try to speed the process of 
leukaemogenesis) and to avoid pooling of the cells used for subsequent 
transfers. In this way we could determine how often individual leukaemias 
arose and whether they occurred predominantly in the expanded BMT groups. 
Additional information could be obtained by performing clonality studies on 
the BMT recipients at varying time points after serial transfer and to look for 
cytogenetic abnormalities. This should provide information on how many 
clones contributed to leukaemogenesis.
Finally, if the first hypothesis is correct and expanded marrow can be 
shown to be depleted in CD5 B cells could the leukaemia be prevented by co­
transplanting expanded marrow with a rich source of CD5 B cells (e.g. from 
peritoneum) thereby removing the signal for host CD5 B cells to proliferate? 
This experiment would be relatively easy to perform and would be of key 
interest.
Clinical Application of Stem/Progenitor Cell Expansion
Over the last few years, attempts have been made to expand human 
haemopoietic progenitor cells ex vivo with a view to transplantation in vivo 
(Brugger et al., 1993; Haylock et al., 1992; Henschler et al., 1994; Shapiro et 
al., 1994). There are several potential clinical applications for stem cell 
expansion. For autologous stem cell rescue, it may be possible to reduce the 
harvesting requirements and, therefore, the likelihood of tumour cell 
contamination. Expanded progenitor cells may be used to ameliorate 
pancytopenia post transplant, or to cover multiple courses of high dose 
chemotherapy and so prevent cumulative myelosuppression. Finally, culture 
conditions may be developed which could be applied to gene transduction 
protocols.
Most investigators initiate stem cell expansion with CD34 cells 
purified by positive selection since these cells appear to be superior to
152
unselected material (Moore, 1995). In addition, up to a 4.0 log depletion of 
contaminating tumour cells can be obtained using CD34 selected starting 
populations (Shpall et al., 1994). A recent study suggested that any remaining 
tumour cells do not increase in number during ex vivo expansion, and this may 
represent a further purging effect (Brugger et al., 1995).
The first clinical studies using progenitor cells expanded ex vivo have 
now been reported, two only in abstract form (Alcom et al., 1996; Brugger et 
al., 1995; Champlin et al., 1995; Zimmerman et al., 1995). In the first of two 
studies performed by our group (these separate studies are not included in this 
thesis), we established the safety and feasibility of transfusing CD34 selected 
cells which had been selected from cryopreserved peripheral blood progenitor 
cells (PBPC) and then expanded ex vivo with a combination of five cytokines. 
Ten patients received >20 x lO^CFU-GM/kg unmanipulated PBPC (i.e. a 
dose sufficient for stem cell rescue in the event that the expanded cells failed 
to mediate engraftment) and in addition an aliquot of expanded cells (range 
33-279 xlO^ CFU-GM/kg). There were no toxic effects from the progenitor 
cells which had been generated ex vivo but no acceleration of either neutrophil 
or platelet recovery was seen (Alcom et al., 1996).
In the study by Brugger et al, in a small number of patients, stem cell 
rescue was performed using only expanded cells, without additional 
unmanipulated cells. One tenth of a standard PBPC product was expanded 
with cytokines ex vivo prior to infusion. Six patients were transplanted with 
expanded cells only, and five of six experienced rapid engraftment following 
high dose, but non-myeloablative, chemotherapy .The remaining patient died 
prior to the anticipated time of engraftment. This study was unable to answer 
the question of whether sufficient LTRC were present in one tenth of a PBPC 
collection either before or after ex vivo culture since the patients did not 
receive myeloablative therapy and would be expected to recover endogenous 
haemopoiesis within a few weeks of chemotherapy.
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In the second study performed by our group, the primary objective 
was to determine whether CD34 cells expanded ex vivo would secure both 
short and long term engraftment following fully myeloablative 
chemo/radiotherapy (Holyoake et al., 1996). To our knowledge, this is the 
first report testing the ability of progenitor cells generated ex vivo to sustain 
haemopoiesis following myeloablative regimens. Only four cases were 
treated. All four cases experienced delayed haematological recovery and were 
therefore given unmanipulated PBPC "back-up" to secure engraftment.
The results of this study were not favourable yet were of considerable 
clinical importance. In vitro data had suggested that LTCIC may be 
maintained during ex vivo expansion culture, but this was the first clinical 
study to test the engraftment potential of expanded cells following fully 
myeloablative conditioning. Although in vivo studies in murine models are 
used to prove the presence of LTRC in cell infusions, such studies are not 
possible clinically. There is, therefore, no evidence to suggest that 
maintenance of LTCIC signifies the presence of cells capable of long term 
reconstitution. The preparative regimen employed in the study by Brugger et 
al (Brugger et al, 1995), although intensive, included neither total body 
irradiation nor melphalan / busulphan (used in our study). Despite re-infusing 
sub-optimal CFU-GM doses, they were still able to demonstrate prompt 
recovery of blood counts, not significantly different from historical controls. 
In our study, all four patients received fully myeloablative conditioning 
regimens. Although, by our standards, the first case received an inadequate 
CFU-GM dose for transplantation, this dose was comparable to some of the 
cases treated in the study by Brugger et al. This case showed no evidence of 
neutrophil engraftment. The other three cases did show early neutrophil 
engraftment but this was not maintained. A biphasic pattern of neutrophil 
recovery was seen in three of the four cases suggesting that the early recovery 
was mediated by committed progenitor cells present in the ex vivo expanded
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material, while late recovery was provided by the unmanipulated PBPC given 
as "back-up" in every case. This provides strong evidence that, under the 
culture conditions used in our study, stem cells expanded ex vivo may not 
contain sufficient LTRC to ensure engraftment following myeloablative 
conditioning. This pattern may not have been observed for the cases reported 
by Brugger et al since the early phase of neutrophil engraftment and the 
subsequent fall in neutrophils may have overlapped with endogenous 
neutrophil recovery from the high dose, but non-myeloablative, chemotherapy 
used in their study. Alternatively, the culture conditions employed in the two 
studies may have been sufficiently disparate, to produce progenitor cells with 
a significantly different profile of myeloid lineage commitment.
Clearly much more work is required before the clinical potential of 
stem cell expansion may be realised. To optimise recovery of LTRC it may 
prove necessary to expand stem cells in the presence of both positive and 
negative regulators of stem cell proliferation and supporting stroma.
The work described in this thesis has provided invaluable information 
regarding the in vitro requirements for haemopoietic stem cell survival. The 
data obtained from animal studies has given us the framework on which to 
develop clinical studies. In parallel with clinical development we now hope to 
investigate in more detail the factors which are crucial for stem cell 
maintenance and expansion ex vivo.
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